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i 
Abstract 
Liver fibrosis is one of the leading causes of morbidity and mortality in the 
western world and represents a significant burden to the health system. The 
continued elucidation of the mechanisms governing liver fibrosis has identified 
the hepatic myofibroblast, derived from quiescent hepatic stellate cells, as the 
principle cell type involved in disease progression with several studies 
demonstrating that hepatic myofibroblast apoptosis correlated with attenuated 
fibrosis severity.  
A recombinant single chain antibody (scAb), termed C1-3, has been developed 
and shown to actively target hepatic myofibroblasts expressing synaptophysin 
both in vitro and in vivo. The aim of this thesis was to use C1-3 (conjugated to an 
appropriate agent) as an imaging agent; to examine the effect of hepatic 
myofibroblast depletion on regeneration following two thirds partial hepatectomy 
(PHx) and to examine if hepatic myofibroblast depletion in a cirrhosis model 
promotes fibrosis regression. 
The data in this thesis show that conjugation of C1-3 to a fluorophore provides a 
novel non invasive method for differentiating between the different stages of 
carbon tetrachloride induced liver fibrosis in animal models, with increasing 
hepatic myofibroblast number (determined by αSMA staining) correlating with 
disease progression.  
Hepatic myofibroblast depletion prior to and during PHx revealed a complex role 
for these cells during liver regeneration through the provision of factors that both 
stimulated and reduced parenchymal cell proliferation.  
C1-3 mediated-depletion of hepatic myofibroblasts in a sustained model of liver 
injury revealed that removal of these cells was not sufficient to stimulate fibrosis 
regression since no difference in collagen deposition was observed. 
The data in this thesis demonstrate the complex role of hepatic myofibroblasts 
during liver regeneration and sustained injury and suggest that further studies are 
required to elucidate the exact mechanisms involved before depletion of hepatic 
myofibroblasts can be a viable therapeutic option.  
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Chapter 1. Introduction 
1.1 The Liver 
The liver is the largest organ in the human body weighing approximately 1.5kg 
and is located in the upper right-hand side of the abdominal cavity, resting just 
below the diaphragm. Apart from a patch where it connects to the diaphragm, the 
liver is entirely covered by a visceral peritoneum, a double layered membrane 
encasing the liver, hepatic blood vessels and bile duct in order to reduce friction 
against other organs. The peritoneum folds back upon itself to form the falciform 
ligament which divides the liver into four lobes: left, right, quadrate and caudate.  
The liver has a unique dual blood supply with the hepatic artery delivering 
oxygenated blood to provide cellular energy via aerobic respiration and the 
hepatic portal vein taking all the blood from the intestines to the liver. Blood from 
the two supplies mixes at the edge of the portal tract and passes through the 
liver’s extensive vascular bed, the sinusoids emptying into the central vein where 
it returns to the circulatory supply via the inferior vena cava. The space between 
the endothelial cell and hepatocytes is known as the space of Dissé which drains 
lymph into the lymphatics. 
Bile, generated by the liver to aid digestion of lipids, is secreted by hepatocytes 
into the bile canaliculi and eventually drains into the left and right hepatic ducts 
which merge to form the common bile duct. The bile can then either drain into the 
duodenum via the common bile duct to be excreted, or be stored in the gall 
bladder via the cystic duct. Each lobe is made up of many functional hepatic units 
which describes the organisation of hepatocytes with regard to blood supply and 
bile drainage. Although different models have been proposed, the liver lobule 
(proposed by Kiernan) and the liver acinus of Rappaport are most favoured. The 
liver lobule is typically described as a hexagonal structure with portal triads, 
consisting of a portal vein, hepatic artery and bile duct, at each corner (Figure 1-
1A). Hepatocytes, arranged in rows, radiate from a central vein with their 
basolateral surface lined with fenestrated endothelial forming the sinusoids. The 
apical surfaces form the bile canaliculus which allows the bile secreted by the 
hepatocytes to drain into the bile ducts.  
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The acinus of Rappaport is a smaller functional unit which describes the 
microcirculatory and secretory function of the liver.  The central vein is located at 
the periphery of each liver acinus, composed of three or more liver acini. Each 
acinus relates to the terminal branches of the portal triad allowing blood to flow 
centrifugally and bile flow centripetally (Figure 1-1B). Blood flow within the acinus 
is divided into three zones, zone 1 has the highest oxygen and substrate supply 
due to its location nearest the portal triad whereas zone 3 has the poorest oxygen 
supply as it is located at the end of microcirculatory system, i.e. next to the 
central vein. This model is highly favoured by pathologists as it explains many 
pathological lesions. 
Both arrangements provide evidence for metabolic zonation of hepatocytes [1, 2], 
meaning hepatocyte function differs depending upon location within the hepatic 
unit. Hepatocytes adjacent to the portal triad (periportal) are responsible for 
catabolism of amino acids and urea synthesis whereas those near the central 
vein (pericentral or perivenous) utilise ammonia to generate glutamine [1, 3].  
Hepatocytes account for 70-80% of the total liver cell population and under a 
normal light microscope, appear to be undistinguished and unspecialised rows of 
cells. Upon closer examination under an electron microscope specialised 
microvilli are revealed (on the membrane in contact with the sinusoids) which 
increase the area available for uptake of substances from the blood. Hepatocytes 
perform the majority of functions in the liver: 
1. Synthesis of bile salts, cholesterol and phospholipids 
2. Protein synthesis including the formation of serum albumin, fibrinogen, 
clotting factors, enzymes, lipoproteins and many others 
3. Carbohydrate metabolism and synthesis 
4. Urea cycle 
5. Lipid metabolism 
6. Hormone & cytokine catabolism 
7. Drug and xenobiotic metabolism 
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Figure 1-1 Proposed models of functional hepatic units. A: The hepatic lobule is a hexagonal 
unit with portal triads at each corner and a central vein at the centre. Hepatocytes, arranged in 
rows, radiate out from the central vein towards to portal triads. B: Acinus of Rappaport is a smaller 
functional unit which describes the microcirculatory and secretory function of the liver. Blood flows 
from the terminal branches of the portal triad toward the central vein located at the periphery. 
Blood oxygenation levels categorised into zones which account for hepatocyte metabolic 
zonation. 
The remaining cellular population is composed of hepatic stellate cells (HSC), 
kupffer cells, biliary epithelial cells, oval cells and endothelial cells. As mentioned 
earlier, the endothelial cells form the sinusoids of the liver, however they are 
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unlike normal vascular endothelial cells as their basement membrane is replaced 
with pores known as fenestrae to allow the exchange of nutrients and oxygen [4]. 
Furthermore, the endothelial cells play a key role in the recruitment of immune 
cells during liver injury by regulating the expression of adhesion molecules. 
Kupffer cells are specialised liver macrophages and reside in the sinusoids. They 
act as scavengers and are responsible for the phagocytosis of old erythrocytes, 
tissue debris, bacteria and foreign proteins. They also play an essential role in 
the innate immune response through the secretion of soluble inflammatory 
mediators [5]. HSC reside in the space of Dissé and are the primary site of 
retinoid (vitamin A) storage in the body. Their dendritic like processes project into 
the sinusoids between the endothelial cells and hepatocytes, with each spindle 
containing numerous microprojections (spines) allowing the cell to sense and 
respond to chemotactic signals [6]. Oval cells are the livers progenitor cells and 
are capable of differentiating into both hepatocytes and biliary epithelial cells.  
Cellular organisation within the liver is shown in figure 1-2. 
 
 
 
 
 
 
 
 
 
Figure 1-2 Cellular organisation within the liver. Hepatocytes are arranged in rows with their 
specialised microvilli in contact with the sinusoidal basement membrane allowing for increased 
uptake of components from the blood delivered by the portal triad. Quiescent HSCs reside in the 
space between the hepatocytes and sinusoidal basement membrane, termed the space of Dissé, 
allowing them to monitor and respond to the microenvironment. Kupffer cells patrol the sinusoids 
providing the first line of defence against injury. PV – Portal vein, PA – portal artery. 
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1.2 Liver Disease 
1.2.1 Clinical perspective 
Liver disease is one of the most common causes of morbidity and mortality in the 
western world and represents a significant burden to the healthcare system. Liver 
failure can present either with an acute onset or after years of long term liver 
disease. Acute liver failure (ALF) is defined by the appearance of severe liver 
complications shortly after the initial symptoms (e.g. jaundice) and implies severe 
impairment in liver function due to widespread cellular necrosis. It is typically 
caused by overdose of paracetamol. 
Due to the huge compensatory ability of the liver, liver failure is typically 
diagnosed at its end stages after years of prolonged illness. Currently the major 
global cause of chronic liver disease is due to viral infection, particularly with the 
hepatitis C virus, which results in inflammation (hepatitis) [7]. However, in the 
western world alone, there is an increasing rate of excessive alcohol 
consumption and high fat diets (Non-alcoholic fatty liver disease (NAFLD) and 
non alcoholic steato-hepatitis (NASH)) which are now accounting for a high 
percentage of deaths per annum. Disease can also result from autoimmune 
disorders where the immune system is triggered into attacking cellular 
components in the liver, such as autoimmune hepatitis [8] or primary biliary 
cirrhosis (PBC) [9]. In rare cases, liver disease may arise from genetic conditions 
caused by the body absorbing and storing too much iron (hereditary 
haemachromatosis [10]) or copper (Wilson’s disease [11]) resulting in toxicity. 
Finally liver disease may also result from the impairment of bile flow, termed 
cholestasis, caused by mechanical blockage by gallstones or the progressive 
loss of bile ducts due to inflammation, cause unknown, termed primary 
schlerosing cholangitis [12].  
1.2.2 Fibrogenesis 
Hepatic fibrosis is a classical wound healing or scarring process in response to 
chronic injury. During acute injury, apoptosis and necrosis of hepatocytes 
stimulates kupffer and hepatic myofibroblasts to release a vast array of 
chemokines and cytokines to recruit both local and circulating lymphocytes [13]. 
This triggers an inflammatory response and upon removal of the insult, the liver 
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will regenerate via hepatocyte mitosis. Unlike other organs, the liver has a 
remarkable ability to regenerate even after 70% of the parenchyma is lost. The 
cellular changes associated with liver injury are illustrated in figure 1-3.  
However, in response to chronic injury, the regeneration process becomes 
overwhelmed and tries to encapsulate the injury [14] but in doing so distorts the 
normal tissue architecture resulting in functional impairment. Even at this stage, if 
the insult is removed there is a possibility that regeneration can occur. 
Nevertheless, the progression to cirrhosis, or end staged liver disease, results 
after long term liver damage and is characterised by extensive fibrosis with 
nodule formation and severe disruption in tissue architecture and vasculature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Cellular changes in response to liver injury. Adapted from [15]. Hepatocyte 
necrosis and apoptosis following liver injury results in the activation of kupffer cell. Kupffer cells 
release proinflammatory cytokines that stimulate the activation and transdifferentiation of 
quiescent HSC into hepatic myofibroblasts. These cells are responsible for the secretion of the 
major components of the ECM as well as a vast array of cytokines/chemokines which cause loss 
of hepatocyte microvilli and sinusoidal fenestrae ultimately affecting liver function. 
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1.2.3 The Extracellular Matrix 
The extracellular matrix (ECM) is thought to have a significant influence on the 
cellular response during injury. It is comprised of macromolecules belonging to 
three main families: collagens, proteoglycans and glycoproteins. In the normal 
liver the ECM is restricted to the central veins, portal tracts and sinusoid walls 
[16] forming a vital barrier between the blood flow and parenchyma. This scaffold 
is not only important in providing tensile strength and resistance, it also regulates 
cell movement and modulates diffusion and vascular flow [17] by allowing 
continuous signalling between the cells within the liver. This signalling can be 
enhanced by the stimulated release of growth factors, enzymes, hormones and 
cytokines, which are stored in their inactive forms in the ECM, to modify the 
cellular microenvironment [16]. 
ECM composition differs depending upon its localisation, for example the matrix 
forming the basement membrane like structure in the space of Dissé is 
composed of non fibril forming collagens (types IV, VI and XIV), glycoproteins 
and proteoglycans. However the matrix surrounding the portal regions and large 
vessel is referred to as an interstitial matrix due to it consisting of fibril forming 
collagens (types I and III), cellular fibronectin and other glycoconjugates [14].  
Different compositions of ECM are essential for maintaining the differentiated 
functions of the resident liver cells. During fibrosis, the ECM in the liver can 
increase 3-5 fold [16] with significant changes initially observed in the 
perisinusoidal space ECM. Nevertheless, the increased ECM deposition results 
in the basement membrane-like matrix representing the interstitial ECM due to 
the presence of fibrillar collagens. This influences a change in sinusoidal 
phenotype resulting in loss of fenestrae inhibiting the exchange in nutrients etc 
between the blood and hepatocytes [16, 18] which impacts on liver function. 
The changing ECM has been shown to affect cellular function due to the changes 
in microenvironment [14], for example proliferation of hepatocytes and their 
function in vitro has been shown to be dependent on the matrix that they are 
cultured on [19]. Additionally, Gaça et al  [20] reported that hepatic myofibroblasts 
replated on Matrigel rather than on plastic or collagen matrix, reduced their 
proliferation by up to 30%. After 3-7 days of culture there was a progressive 
reduction in the levels of mRNA for collagen type I and alpha smooth muscle 
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actin, both associated with the hepatic myofibroblast phenotype. Furthermore, 
Zhou et al [21] have demonstrated that interaction with the ECM also regulates 
the proliferation and apoptosis of HSCs.  
Whilst it is widely known that the primary producer of ECM under both normal 
and fibrotic conditions is the hepatic myofibroblast, recent evidence implicates 
portal myofibroblasts [22, 23], bone marrow derived cells [24] and fibroblasts 
derived from epithelial-to-mesenchymal transition [25, 26] in ECM deposition 
during the fibrogenesis process. Determining the contribution of each cell type to 
ECM deposition is essential in understanding fibrosis and identifying targets for 
therapeutics.   
1.2.4 Role of Myofibroblasts in Fibrosis 
Myofibroblasts are a morphological and functional intermediate between 
fibroblasts and smooth muscle cells and contain cytoplasmic bundles of 
microfilaments [27]. Myofibroblasts are found in many organs and are known to 
be the principle cell type involved in both matrix deposition and the production of 
enzymes involved in matrix degradation, tissue remodelling and scar formation. 
Research to date has focused on the hepatic myofibroblast as the main 
contributor of fibroblasts in the liver. These cells are typically characterised by 
their transformation to a fibroblast phenotype upon activation and their 
expression of αSMA [28]. 
1.2.4.1 The Hepatic Stellate Cell 
Historical Perspective 
As mentioned previously, the HSC resides in the subendothelial space between 
the sinusoidal epithelial cells and the hepatocytes. In its quiescent state it is the 
primary storage site for retinoids (vitamin A) in the body. It was this function 
which led to its discovery by von Kupffer in 1876 when he used a gold chloride 
method to detect vitamin A containing droplets in liver tissue. This was the first 
non-parenchymal cell described in the liver, however its function was unknown. In 
1980, Wake suggested that the name of the cell should reflect its morphology 
until its functions were fully discovered, thus proposed the terms ‘perisinusoidal 
stellate cell’ or ‘stellate cell’ [29].  
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Interest in this cell began to grow and it was not long before the functional 
significance of HSCs was realised. Immunofluorescence studies by Kent et al 
[30] demonstrated that vitamin A storing cells accumulated in necrotic regions in 
livers from rats treated with carbon tetrachloride (CCl4). Furthermore, Friedman et 
al [31] used immunofluorescence of HSCs in culture to demonstrate that they are 
the principal collagen-producing cells in the liver and were capable of producing 
large amounts of collagen type I with lower levels of collagen type III and IV also 
detected [32]. 
The development of reproducible techniques for isolating HSCs has been 
essential in defining their role in fibrosis [33, 34]. The quiescent HSC undergoes 
a process of activation, transforming into a proliferating, fibrogenic and contractile 
hepatic myofibroblast [14, 35]. It can be defined as a two stage process, initiation 
followed by perpetuation [14, 36].  
Initiation is defined by early changes in gene expression and phenotype which 
occur as a result of paracrine stimulation and render the cells responsive to 
further stimuli e.g. cytokines [36, 37]. Typically, damage to the liver by toxins, e.g. 
CCl4, results in hepatocyte necrosis and apoptosis which in turn causes the 
release of reactive oxygen species (ROS) and apoptotic fragments into the 
microenvironment that are fibrogenic for HSCs [38]. These fragments are also 
engulfed by Kupffer cells which induces expression of Fas and Death ligands 
further promoting hepatocyte apoptosis in a ‘feed-forward’ loop favouring fibrosis 
[39]. Kupffer cells also stimulate HSC activation, proliferation and matrix 
synthesis through cytokine secretion, particularly TNFα and ROS [36]. 
Endothelial cells and platelets have also been implicated in the activation process 
though conversion of latent TGFβ to its active form and the provision of PDGF, 
EGF and TGFβ [40].  
HSC activation can also be influenced by the microenvironment through subtle 
changes in matrix interactions [16], for example in vitro co-culture of HSCs with 
freshly isolated differentiated sinusoidal epithelial cells promoted HSC 
quiescence. However, co-culture with capillarized sinusoidal epithelial cells 
promoted HSC activation into hepatic myofibroblasts [41]. This may be explained 
by the expression of a splice variant of fibronectin, EIIIA, which is synthesised by 
sinusoidal epithelial cells following injury [42].  
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Following initiation, the continued activation of HSCs is the result of autocrine and 
paracrine feedback loops [14, 36] as well as discrete changes in cell behaviour 
which are characterised as follows: 
1. Proliferation: Early expression of PDGF receptors [43] during activation 
allows the cells to respond to the potent mitogen PDGF [44]. Other 
mitogens have been identified to play a potential role in fibrogenesis, for 
example: VEGF, EGF and TGFα. 
2. Chemotaxis: Migration by HSCs to the site of injury is dictated by cytokine 
chemoattraction [45], particularly PDGF [46], MCP-1 [47] and CXCR3 [48]. 
3. Fibrogenesis: Activation of rat HSCs in culture has shown to increase 
matrix production, particularly collagen type I [32, 49]. This is mainly driven 
by autocrine and paracrine sources of TGFβ. 
4. Contractility: The contractility of HSCs plays an important role in portal 
resistance during fibrosis due to their location in the scar regions causing a 
reduction in blood flow in the sinusoids.  
5. Matrix Degradation: The course of fibrosis is dictated by the delicate 
balance in matrix production and degradation. HSCs have been shown to 
be principle sources of both matrix–metalloproteinases (MMPs) [36] as 
well as the tissue inhibitors of metalloproteinases (TIMPs) [50].  
6. Retinoid loss: Activation of HSCs is associated with the loss of the 
retinoid stored in the perinuclear space. Recent research has 
demonstrated that upregulation of adipose differentiation-related protein 
(ADRP) by retinol and palmitate is directly associated with the down 
regulation of fibrogenic genes in hepatic myofibroblasts [51] suggesting 
that ADRP expression correlates with the state of HSC activation and 
potentially represents a new therapeutic target in hepatic fibrosis. 
Taken together, these changes in HSC behaviour result in the increased 
deposition of ECM disrupting normal tissue architecture causing liver failure.    
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1.2.4.2 Portal Myofibroblasts 
Studies by Ramadori’s group were the first to show morphologically and 
functionally distinct populations of fibroblasts within the liver [52, 53] confirming 
theories that other cell types contribute to ECM production during fibrosis. These 
cell populations were investigated further by Cassiman et al [54] by means of 
immunohistochemistry to try and identify precursor populations of (myo)fibroblast-
like cells in fibrotic liver. They showed that in rat and human cirrhotic livers three 
different populations of myofibroblast-like cells existed, these were: 
(i) Activated hepatic stellate cells (myofibroblasts) 
(ii) Interface myofibroblasts 
(iii) Peribiliary myofibroblasts 
All cells expressed varying levels of αSMA, but were distinguished by their 
differential expression of other cellular markers such as desmin, GFAP and 
synaptophysin. These data agreed with previous studies by Tang et al [55] which 
showed that bile duct ligation in rats resulted in the proliferation of portal 
fibroblasts, identified by expression of αSMA and lack of desmin, that were 
associated with the scar deposited.  
More recently the portal myofibroblast response has been investigated using two 
animal models of self limited and persistent cholestatic liver injury: arterial liver 
ischemia and bile duct ligation [56]. Surprisingly, immunohistochemistry revealed 
an increase in desmin expression suggesting that a proportion of HSCs were 
beginning to activate during the early stages of liver injury in both animal models. 
However as fibrosis progressed in both models, the predominant cell type 
identified was the portal myofibroblast, with few hepatic myofibroblasts observed. 
It has been postulated that the hepatic myofibroblasts are essential for matrix 
remodelling and fibrosis regression. 
Portal myofibroblasts can be identified by their expression of elastin and αSMA 
and lack of desmin [57]. In culture their activation was dependent upon two 
factors, matrix stiffness and TGFβ expression. When placed on a soft support 
matrix the cells remained quiescent however when this was changed to a stiff 
support matrix the cells subsequently activated [57]. This data fit with previous 
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research which has shown that during cholestasis the proliferating biliary 
epithelial cells release vast amounts of TGFβ2 [58] which stimulates the 
activation and proliferation of portal myofibroblasts to release TGFβ thus self 
perpetuating growth [23].  
1.2.4.3 Bone Marrow Derived Myofibroblasts 
Recent studies by Forbes et al [59] proposed that circulating cells may also play 
an essential role in fibrogenesis. When staining tissue biopsies from male 
transplant recipients who received donor female livers, they noted that a 
significant proportion of myofibroblasts in fibrotic areas were positive for the Y 
chromosome indicating these cells were of bone marrow (BM) origin.  
The contribution of the BM to the population of hepatic myofibroblasts was further 
investigated by Russo et al [60]. To do this, they depleted the BM from female 
mice and replaced it with BM from male mice. Following liver injury, the number 
of BM derived HSCs and myofibroblasts was markedly increased suggesting that 
these cells are actively recruited. Furthermore, during liver recovery, the number 
of BM-derived stellate cells fell noticeably signifying an intra-hepatic source of 
renewal. 
However the contribution of the bone marrow derived myofibroblasts in liver injury 
is still subject to debate. Bile duct ligation in mice transplanted bone marrow from 
collagen alpha1(I)-GFP+ reporter mice found that the bone marrow cells detected 
in the liver did not express αSMA and thus could not be defined as a 
myofibroblast [61]. The group propose that these cells represent a unique 
population of fibrocytes which are recruited to the liver following injury however 
their role in the fibrogenic process is unknown. 
1.2.4.4 Biliary Epithelial Cells 
Studies of fibrogenesis in other organs, for example the kidney, has shown 
convincing evidence that the predominant source of fibroblasts are from the 
epithelia themselves, by undergoing a process called epithelial to mesenchymal 
transition (EMT) [62, 63] which could be detected by staining with anti-S100A4 
antibody (fibroblast specific protein 1), an early marker of the EMT process [64, 
65].  
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The presence of this marker has also been confirmed in diseased liver sections in 
small duct cells and ductular proliferation [66, 67] and is typically associated with 
expression of epithelial cell markers, e.g. cytokeratin 19, down regulation of E-
cadherin and the nuclear localisation of the downstream TGFβ signalling 
molecules smad 2 and 3 [26, 67]. In vitro studies have found that the 
differentiation of biliary epithelial cells is enabled by the treatment of cells with 
TGFβ and regulated by expression of S100A4 [26]. Furthermore, EMT could be 
induced in 3D biliary structures in culture through chemokine mediated T cell 
infiltration, with close proximity observed between infiltrating TGFβ presenting T 
cells and the expression of mesenchymal markers by the cholangiocytes.  
1.2.5 The Inflammatory Response 
Hepatic fibrosis caused by persistent infection with hepatitis B and C viruses is 
characterised by large quantities of inflammatory cell infiltrate. The liver’s 
response to injury can be split into 3 distinct phases, initially inflammatory cells 
are recruited to the site to try and neutralise the damaging agents and remove 
necrotic material. This is closely followed by the activation of HSCs into hepatic 
myofibroblasts which secrete vast amounts of ECM to encapsulate the injury and 
provide a matrix for hepatocyte regeneration. Finally, if the inflammatory stimulus 
is removed, the matrix is remodelled and hepatocytes regenerate lost tissue by 
undergoing proliferation. The complex interactions between the immune 
mediated response and the resident liver cells are known to play an essential role 
in determining the outcome of liver injury, whether it leads to fibrosis or 
regression. For example, animals lacking macrophages or the T/B cell response 
have been shown to have reduced fibrotic responses [68]. 
The understanding of HSC biology has led to suggestions that HSCs play an 
essential role in the recruitment and modulation of the inflammatory response. 
HSC activation, by hepatocyte necrosis or apoptosis for example, stimulates the 
secretion of a vast array of chemoattractants and chemokines such as platelet 
activating factor [69] and MCP-1 [70]. A selection of these chemokines, along 
with those produced by hepatocytes, biliary epithelial cells and the sinusoidal 
endothelial cells themselves are presented on the surface of the sinusoidal cells 
to aid in the recruitment of leukocytes [68]. The chemokine gradient is also 
responsible for increasing the affinity of the adhesion molecules on the surface of 
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the sinusoidal endothelium for their target thus favouring the recruitment and 
infiltration of the inflammatory cells [71].  
Following infiltration of the inflammatory cells into the tissue, HSCs have been 
shown to be important in the presentation of antigen to the lymphocytes allowing 
them to directly modulate lymphocyte behaviour [72, 73]. Interestingly, recent 
research has demonstrated that immune cells are also capable of modulating 
HSC behaviour. Ingestion of disease associated lymphocytes leads to HSC 
activation [74] representing a novel pathway of fibrogenesis. Some confusion 
surrounds the function of NK cells during fibrosis with one research group 
showing that the NK cells perpetuate liver inflammation through TRAIL-mediated 
hepatocyte apoptosis during HBV infection [75]. However, two other research 
groups have demonstrated that NK cells had an anti fibrotic response through 
TRAIL-mediated apoptosis of hepatic myofibroblasts [76, 77]. 
Positioning of lymphocytes within the liver tissue is an issue which has only been 
recently investigated. Four weeks of CCl4 induced liver injury was associated with 
the infiltration of NK and CD8 T cells and to a lesser extent CD4 T cells [78]. 
Confocal microscopy revealed that the positioning of lymphocytes was in close 
proximity to hepatic myofibroblasts in the periportal area and fibrotic scar 
suggesting a direct interaction between the two cells types [78]. In vitro studies of 
hepatic myofibroblasts, freshly isolated from diseased and normal liver tissue 
revealed that both cell populations were capable of producing chemotactic factors 
provoking strong and rapid lymphocyte chemotaxis that could be enhanced 
following proinflammatory cytokine stimulation [79]. Migration was regulated by 
both chemokine dependent and independent mechanisms, particularly through 
HSC expression of ICAM-1 and VCAM-1 and secretion of VEGF, HGF and IL-6.  
Kupffer cells, which patrol the liver sinusoids and phagocytose foreign particles, 
respond to liver injury by the secretion of proinflammatory cytokines which 
promotes the expression of molecules involved in leukocyte adhesion. Their 
position in the sinusoids also aids in leukocyte trapping, forcing the cells to 
interact with the adhesion molecules expressed on the surface of the sinusoidal 
epithelium. Elegant experiments by Duffield et al [5] have indicated that there are 
two functionally distinct populations of macrophages which have opposing roles 
in liver injury and repair. The group demonstrated that during injury, 
macrophages are important in promoting myofibroblast proliferation thus 
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depletion during this time ameliorates fibrosis. However during fibrosis resolution, 
the predominant population of macrophages favour myofibroblast apoptosis with 
depletion resulting in the prevention of matrix degradation.  
 
1.3 Carbon tetrachloride induced liver fibrosis 
Animal models of disease are necessary for the advanced understanding of 
human disease. Currently, there are several well established animal models to 
study liver fibrosis, the most common of which is iterative toxic damage (e.g. CCl4 
intoxication) [80]. CCl4 is a hepatotoxin which elicits hepatocyte necrosis and 
steatosis of the liver and is used to study the effects of acute and chronic liver 
injury in animals [81].  
CCl4 is administered twice weekly, at a dose of 0.5-2ml/kg, by intraperitoneal 
injection since subcutaneous injection did not affect serum enzymes markers 
used to measure hepatotoxicity [82]. CCl4 is predominately metabolised by 
cytochrome P450 (CYP) 2E1, which is expressed by hepatocytes in the 
centrilobular region [83], since CYP2E1 knockout mice are resistant to CCl4 
induced injury [84]. Although CCl4 is dispersed throughout the whole body 
following injection, toxic effects are observed in the liver since metabolism is 
required for the production of the damaging agents [85]. Metabolism begins with 
the release of the trichloromethyl free radical CCl3* through reductive cleavage of 
a carbon-chloride bond [85]. Whilst this free radical is in itself reactive, it can also 
react with oxygen to form the more reactive trichloromethylperoxyl (CCl3O2*) 
which is more likely to extract hydrogen from polyunsaturated fatty acids initiating 
lipid peroxidation [85] resulting in cell membrane damage. Resulting liver damage 
is caused by the free radicals produced by CCl4 metabolism, which are 
summarised in figure 1-4. 
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Figure 1-4 Mechanism of CCl4 induced liver injury. Adapted from [85]. CCl4 is metabolised by 
P450, expressed by hepatocytes in centrilobular regions of the liver, generating the free radical 
CCl3*. CCl3* can covalently bind nucleic acids, protein or lipids causing numerous downstream 
effects, one of which is the activation of non parenchymal cells e.g. kupffer cells of myofibroblasts 
that stimulates the release inflammatory cytokines and an inflammatory response. If oxygen is 
present, the highly reactive free radical CCl3O2* is produced which removes H+ from unsaturated 
fatty acids resulting in membrane dysfunction and the production of reactive aldehydes which 
inhibit enzymes, damage DNA and block lipoprotein secretion. They also stimulate the activation 
of enzymes that lead to hepatocyte cell death. Together, all processes result in hepatotoxic 
damage, fibrosis and ultimately cirrhosis if the injurious stimulus is not removed.  
 
CCl3* exerts it effects through covalently reacting with biological substances, e.g. 
nucleic acids, protein and lipids, and altering their activity. For example CCl4 
metabolism is associated with a reduction in protein synthesis due to 
hypomethylation of ribosomal RNA [86] and steatosis due to the inhibition and/or 
blockage of lipoprotein secretion from hepatocytes into the circulation [87] 
possibly due to functional  impairment of the Golgi apparatus [88].  
Lipid peroxidation, initiated by CCl3O2*, results in the release of carbonyl 
compounds, termed reactive aldehydes, that cause toxic damage to cells through 
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enzyme inhibition, DNA damage [89] and the blockade of lipoprotein secretion 
[85]. Furthermore, cellular membranes are disrupted due to extraction of H+ by 
the free radicals. When coupled with the loss of calcium homeostasis, due to 
CCl4 mediated inhibition of calcium pumps [90], the surge in intracellular calcium 
concentrations activates catabolic enzymes and destroys cytoskeletal structures 
resulting in cell death via necrosis [85].  
1.4 Resolution of Fibrosis 
To date, the majority of anti-fibrotic therapies available for patients deal with the 
aetiological agent itself rather than the disease mechanism. For some types of 
liver injury, for example the removal of excess copper or iron in the genetic 
conditions Wilson’s disease and haemachromatosis, or the abstinence from 
alcohol, this approach is highly effective. For other conditions, the drugs currently 
available may prevent or slow the progression of fibrosis, for example 
immunosuppressive drugs are commonly used to treat autoimmune hepatitis. 
However, for diseases where the underlying cause is not known, it is important 
that other therapeutic targets are identified which do not necessarily cure fibrosis 
completely but prevent the progression to cirrhosis and ultimately liver failure. 
Currently, the only effective method for liver fibrosis is transplantation yet the 
majority of patients with liver failure will die whilst waiting for a transplant due to 
the shortage of donors available. The continued understanding of the fibrogenic 
mechanisms has led to speculation that fibrosis is reversible [36, 91] and the 
development of drugs which target the fibrogenic mediators. Whilst no drugs 
have yet been deemed suitable for human use, it has been agreed that the ideal 
drug should be easy to administer, with few adverse side effects, high liver 
specificity and promote the resorption of the interstitial ECM generated by the 
hepatic myofibroblasts.  
Several current targeted therapies have been against the signalling pathway for 
the profibrogenic cytokine TGFβ through use of soluble TGFβ type II receptor 
[92], neutralising antibodies or molecules which interfere with the downstream 
signalling pathway e.g. Smads [93]. Whilst this provides a novel therapeutic 
target, TGFβ is a complex cytokine involved in many biological process thus 
inhibition may result in uncontrolled inflammation, prevent epithelial differentiation 
and apoptosis [93]. Other targets include TIMP-1 and the integrin α5β6 
expressed by cholangiocytes which tethers latent TGFβ1 [93-95]. 
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1.4.1 Targeting Myofibroblasts 
In vitro studies have been essential in determining the role of hepatic 
myofibroblasts in the initiation, progression and termination of liver injury.  
Saile et al [96] isolated HSCs from rats to examine mechanisms for terminating 
uncontrolled proliferation. They noted that culture on plastic resulted in the 
activation of some HSCs into hepatic myofibroblasts but more importantly 
activation resulted in the increased expression of CD95 and CD95L allowing the 
cells to undergo spontaneous cell death which could be blocked by incubation 
with CD95 blocking antibodies. Studies using an immortalised hepatic 
myofibroblast cell line, LX-2, have shown that progressive cellular activation was 
also associated with an increase in TRAIL receptor expression, particularly 
TRAIL-R2/DR5 which was unique to hepatic myofibroblasts, increasing 
susceptibility to TRAIL-mediated apoptosis and representing a potential target in 
the regulation of HSC activation [97].  
More importantly, however, in vitro studies have revealed that cytokines present 
in the cell microenvironment may influence the outcome of liver injury. 
Spontaneous apoptosis of rat hepatic myofibroblast in culture could be prevented 
through addition of TGFβ, and to a lesser effect TNFα, to the culture medium and 
was associated with down regulation of CD95L [98]. Furthermore, the anti-
apoptotic effect of these cytokines was associated with inhibition of proliferation 
characterised by G1 cell cycle arrest [98]. Conversely, the presence of IFNγ in the 
microenvironment could stimulate apoptosis of hepatic myofibroblasts [99] 
suggesting that in vivo the lifespan of these cells and thus the course of fibrosis 
was directly related to cytokine signalling.  
In vivo translation work by Iredale et al  [100] investigated the cellular 
mechanisms during the spontaneous resolution of CCl4 induced liver fibrosis in 
rats. Rats were subjected to twice weekly injections of CCl4 for a period of four 
weeks, following this they were sacrificed at four different time points after 
receiving the final dose. Immunohistochemical staining of liver sections from all 
four time points showed a 12 fold reduction in αSMA positive cells in sections 
from the 28 day time point. In conjunction with this, dual immunostaining found 
that TUNEL positive nuclei were within αSMA positive cells suggesting that the 
hepatic myofibroblasts were undergoing apoptosis. Similarly, a 5 fold decrease in 
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hepatic myofibroblasts (as determined by αSMA staining) was associated with 
the progressive resolution of biliary fibrosis following bile duct ligation and 
subsequent bilio-jejunal anastomosis after 21 days [101]. Both studies support 
the concept that apoptosis of hepatic myofibroblasts regulates fibrosis resolution.  
Proof of concept studies by Wright et al [102] showed that the addition of 
gliotoxin, a fungal toxin, to rat and human hepatic myofibroblasts (characterised 
by the expression of αSMA) resulted in the cells undergoing apoptosis. 
Furthermore, administration of gliotoxin to rats with CCl4 induced fibrosis, resulted 
in a 57% reduction of hepatic myofibroblasts in a recovery model. Gliotoxin is 
thought to work by inhibiting the degradation of NF-κB super-repressor IκBα [103, 
104], however it has also been suggested that it can work via a mitochondrial 
dependent pathway through interactions with the adenine nucleotide transporter 
(ANT) [105].  
Oakley et al [106] set about to prove that NF-κB signal transduction was the 
major pathway involved in hepatic myofibroblast activation. They found that rats, 
which were administered sulfasalazine following CCl4 induced liver damage, had 
a reduced fibrosis pathology score as well as a significant dose dependent 
reduction in the number of hepatic  myofibroblasts.   
Whilst administration of gliotoxin significantly reduced the number of hepatic 
myofibroblasts in a recovery model of CCl4 induced liver fibrosis, its use as an 
anti fibrotic therapy is somewhat limited. Systemic administration of gliotoxin is 
known to be associated with immunosuppressive effects through induction of 
immune cell apoptosis [107, 108] as well as inducing non specific apoptosis of 
liver cells, e.g. kupffer cells, which are necessary for promoting liver regeneration 
[109]. To overcome this problem for a range of therapeutics, a vast amount of 
research is now focused on targeting therapeutics to hepatic myofibroblasts. In 
1999, Beljaar et al [110] identified that the expression of the mannose-6-
phosphate/insulin-like growth factor II (M6P/IGF-II) receptor increased on hepatic 
myofibroblasts during liver fibrosis [111] and developed a modified version of 
human serum albumin (HSA) with M6P to specifically target these cells. M6P-
HSA was conjugated to gliotoxin via an ester backbone to ensure efficient 
release following receptor mediated endocytosis and lysosomal degradation 
[112]. Gliotoxin-M6P-HSA administration at 6 days following bile duct ligation 
resulted in a significant decrease in the number of αSMA positive cells, similar to 
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gliotoxin treatment, however gliotoxin-M6P-HSA did not significantly affect other 
liver cell populations demonstrating that cell specific targeting of gliotoxin is a 
viable therapeutic option [112]. 
To overcome the limitations associated with the development of new anti fibrotic 
therapies a number of drug companies are trying to find novel applications for 
drugs currently in clinical practice; this is termed drug repositioning [93, 113]. At 
present, there are a few drugs in clinical use which may possibly be used as an 
anti-fibrotic therapeutic [114]. Relaxin, a hormone normally associated with 
pregnancy, has been shown to be able to reduce the deposition of interstitial 
collagen by hepatic myofibroblasts both in vitro and in vivo in a rat model of liver 
fibrosis [115]. The expression levels of peroxisome proliferator-activated receptor 
γ (PPARγ) have been shown to correlate with HSC activation with agonists 
reducing proliferation, collagen I gene expression and chemotaxis [116]. More 
importantly, these agonists are already in clinical use for the treatment of type 2 
diabetes and have shown great promise in the clinical trials treatment of NAFLD 
[117-119]. 
1.4.2 Synaptophysin & C1-3 
Synaptophysin, initially identified in 1985, is a transmembrane glycoprotein found 
on small electron-translucent (SET) vesicles [120] and is associated with 
neurotransmitter release and control of exocytosis [121]. Previous research has 
shown that this was only expressed on neural and neuroendocrine cell types 
[122], with the exception of rabbit thrombocytes [123]. However a series of 
immunohistochemical staining experiments carried out by Cassiman et al [124] 
demonstrated that synaptophysin was also a novel marker of quiescent and 
activated hepatic stellate cells.  
This unique marker was exploited by Elrick et al [125] in the generation of a 
monoclonal single chain antibody fragment which was specific for hepatic 
myofibroblasts. The group identified two peptide regions on the exoplasmic side 
of the synaptophysin protein (see Figure 1-5) and once synthesised, they could 
be used to isolate a phage antibody with specificity for either sequence. The 
result was a single chain antibody fragment with specificity to peptide 2 and was 
termed C1-3. A sequence of elegant studies to demonstrate functionality proved 
that the recombinant antibody was capable of binding to human hepatic 
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myofibroblasts in culture and upon the addition of peptide 2 to the culture, binding 
with C1-3 was competitively reduced in a dose dependent manner.  
 
Figure 1-5: taken from [125]. A diagram of the synaptophysin protein in hepatic 
myofibroblast membrane.  The transmembrane spanning glycoprotein has two extracellular 
domains. On these domains, two peptide sequences were identified and termed peptide 1 and 2. 
C1-3 binds to the peptide 2 region of synaptophysin with peptide 1 sequence being used as a 
negative control in ELISA. 
Analysis of the liver tissue containing C1-3-FITC found that the antibody 
specifically labelled hepatic myofibroblasts with no co-localisation with kupffer 
cells observed.  To target the apoptotic effects of gliotoxin the Wright group 
conjugated the fungal metabolite gliotoxin to C1-3. When injected into fibrotic 
mice, 60% of the hepatic myofibroblasts underwent apoptosis and fibrosis 
severity was significantly reduced in a sustained injury model [126].  
1.5 Liver Regeneration 
The ability of the liver to regenerate was recognised as far back as the ancient 
Greeks in the myth of Prometheus, who having stolen the secret of fire from the 
Gods of Olympus was condemned to having a portion of his liver eaten by an 
eagle. Overnight the liver regenerated providing Prometheus with eternal torture 
and the eagle with an eternal supply of food [127].  
Today, liver regeneration is investigated using a slightly modified method of the 
two thirds partial hepatectomy (PHx) model first proposed by Higgins and 
Anderson in 1931 [128]. This is a useful model as the tissue is removed ‘cleanly’ 
due to the multi-lobular structure of the liver allowing the remaining tissue to 
regenerate by processes mediating only to the liver tissue itself and not an 
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inflammatory response which may result from tissue necrosis. The process itself 
is relatively straight forward and can be accurately monitored.  
Liver regeneration is a complex process with many genes involved, the majority 
of which has been discovered using various knockout strains of mice. Unlike 
other organs, liver regeneration does not rely upon stem cells to restore tissue 
mass, instead the mature cells of the liver parenchyma are stimulated to enter the 
cell cycle and undergo DNA replication [129]. Work to date has shown that this is 
a highly synchronised event starting with the replication of the hepatocytes 
followed by biliary cells, kupffer and stellate cells and finally the sinusoidal 
epithelial cells [127]. 
The initial stimulus required to initiate the regenerative process is still debated. A 
recent paper by Tumanov et al [130] reported the importance of the adaptive 
immune system in liver regeneration. They demonstrated that mice deficient in T 
cells showed reduced capacity for liver regeneration, furthermore mice 
specifically deficient in T cell lymphotoxin had a decreased ability to initiate DNA 
synthesis following PHx and had increased liver injury.  
Following initiation, liver regeneration can be divided into three main stages: 
priming, proliferation and termination. Each is a carefully controlled event 
regulated by many cytokine, growth factor and metabolic pathways. Figure 1-6 
summarises the main pathways controlling liver regeneration. 
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Figure 1-6 Pathways contributing to liver regeneration. Adapted from [129, 131]. After partial 
hepatectomy kupffer cells and hepatic myofibroblasts are activated by soluble factors such as 
lipopolysaccharide (LPS), lymphotoxin and vascular endothelial growth factor. TNFα binds to its 
receptor TNFR1 on kupffer cells leading  to the activation of NFκB and the production of IL-6 and 
more TNFα. TNFα and IL-6 bind to their receptors on hepatocytes and stimulate the activation of 
STAT-3 by phosphorylation allowing it to translocate to the nucleus to transcribe a number of 
important genes, one of which is SOCS-3. SOCS-3 is an inhibitor of cytokine signalling through 
prevention of STAT-3 phosphorylation. Once primed, the hepatocytes are responsive to growth 
factors which promote their entry into the cell cycle. Proliferation can be inhibited by TGFβ and 
Activin A.   
 
1.5.1 Priming Phase 
Priming of liver regeneration begins in the first few hours following surgery and is 
thought to be mainly mediated by cytokine pathways. Research using neutralising 
antibodies and knockout strains of mice has implicated two main cytokines 
involved in this process, tumour necrosis factor alpha (TNFα) and interleukin 6 
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(IL-6) [132-136]. The network is initiated through the binding of TNF to its 
receptor, TNFR1, on non parenchymal cells (NPCs) in the liver (e.g. Kupffer 
cells) which leads to the activation of the NFκB pathway and the production of IL-
6 [129]. IL-6 subsequently binds to its receptor, IL-6R, on hepatocytes stimulating 
the phosphorylation of the STAT-3 transcription factor allowing it to translocate to 
the nucleus and transcribe a number of important genes [129]. STAT-3 also leads 
to the transcription of the gene suppressor of cytokine signalling-3 (SOCS-3), a 
suppressor of cytokine signalling responsible for the inhibition of STAT-3 
phosphorylation to prevent ongoing IL-6 signalling [137].  
The role of IL-6 is complex. Whilst it is widely accepted that the production of IL-6 
by kupffer cells and hepatic myofibroblasts [131, 138] is a critical event in the 
priming phase of liver regeneration, the consequences resulting from lack of IL-6 
are somewhat debated. Initial work by Cressman et al [132] reported that partial 
hepatectomy in IL-6 knockout mice resulted in severe liver necrosis and mortality. 
However, in those that survived, hepatocyte replication was severely impaired 
resulting in delayed regeneration in comparison to wild type mice by up to 5 days. 
When this was repeated by Sakamoto et al [139] they found that IL-6 knockout 
mice had a reduction in proliferating hepatocytes at 24hrs, determined by BrDU 
labelling, in comparison to controls however a higher percentage of BrDU positive 
hepatocytes were observed at 36, 48 and 60hrs following PHx in IL-6 knockout 
mice. More importantly this study resulted in less mortality with no liver necrosis 
or differences in liver injury test between the treatment groups.  
Work by Wuestefeld et al [140] attempted to clarify the role of IL-6 and its family 
members in liver regeneration using conditional glycoprotein 130 (gp130) 
knockout mice. Gp130 is a transmembrane protein forming one subunit of the 
type 1 receptor used in signal transduction by all IL-6 family members. Since 
gp130 knockout mice die in uteri or shortly after birth due to myocardial 
hypoplasia and haematopoiesis disorders [141], knockout mice were generated 
using the Cre/LoxP system. To do this gp130 loxP mice were crossed with Mx-
Cre mice resulting in approximately 50% of the gp130 litter receiving the Mx-Cre 
transgene. Cre recombinase, under the control of Mx promoter (Mx gene 
mediates resistance against influenza), was induced through injection of agents 
(e.g. polyinosinic-polycytidylic acid (pIpC)) that stimulate IFNα expression which 
in turn activate the promoter [142]. Ten days after gp130 depletion mice were 
25 
subjected to two thirds PHx and liver regeneration monitored. Mice lacking an 
inducible cre recombinase enzyme were used as controls. The group found that 
mice lacking gp130 had no STAT-3 DNA binding suggesting that activation was 
cytokine mediated. Furthermore, gene array analysis revealed basal and 
inducible expression levels of TNFRI and II were significantly reduced in the 
knockout mice suggesting that these receptors are under IL-6 control. Although 
DNA proliferation was markedly decreased in conditional gp130 knockout mice, 
gene array analysis demonstrated that IL-6 had no significant influence on cell 
cycle progression genes, thus liver regeneration was only delayed not inhibited 
by gp130 depletion.  
Whilst the conflicting data in the literature may reflect a lack of standardisation of 
experimental conditions in animal studies, a general consensus is that the liver 
has compensatory mechanisms available to overcome the loss of TNF and IL-6 
to allow regeneration to occur. 
There is also conflicting evidence surrounding the role of serotonin during the 
initiation of liver regeneration. Serotonin is both a neurotransmitter and a 
hormone [143] and is primarily found in the gastrointestinal tract, platelets and 
central nervous system.  
Lesurtel et al [144] subjected mice with reduced platelets (due to 
thrombocytopenia) or inhibited platelet activity (via administration of clopidogrel) 
to PHx. They found that both defects resulted in decreased liver regeneration 
with normal proliferation levels restored in the thrombocytopenic mice by the 
administration of a serotonin agonist. Additionally mice lacking tryptophan-
hydroxylase 1 (TPH1), an enzyme essential for the synthesis of peripheral 
serotonin, had a significant reduction in cellular proliferation following PHx which 
could be restored following injection of a serotonin precursor 5-HTP to reload 
their platelets. The authors proposed that the data provide evidence for the role 
of platelet derived serotonin in the initiation of liver regeneration. Papadimas et al 
[145] exerted a blockade on the serotonin receptor 2 through intraperitoneal 
injection of ketanserin at different doses and different time points. The group 
found that ketanserin only arrested liver regeneration when given at 16hr post 
PHx suggesting that serotonin was only essential close to the G1/S phase 
transition point and not involved in the initiation of liver regeneration.  
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Serotonin receptors have recently been identified on hepatic myofibroblasts with 
expression being induced upon activation [146]. Furthermore, hepatic 
myofibroblasts were shown to have a functional serotonin transporter as well as 
participate in active serotonin uptake and release [146]. The data suggest that 
hepatic myofibroblasts express key regulatory components of the serotonin 
system which may influence liver regeneration.  
1.5.2 Proliferative Phase 
The priming phase of liver regeneration corresponds with the passage of 
hepatocytes from their quiescent G0 state into the cell cycle G1 state. Without the 
priming phase the liver would be unable to respond to the growth factors thus 
inhibiting regeneration [147]. The literature to date implicates hepatocyte growth 
factor (HGF) and the ligands of the epidermal growth factor receptor (EGFR) as 
the main regulators of cellular proliferation following PHx. The ligands which bind 
EGFR are as follows: EGF, TGFα, heparin-binding EGF-like growth factor (HB-
EGF), amphiregulin, cripto, epiregulin and betacellulin [129, 148].  
Hepatocyte Growth Factor 
HGF, also known as scatter factor, is synthesised mainly by non parenchymal 
cells of the liver, e.g. hepatic myofibroblast [131, 138], and is secreted as an 
inactive single chain polypeptide which is activated through cleavage by either 
urokinase plasminogen activator (uPa) or HGF activator (HGFa) [149-151]. 
Studies using knockout mice have demonstrated that HGF and its receptor, c-
met, are essential for normal embryo development [152, 153] since mice lacking 
either gene have a much smaller liver characterised by extensive loss of 
parenchymal cells resulting in death in uteri. 
Following PHx, work by Lindroos et al [154] demonstrated an increase in serum 
levels of active HGF as early as one hour post hepatectomy. Further work by 
Schuppan et al [155] revealed that HGF was capable of binding to matrix 
proteins, in particularly collagens I, III, V, VI suggesting that the initial source of 
HGF post hepatectomy may be due to release from the matrix due to 
remodelling. Approximately three hours following PHx, synthesis of HGF begins 
by the non parenchymal cells of the liver, particularly the hepatic myofibroblast, 
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and proceeds for up to 24hrs following surgery [149, 156] allowing for efficient 
DNA replication.  
Further investigation of the HGF signalling pathway was done using a conditional 
c-met knockout mouse where the c-met gene is flanked by LoxP sites and can be 
removed upon induction of Cre recombinase. Huh et al [157] reported that loss of 
c-met did not appear to affect the hepatocytes under normal physiological 
conditions, however massive mortality resulted after PHx with the regenerating 
livers displaying vast areas of necrosis. Borowiak et al [158] also used the 
Cre/LoxP with a slightly modified protocol to that described by [157].The group 
monitored the expression of the cyclins by Western blot analysis to investigate 
hepatocyte proliferation and found that cyclin expression was significantly lower 
in c-met mutated mice suggesting that c-met signalling is necessary for cell cycle 
entry after PHx. The group also demonstrated persistently high levels of HGF and 
IL-6 in the serum of the mutant mice for many days following PHx indicating that 
the liver was trying to compensate for the lack of c-met signalling.  
The difference in animal protocols makes it difficult to interpret the results 
obtained through the Cre/LoxP removal of the c-met gene. In an attempt to 
overcome this, a group developed a method to silence either HGF or its receptor, 
c-met, through RNA interference [159]. siRNA/PEI complexes were injected into 
rats 24hrs prior to and at the time of PHx and the amount of suppression 
calculated using RT-PCR. C-met suppression resulted in the inhibition of 
hepatocyte proliferation for up to 24hrs following surgery in comparison to 90% 
proliferation observed in controls. This implies that c-met signalling is crucial in 
the initiation of hepatocyte proliferation and that the liver cannot compensate for 
its loss. The loss of the silencing plasmid after 24hrs correlates with the near 
normal levels of cellular proliferation in the mice. 
Epidermal Growth Factor 
Due to the multiple binding ligands for the EGFR, the associated signalling 
pathway is more complex than that of HGF. Work by Jones Jr. [160] found that 
removal of the salivary gland of rats prior to one third and two thirds PHx resulted 
in severe impairment of DNA replication in animals subjected to the two thirds 
PHx only. Even at 12 days post surgery the percentage liver weight remained at 
55% suggesting that the release of EGF from the salivary gland post 
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hepatectomy was essential for liver regeneration to begin. Normal levels of DNA 
synthesis could be achieved by a single dose of EGF into salivectomized rats 
prior to PHx surgery.  
Further work by Berasain et al [161] focused on the EGFR ligand amphiregulin  
and examined its gene expression in healthy and cirrhotic human and rat liver. 
RT-PCR revealed that amphiregulin mRNA was undetectable in healthy human 
livers and in rat/mouse livers prior to PHx. However following injury to the liver, 
either by cirrhosis or PHx, gene transcription of amphiregulin mRNA significantly 
increased. Amphiregulin knockout mice had severe reduction in cellular 
proliferation indicating that signalling is necessary in the early stages of liver 
regeneration and cannot be substituted by other EGFR ligands.  
In an attempt to investigate the EGFR signalling pathway itself instead of just the 
ligands, Paranjpe et al [162] designed two EGFR specific short hairpin silencing 
RNAs to inhibit EGFR expression in the rat liver. Suppression of the EGFR 
resulted in a significant decrease in cellular proliferation at 24hrs following PHx, 
as measured by mitotic indices and BrDU incorporation. However liver 
regeneration, as determined by liver weight, was seemingly unaffected with H&E 
stains revealing that sh-EGFR treated animals compensated for reduced 
proliferation through hepatocyte hypertrophy.  
Whilst siRNA silencing of genes has provided a useful insight into EGFR 
signalling and clearly results in suppression of both mRNA and protein levels of 
EGFR, it is important to interpret these results carefully. Firstly results may be cell 
specific as transfection efficiency depends upon cell type, with hepatocytes taking 
up the majority of the plasmid whilst endothelial cells are scarcely affected. 
Additionally, EGFR is also present in its phosphorylated form in the resting liver 
meaning that at the time of PHx EGFR signalling can occur.  
1.5.3 Termination 
Following PHx the liver grows back to its precise mass and does not exceed it 
with molecules such as TGFβ (produced by hepatic myofibroblasts [163]), IL-1β  
[164] and Activin A [165, 166] implicated in controlling the process although their 
exact mechanisms still remain elusive.  
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The importance of TGFβ was realised when addition of this molecule to 
hepatocytes in vitro resulted in the inhibition of cellular proliferation [167, 168]. 
This work was taken one step further in 1988 when a group isolated hepatocytes 
from normal resting liver and compared the mRNA levels of TGFβ from these 
cells to those isolated from rat livers under various stages of liver regeneration 
following PHx [169]. The data showed that there was a significant increase in 
TGFβ mRNA in cells isolated from the regenerating liver which peaked after the 
majority of hepatocyte proliferation had taken place. However TGFβ over 
expression in hepatocytes of transgenic mice led to high serum levels of TGFβ1 
causing multiple tissue lesions and glomerulonephritis but did not appear to affect 
liver regeneration [170].  
In an attempt to understand the precise mechanistic actions of TGFβ, Oe et al 
[171] selectively deleted the TGFβ type 2 receptor (tgfbr2) in hepatocytes by 
crossing floxed tgfbr2 mice with transgenic mice expressing Cre under the control 
of the albumin promoter. The group found that DNA synthesis peaked much 
earlier in the knockout mice in comparison to the controls and this was 
associated with an accelerated entry in the S phase of the cell cycle, as 
demonstrated by the early upregulation of cyclins D1 and E. However 
proliferation in the knockout mice halted when the correct liver mass had been 
reached suggesting that complete TGFβ signalling was not required for 
termination of liver regeneration. The authors propose that TGFβ is required to 
limit proliferation of hepatocytes by inhibiting the cells passing from G1 to S 
phase in the cell cycle. This agrees with previous work published by Russell et al 
[172] which found that intravenous administration of porcine TGFβ1 during PHx 
and at specified time points following surgery had reduced hepatocyte 
proliferation in a dose dependent manor however restoration of liver mass 
occurred as normal.  
Work using the knockout mice did reveal an upregulation in Activin A, a dimeric 
protein thought to be an autocrine growth inhibitor of hepatocytes, suggesting 
that the liver was trying to compensate for the loss of TGFβ. When the group 
administered follistatin, a glycoprotein known to bind and inhibit Activin signalling 
thus promoting continued liver regeneration [165, 166], to the tgfbr2 knockout 
mice they found a significant increase in cellular proliferation, as measured by 
BrDU incorporation, compared to their controls. Interestingly, the increase in 
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proliferation was not associated with an increase in liver weight in the knockout 
mice treated with the follistatin. Nevertheless, the experiments suggest that 
Activin A rather than TGFβ signalling is more important in the termination of liver 
regeneration. 
There is now growing evidence to suggest that termination of liver regeneration is 
controlled by the remodelling of the ECM. Many in vitro studies have 
demonstrated that the hepatocyte phenotype can be maintained for longer when 
cultured on a matrix similar to that present in the liver [173-176]. Groups that 
have investigated the changes in key ECM components following PHx found that 
between 3-7 days following surgery the decrease in cellular proliferation is 
associated with an increase in collagen synthesis [177, 178]. Unexpectedly, the 
study revealed a peak in TIMP-1 at the start of DNA synthesis [177]. This result 
can be explained by data published by Mohammed et al [179] who found that 
loss of TIMP-1 function in knockout mice resulted in accelerated hepatocyte cell 
cycle progression as demonstrated by the early expression of cyclin D1 and 
PCNA. Furthermore, this was associated with an increase in HGF/c-Met 
signalling suggesting that TIMP-1 is a novel regulator of cell cycle progression 
through its interactions with the HGF signalling pathway. 
The ECM not only provides a scaffold for cellular growth and proliferation. It is 
also a rich source of signalling for the cells it surrounds mediated via integrins 
[180]. Recent work investigating the role of integrin signalling revealed that 
elimination of this signalling pathway by hepatocyte targeted genetic ablation of 
integrin linked kinase resulted in mice born with livers twice the size of wild type 
controls and are characterised by increased proliferation of hepatocytes and 
biliary cells, disorderly hepatic plates and increased deposition of ECM [181]. 
When subjected to PHx they exhibit a 58% increase in liver mass compared to 
pre hepatectomy weight [182] suggesting a defect in the mechanism associated 
with the termination of liver regeneration. This defect was associated with an 
increase in HGF/c-Met, β-catenin and Hippo kinase signalling pathways.  
Whilst the literature alludes to possible mechanisms responsible for the 
termination of liver regeneration it is difficult to pinpoint an exact answer as there 
seems to be great redundancy within the pathways.  
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1.5.4 Model Limitations 
The two thirds PHx model adapted from the original 1931 model proposed by 
Higgins and Anderson [128] is useful in understanding the mechanisms involved 
in the regenerative process. Although the model has discovered many 
therapeutic targets which may enhance regeneration, the model does not include 
outside factors which may influence the regenerative process in the clinical 
human disease setting. For example the innate immune response or removal of 
necrotic material [180]. Whilst some may argue that the addition of these factors 
may complicate matters even further, it is important to provide a realistic 
environment in order to discover if any therapeutic targets discovered are actually 
of clinical use.  
1.6 Evaluation of Liver Fibrosis 
The understanding of the complex mechanisms which initiate and perpetuate 
liver fibrosis has led to the development of many potential therapeutic agents 
which specifically target and interfere with the process of fibrosis. The majority of 
these studies have been tested in animals but in order to test the efficacy in 
humans, new diagnostic tests are required to evaluate the severity of fibrosis 
throughout an organ. 
Currently the gold standard for the diagnosis of liver disease is histochemical 
analysis of a needle biopsy. Complications, such as prolonged hospital admission 
and mortality, are linked to the invasive procedure for 1:1000 to 1:10,000 [183, 
184] of patients and is the main reason why this technique is avoided where 
possible. 
Biopsies are typically stained with haematoxylin and eosin (although other stains 
may be used if required) and graded and staged by a pathologist. Ishtak et al 
[185] used tissue from chronic hepatitis patients to define it as the following: 
“Grading may be used to describe the intensity of necroinflammatory activity in 
chronic hepatitis. Staging, on the other hand, is a measure of fibrosis and 
architectural alteration, i.e. structural progression of the disease; these features 
are currently believed to be the consequence of the necroinflammatory process.” 
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Typically, numerical scores are given to both the staging and grading, in 
conjunction with written recordings, providing a semi-quantitative assessment of 
the histological features observed in the tissue. Various scoring systems have 
been developed for assessing liver tissue, these are METAVIR [186], Scheur 
[187] and Ishak [188]. However, the biopsy only represents 1/50,000 of the total 
liver mass [183] and is therefore associated with substantial sampling error, 
especially in patients with diffuse parenchymal liver disease [189]. 
Analysis of 124 patients with chronic HCV by Regev et al [189] found that in 
33.1% of patients a difference of at least one stage was observed between 
biopsies taken from the left and right lobe of the liver. More importantly in 14.5% 
of the cohort the pathologists diagnosed stage 3 disease in one biopsy and 
cirrhosis in the other showing that sampling error may mean that the severity of 
the disease is under-diagnosed. However, the costs associated with multiple 
biopsies as well as the increased risks favour the use of other non invasive 
diagnostic tests.  
Currently, serum biochemistry is used to measure the extent of liver damage. 
These are classified as: 
(i) Hepatocellular leakage enzymes: Following injury or alteration in 
membrane permeability to the hepatocyte, enzymes ‘leak out’ into the 
peripheral blood where they can be measured [190]. The two most 
commonly measured are alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST). 
(ii) Cholestatic-induction parameters: Alkaline phosphatase (ALP) and 
gamma-glutamyltransferase (γGT) are enzymes of hepatobiliary origin 
and are induced during cholestasis due to impaired bile flow [190]. Total 
serum bilirubin also increases during cholestasis due to regurgitation of 
conjugated bilirubin into the blood [190] or failure to excrete due to 
obstruction in the liver. 
(iii) Liver function parameters: Hepatobiliary function is evaluated by 
measuring markers such as albumin, which may suggest a decrease of 
liver synthetic capacity [190].   
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These markers are useful tools in assessing the extent and severity of liver 
damage, however serum markers are unable to distinguish between the early 
stages of fibrosis [191] thus many research groups are proposing other novel 
fibrosis markers. Afdal and Nunes (2004) [183] define the features of an ideal 
liver fibrosis marker as follows: 
(i) Liver specific 
(ii) Levels not influenced by alterations in liver, renal or reticuloendothelial 
functions 
(iii) Can measure the stage of fibrosis and the activity associated with matrix 
deposition and removal 
(iv) Easy to perform.  
To date many alternative markers of fibrosis have been suggested and typically 
include enzymes involved in matrix synthesis and degradation [192, 193], 
extracellular matrix glycoproteins and glycosaminoglycans [193, 194], products of 
collagen synthesis and degradation. These biomarkers can be subdivided into 
two categories, those which are pathophysiologically derived from ECM turnover 
and/or from components produced by the fibrogenic cells themselves (Class 1 
biomarkers) or markers which have been statistically proven to indirectly reflect 
fibrosis (Class 2 biomarkers) [195]. Biomarker combinations currently proposed 
are summarised in table 1-1. 
Index Parameters Theory Advantage Disadvantage Reference 
Indirect Serum Markers 
AST/ALT 
ratio 
ALT & AST 
serum enzyme 
concentration 
Enzymes 
released 
following 
hepatocellular 
injury. 
Ratio 
increases with 
fibrosis 
severity.  
Confounded by 
alcohol. 
Not capable of 
clearly 
distinguishing 
between 
stages of 
fibrosis. 
[190, 196-
199] 
AST/platelet 
ratio (APRI 
or Wai-
index) 
AST  
Platelet count 
AST released 
following 
hepatocellular 
injury.  
Worsening 
fibrosis 
associated 
with increase 
in platelet 
sequestration 
to the spleen. 
Differentiate 
between 
patients with 
and without 
significant 
fibrosis. 
Cannot 
different 
between 
fibrosis stages. 
[200, 201] 
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Index Parameters Theory Advantage Disadvantage Reference 
Fibrotest/ 
Fibrosure 
α2-globulin 
γ-globulin 
α2-
macroglobulin 
Apolipoprotein 
A1 
γGT 
Billirubin 
Age 
Gender 
Combines 6 
indirect 
markers of 
fibrosis with 
patient age & 
gender in an 
algorithm to 
generate a 
score which 
correlates with 
fibrosis. 
Can 
distinguish 
between mild, 
intermediate & 
significant 
fibrosis. 
Not reliable for 
HCV patients 
unless chronic 
disease. 
[202, 203] 
ActiTest 
As above 
(Fibrotest) but 
includes ALT 
Reflects 
fibrosis and 
necro-
inflammatory 
activity. 
Improves 
diagnosis of 
the later 
stages of 
fibrosis 
associated 
with 
inflammation & 
necrosis. 
Only validated 
in HCV 
patients. 
[204, 205] 
Forns Index 
Age 
Platelet Count 
Cholesterol 
γGT 
Define 
thresholds for 
individuals with 
low or high 
probability of 
significant 
fibrosis. 
Predicts no to 
low levels of 
fibrosis. 
Cannot detect 
severe fibrosis 
Influenced by 
medications. 
Staging can be 
affected by 
platelet 
variations. 
Only validated 
in HCV 
patients. 
[206] 
FibroIndex 
AST 
γGT 
Platelet Count 
Change in 
FibroIndex  
correlates with 
variation in 
fibrosis stage. 
Still being validated. 
 [207] 
FIB-4 
Platelet Count 
AST 
ALT 
Age 
Similar to 
fibrotest. 
Good at 
predicting 
advanced 
fibrosis. 
Similar 
accuracy to 
Fibrotest. 
Only validated 
in HCV 
patients with 
advanced 
disease. 
[208, 209] 
Hepascore 
Age 
Gender 
Bilirubin 
γGT 
Hyaluronan 
α2-
macroglobulin 
As fibrosis 
progresses α2-
macroglobulin, 
hyaluronan 
and bilirubin 
levels 
increase. 
Hyaluronan 
improves 
distinction 
between 
significant & 
advanced 
fibrosis & 
cirrhosis. 
Cannot 
distinguish 
between the 
early stages of 
fibrosis. 
[191, 210] 
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Index Parameters Theory Advantage Disadvantage Reference 
PGAA-Index 
Prothrombin 
time 
γGT 
α2-
macroglobulin 
Apolipoprotein 
A1 
As fibrosis 
progresses α2-
macroglobulin 
levels increase 
and 
apolipoprotein 
A1 levels 
decrease. 
Useful for 
detecting liver 
damage in 
alcoholics. 
Can only 
detect 
cirrhosis. 
[211] 
Direct Serum Markers 
Enhanced 
Liver 
Fibrosis 
(ELF) Test 
Hyaluronic 
Acid 
Type III 
procollagen N 
terminal Pro-
peptide 
(PIIINP) 
TIMP-1 
 
Direct serum 
markers which 
reflect ECM 
turnover. 
Validated in 
alcoholic liver 
disease, 
NAFLD & HCV 
patients. 
 
Good at 
predicting 
clinical 
outcome of 
chronic liver 
disease. 
Sensitivity only 
allows 
distinction 
between no 
and significant 
fibrosis. 
[212, 213] 
ECM related 
enzymes 
e.g. 
Lysyloxidase 
Monoamine-
oxidase 
Collagen 
peptidase 
Levels of 
enzymes 
reflective of 
ECM turnover. 
Levels of 
collagen 
peptidase 
increase with 
increasing 
fibrosis. 
Levels do not 
reliably reflect 
matrix 
synthesis. 
[183, 214] 
Collagen 
Fragments 
e.g. Type I 
procollagen & 
PIIINP 
Serum mRNA 
and protein 
levels 
measured, 
reflective of 
collagen 
deposition. 
Increasing 
PIIINP 
correlates with 
amino-
transferase 
levels and 
degree of 
fibrosis. 
Limited clinical 
applicability in 
liver disease. 
Not suitable for 
chronic HCV 
patients . 
[183, 197, 
215, 216] 
MMPs & 
TIMPs 
e.g. MMP2 
TIMP1 
Levels of 
enzymes that 
regulate ECM 
accumulation 
& breakdown. 
TIMP1 
correlates with 
cirrhosis in 
explant tissue. 
MMP1 
correlates with 
liver 
inflammation. 
Limited clinical 
value when 
used in 
isolation. 
[183, 217] 
MFAP-4 
microfibril-
associated 
protein 4 
(MFAP-4) 
Ubiquitous 
protein 
involved in 
ECM turnover. 
Serum levels 
increase with 
progressive 
fibrosis. 
Only validated 
in HCV 
patients. 
[218] 
Hyaluronan Hyaluronan 
GAG secreted 
by hepatic 
myofibroblasts. 
Levels 
correlate with 
inflammation 
and fibrosis. 
Only validated 
in HCV 
patients. 
[189,192] 
36 
Index Parameters Theory Advantage Disadvantage Reference 
Cytokines 
e.g. TGF β 
CTGF 
 
Cytokines 
mediate 
fibrosis. 
TGFβ levels 
correlate with 
fibrosis 
severity in 
HCV patients. 
No correlation 
with amino-
transferases 
Only validated 
in HCV 
patients. 
[183, 197, 
219] 
Glycoprotein e.g. Laminin YKL-40  
Laminin 
synthesised by 
HSC 
YKL-40 novel 
glycoprotein 
associated 
with fibrosis. 
Laminin more 
effective than 
PIINP 
YKL-40 
expressed in 
fibrotic areas, 
more accurate 
than 
hyaluronan. 
Only validated 
in HCV and 
alcoholic liver 
disease 
patients. 
[197, 220] 
Table 1-1 Summary of biomarker combinations used in the diagnosis and monitoring of 
liver fibrosis. 
The class 1 biomarkers measure components directly related to fibrosis, however 
extreme caution is required when interpreting the results to ensure that the 
patient has no further underlying chronic fibrogenic diseases which may interfere 
with the test result since no marker is liver specific. Furthermore, the lack of 
assay standardisation, variations in patient populations, variation of marker being 
dependent upon the aetiology of liver disease [183] and high costs associated 
with the tests has prevented many of the biomarkers from being used in clinical 
situations. Of those which have reached clinical importance, hyaluronan has 
proved to be the most sensitive and specific [195]. Activation of quiescent HSC to 
hepatic myofibroblasts in culture is associated with an increase in hyaluronan 
[221]. This correlates with increasing hyaluronan levels in patients with hepatitis 
C induced liver fibrosis [194, 222] due to dysfunction of the sinusoidal epithelial 
cells resulting in reduced clearance from the blood.  
Class 2 biomarkers are typically used in multi-parameter combinations, which are 
selected by statistical models and mathematical algorithms, to aid in the detection 
and staging of fibrosis [195]. Although they typically measure factors indirectly 
related to fibrosis, these biomarkers satisfy the majority of diagnostic criteria and 
are being increasingly used in clinical practice. Of all the different indices listed 
above, the fibrotest and actitest hold the most promise and are commercially 
distributed by Biopredictive (Paris, France) and LabCorp (Burlington, USA). 
Furthermore, following an independent review, they have been recently approved 
by the French Health Authorities for first line assessment of fibrosis in HCV 
patients [223, 224].   
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However, further research is required to generate a fibrosis marker which meets 
all the criteria of an ideal marker (specified above) since the majority of 
biochemical and haematological tests, serum markers of connective tissue and 
the scoring systems described above fail to quantify the extent of fibrosis in 
approximately 50% of people [225]. Thus various imaging techniques have been 
proposed, described in table 1-2, which aim to overcome these problems.  
Technique Comments Advantage Disadvantage Reference 
Diffusion 
mediated MRI 
Measures the 
apparent diffusion 
coefficient (ADC) of 
water, a parameter 
that is dependent on 
the tissue structure. 
 
Fibrotic tissue 
has distorted 
architecture due 
to the deposition 
of extra ECM 
components. 
Thus a cirrhotic 
liver will have a 
lower ADC 
value. 
Only validated in 
chronic HCV 
patients. 
Difficult to 
distinguish early 
stages of fibrosis. 
[226] 
Ultrasonography 
Use Duplex Doppler 
ultrasonography to 
estimate the 
maximum velocity of 
blood in the hepatic 
artery and PV. This 
value is expressed 
as an A/P ratio. 
The A/P ratio is 
significantly 
higher in patients 
with liver 
cirrhosis 
compared to 
controls. 
Only diagnose late 
stages of fibrosis. 
[227] 
Transient 
Elastography 
Termed ‘Fibroscan’. 
Combination of 
ultrasound (5MHz) 
and low frequency 
(50Hz) elastic waves, 
propagation velocity 
directly related to 
elasticity. 
Liver stiffness 
directly reflects 
fibrosis. 
Reproducible 
Accurate at 
predicting 
significant 
fibrosis and 
cirrhosis. 
 
 
Cannot 
discriminate 
between 
intermediary 
fibrosis stages. 
False positive 
results in acute 
hepatitis & 
extrahepatic 
cholestasis. 
Unsuitable for 
obese patients or 
those with ascites.  
[224, 228-
230] 
Acoustic 
radiation force 
impulse imaging 
(ARFI) 
Mechanical 
excitation of tissue 
using short duration 
acoustic waves 
(~262μs) to generate 
shear wave 
propagation and 
tissue displacement. 
Quantify shear wave 
velocity 
Reproducible 
Already in 
clinical use for 
other diseases. 
Accurate at 
predicting severe 
fibrosis and 
cirrhosis. 
Not influenced 
by steatosis. 
Narrow range of 
results produced 
thus difficult to 
define fibrosis 
stage. 
Only preliminary 
results are 
currently available. 
Not tested on 
patients with 
ascites. 
[224, 231-
233] 
Table 1-2: Imaging techniques proposed to replace liver biopsy 
All the imaging techniques exploit the changes in liver architecture and provide a 
safe, non invasive and reproducible test for liver fibrosis. However, a major 
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limitation of these techniques is the failure to accurately distinguish between 
normal tissue and the early stages of fibrosis [197]. This is crucial in the early 
diagnosis of liver fibrosis for the implementation of therapeutic strategies as well 
as accurately monitoring disease progression. Whilst the Fibroscan holds the 
most promise the technique itself is also subject to some limitations. Its ability to 
distinguish between the early and intermediary stages is somewhat debated [197, 
232], furthermore it is associated with false positive results in patients with acute 
hepatitis, cholestasis and congestive heart failure, is unsuitable for patients who 
are obese or suffer from ascites and has mainly been validated in HCV patients.  
To date, no serum marker or imaging technique proposed can accurately 
distinguish between the stages of fibrosis meaning that the liver biopsy remains 
the gold standard.  These diagnostic techniques will be essential upon the 
implementation of anti fibrotic therapies to monitor alterations in the course of 
disease and the effectiveness of the therapeutic itself. In order to solve this 
problem, new imaging techniques or serum markers need to be developed or 
analysis of liver fibrosis needs to be diagnosed by a combination of different 
methods [234, 235]. For example the fibroscan is currently being used in 
conjunction with fibrotest [236], to maximise testing potential and improve the 
accuracy of fibrosis staging [183, 197]. Furthermore, the majority of tests 
proposed in tables 1-1 and 1-2 have only been validated in HCV patients thus 
further evaluations are required before they can be used as standardised 
screening tools. 
1.7 Specific Aims and Objectives 
For many years research has demonstrated that the hepatic myofibroblast has 
been responsible for the initiation and perpetuation of liver fibrosis [14, 101, 237]. 
Furthermore, proof of concept studies have shown that the apoptosis of these 
cells, by drugs such as gliotoxin and sulfasalazine results in the resolution of 
fibrosis and partial return of normal tissue architecture.  
However, there is emerging evidence that myofibroblasts may also play a 
significant role in angiogenesis and ECM remodelling during the resolution of 
fibrosis [237]. Thus, in order to design drugs capable of targeting the cells 
involved in fibrosis, it is essential to define the role of the myofibroblasts during 
liver fibrosis and resolution. More importantly, in order to evaluate the 
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effectiveness of the new therapeutics it is crucial that a safe, reproducible, 
accurate and non invasive diagnostic test is available. 
This project will utilise the C1-3 antibody to investigate the following: 
• Determine whether a quantifiable image of fibrosis can be obtained by 
using imaging agents conjugated to C1-3 
• Investigate the effect of myofibroblast depletion during sustained liver 
injury 
• Investigate the effect of myofibroblast depletion during liver regeneration 
following two thirds partial hepatectomy.  
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Chapter 2. Materials and Methods 
2.1 Materials 
All chemicals were purchased from Sigma-Aldrich (Dorset, UK) unless specified 
otherwise. 
2.2 C1-3 Production 
 All bacterial culture was performed using aseptic technique with care taken to 
prevent contamination. 
2.2.1 Bacterial Culture & Protein Expression for C1-3 
Escherichia coli XL-1 blue cells (Stratagene, Amsterdam, Holland) transfected 
with the PIMS147 C1-3 [125] plasmid were cultured in baffled flasks containing 
50ml sterilised Luria-Bertanni medium (10g/L Bacto-tryptone, 5g/L Bacto-yeast 
extract and 10g/L Sodium chloride, pH 7.0). Routinely glucose (1%) and 
antibiotics (Ampicillin 50μg/ml and Tetracycline 15μg/ml, Sigma) were added to 
ensure selection for transformed cells containing the plasmid. 
After overnight incubation at 37ºc, 250rpm in a shaking incubator, one percent of 
the primary culture was added to 1litre of sterilised TB medium (24g/l Bacto-yeast 
extract, 12g/l tryptone, 0.5% glycerol) containing phosphate salts (0.17M 
potassium phosphate monobasic, 0.72M potassium phosphate dibasic), 1% 
glucose and the antibiotics specified above. The culture was grown for a further 8 
hours at 37ºc, 250rpm. Following this the cells were pelleted by centrifugation at 
2800g for 15 minutes, re-suspended in 1 litre of fresh supplemented TB medium 
and cultured overnight at 25ºc.  
The following morning, the cells were pelleted by centrifugation as described 
previously, and resuspended in 1 litre of fresh TB medium containing phosphate 
salts, 1% glucose and ampicillin only. After one hour of culture at 25ºc, the cells 
were induced to produce the C1-3 antibody by the addition of 500μl of 0.5M IPTG 
(final concentration 0.5mM). The culture was left for a further 4 hours before 
being harvested by centrifugation at 6350g for 20 minutes. 
The pellets were resuspended in 100ml of osmotic shock solution (200mM Tris-
Hcl, 20% sucrose, 1mM EDTA pH7.5) with the addition of 50mg of lysozyme to 
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enzymatically and chemically lyse the cell walls of the bacteria. All solutions had 
to be ice-cold and the procedure carried out on ice to ensure efficient lysis. After 
15 minutes incubation, 100ml of 5mM magnesium sulphate was added and the 
solution left for a further 15 minutes. 
The cells were pelleted by centrifugation at 6350g for 30 minutes at 4ºc. The 
osmotic shock solution containing the recombinant antibody was sterile filtered 
through 0.45µm filters. 
2.3 Protein Isolation 
2.3.1 Preparation of Column  
The C1-3 was purified via the hexahistidine C-terminal tag tail using Ni2+ charged 
IMAC (immobilised metal ion affinity chromatography) fast flow sepharose resin 
(Amersham Biosciences). IMAC exploits the interaction between chelated 
transition metal ions and side chains of certain amino acids on proteins, e.g. 
histidine.  
Briefly, 2ml of nickel sepharose was removed from the stock solution and 
sedimented by centrifugation at 500g for 5 minutes. The ethanol was removed 
and sepharose resuspended in 5ml of distilled water. The centrifugation step was 
repeated and supernatant discarded. Finally, 5ml of binding buffer was added 
(10mM imidazole) and centrifugation repeated. The pellet was resuspended in 
5ml fresh binding buffer and was ready for purification. 
2.3.2 Protein Purification 
The prepared nickel sepharose (described above) was added to the osmotic 
shock solution and incubated overnight at 4ºc with gentle agitation. The following 
morning, the osmotic shock solution was allowed to pass through a disposable 
econo-pac chromatography column (Biorad, Hertfordshire, UK) twice, followed by 
a final wash of 5ml binding buffer to remove non-specifically bound proteins. This 
wash was saved for future analysis. The protein was eluted with 10x 1ml volumes 
of 400mM imidazole and dialysed in 10l PBS overnight to remove the presence of 
imidazole by diffusion.  
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2.4 Protein Quantification 
2.4.1  ELISA 
Enzyme linked immunosorbant assay (ELISA) is a sensitive immunoassay relying 
on the specific binding of a protein to an antibody or antigen. Two different 
varieties of ELISA have been used: a binding ELISA to determine ability of an 
antibody to bind to antigen, and secondly a capture ELISA to calculate antibody 
concentration.  
2.4.2 Peptide1/ 2-BSA conjugation 
Initially, conjugation of peptide 1 and 2 (peptide 1, ATDPENIIKEMPMC; peptide 
2, YPFRLHQVYFDAPSC) to BSA was carried out. Briefly 40mg of BSA 
(10mg/ml) was reacted with 1ml 24mM m-maleimido benzoyl-N-
hydroxysuccinimide ester (MBS) dissolved in dimethylformamide (DMF). After 30 
minutes of reacting, unreacted compounds were removed by PD-10 filtration. 
Following this, peptide 1 or 2 was dissolved in DMF and 10µmoles added to 
every 100-200nmoles of the BSA-MBS conjugate and left incubating at 4ºc 
overnight. Unreacted compounds were removed by PD-10 filtration. 
2.4.3 Binding Elisa 
Flat bottomed 96-well Immulon-4 microtitre plates (Dynex, Sussex UK) were 
coated with 2µg (100μl/well) of BSA, BSA-peptide1 or BSA-peptide2 and 
incubated for 2 hours at room temperature.  All steps were carried out on a rocker 
at 300rpm to ensure components evenly mixed. In between each incubation step, 
the plate was washed at least three times with PBS+0.05% (v/v) Tween (PBS-T). 
Non specific binding was blocked by incubating wells with 2% milk protein (w/v) in 
PBS at 4ºc overnight. 
Following washing, the C1-3 and human IgG samples were added to the plate. 
All samples were serially diluted, briefly 200μl was added to the first well, 100µl of 
which was subsequently removed and mixed with 100µl PBS and so on. The 
plate was incubated for one hour, washed and the secondary antibody added, 
goat anti human C kappa light chain-HRP (Sigma-1/1000 dilution). The antibody 
was diluted in 2% (w/v) Marvel/PBS. After one hour incubation, the well contents 
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were removed and washed five times with PBS-T. Bound antibody was detected 
using TMB tablets as described in 2.4.6. 
2.4.4 Capture ELISA 
Flat bottomed 96-well Immulon-4 microtitre plates were coated with 0.53µg/well 
of goat anti human Cκ Light Chain (bound and free, Sigma) for 2hours at room 
temperature. In between steps, the plate was washed with PBS-T as described 
previously. Non-specific binding was blocked by incubating wells overnight at 4ºc 
with 200µl/well of 2% w/v BSA in PBS.  
The following day C1-3 protein was diluted 1/10 and then serially diluted across 
the plate. IgG was prepared at a concentration of 1250ng/ml and serially diluted 
across the plate, finishing at a concentration of 0.610ng/ml. After 90 minutes 
incubation at room temperature, the plate was washed and secondary antibody 
added, HRP-conjugated goat anti human Cκ Light Chain (1/1000 dilution). Finally 
the plate was washed 5 times with PBS-T and ready for detection of bound 
antibody (2.4.6).  
2.4.5 Synaptophysin binding ELISA 
To determine if synaptophysin is a serum marker of fibrosis, serum samples from 
4/8/12wk CCl4 and olive oil control mice were diluted 1/10 in coating buffer (0.1M 
sodium carbonate, 0.1M sodium bicarbonate pH9.6) and serially diluted across 
the flat bottomed 96-well Immulon-4 microtitre plates. Plates were incubated for 2 
hours at room temperature. Plates were washed twice with PBS-T and blocked 
overnight with 5% w/v marvel/milk solution in PBS. After five washes with PBS-T, 
the plate was incubated with C1-3 (2μg/ml) or rabbit anti albumin (MP 
Biomedicals, USA (1.25μg/ml)) in 5% w/v marvel/milk solution in PBS for 1 hour 
at room temperature. The plates were washed 5 times with PBS-T and incubated 
with the appropriate secondary antibody, goat anti human Cκ light chain-HRP 
(1:1000) or goat anti rabbit-HRP (1:3000) in 2% w/v marvel/milk in PBS for a 
further 1 hour at room temperature. Finally the plate was washed five times with 
PBS-T and ready for detection (2.4.6). 
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2.4.6 Detection of bound antibody 
Bound antibody was detected by incubation with 3,3’,5,5’-Tetramethylbenzidine 
dihydrochloride monohydrate (TMB) tablets (Sigma). 1mg of TMB was dissolved 
in 10ml of 0.05M phosphate-citrate buffer pH5 with the addition of 2µl of 30% 
hydrogen peroxide. After 10 minutes, the reaction was stopped by the addition of  
50μl 2M H2SO4, turning the reaction product from blue to yellow. This colour was 
then analysed using a spectrophotometer at 450nm. 
2.5 Conjugation of C1-3 to other compounds 
2.5.1 Removal of Endotoxin  
Before conjugation could take place it was necessary to remove endotoxin from 
the C1-3 preparation using Q maxi H columns (Fisher Scientific, Loughborough, 
UK). Briefly, the columns were washed sequentially with 17ml of sterile water, 
17ml 0.5M sodium hydroxide, 3x17ml sterile water and 2x17ml PBS pH 7.4 by 
loading each solution into the device followed by centrifugation at 2000g for 5 
minutes.  
The antibody was loaded onto the column and centrifuged as above for ten 
minutes. The flow through, containing the antibody, was sterile filtered through a 
0.45μm filter and stored for downstream applications.  
2.5.2 Conjugation to Alexa Fluorophore 594 
Conjugation of C1-3 and CSBD9 (control scAb) [126, 238] to alexa fluorophore 
594 was carried out using a kit from Molecular Probes (A-10239, Invitrogen, 
Paisley, UK). Absorption and emission of this fluorophore peak at approximately 
590nm and 617nm, respectively. 
Briefly, 50μl of 1M sodium bicarbonate buffer, pH8, was added to 0.5ml of the 
C1-3 antibody (2mg/ml) to increase the pH. This mixture was added to one vial of 
fluorophore and incubated on a magnetic stirrer for 2 hours.  Following this, 
unconjugated fluorophore was removed via gel filtration through sepharose. To 
determine if conjugation was successful the samples were run on an SDS-PAGE 
gel. 
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2.5.3 Conjugation to FITC 
Fluorescein isothiocyanate (FITC) powder, purchased from Thermo Scientific 
(Loughborough, UK), was prepared at a concentration of 10mg/ml in DMF. The 
reaction, which involved the isothiocyanate groups reacting with the free amine 
groups on C1-3, must be performed in an amine free buffer and is most effective 
at pH 8-9. Thus, PD-10 columns (GE Healthcare, Buckinghamshire, UK) were 
equilibrated with 50mM borate buffer pH 8.5 and used for buffer exchange by 
adding 2.5ml of C1-3 in PBS to the column and centrifuging at 1000g for 2 
minutes. A 20 fold molar excess of FITC was added to the C1-3, in the 
conjugation buffer, and incubated at room temperature for 1 hour with occasional 
mixing. Unconjugated fluorophore was removed via PD-10 (GE Healthcare) 
columns equilibrated with PBS and centrifuged as before.  
2.5.4 Conjugation to Gliotoxin  
The conjugation process is based on [239] and outlined in Figure 2-1. All 
products used for the reaction were free from endotoxin. 
750nmole of endotoxin free C1-3 was reacted with 22μmole of S-acetyl 
thioglycolic acid N-hydroxysuccinimide (SATA) and 1mM EDTA for 1 hour. 
Unreacted SATA was removed by PD-10 gel filtration. Following this, reactive 
sulphydral groups in the C1-3-SATA were exposed (deblocked) by incubation 
with 460μmole hydroxylamine for 1 hour. 
12μmoles of gliotoxin, prepared as a 2mg/ml stock in DMSO, was activated 
through available hydroxyl groups by reaction with 60μmole of N-p-
maleimidophenyl isocyanate (PMPI, ratio of 1:5). 
After one hour of reacting, 12μmole of gliotoxin-PMPI was added to 600nmole of 
C1-3-SATA-deblocked and incubated for a further 2 hours. Unreacted 
compounds were removed by PD-10 gel filtration.  
The C1-3-gliotoxin was aliquoted and stored at -20ºc. 
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Figure 2-1. Taken from [126] a schematic diagram illustrating the reactions involved in 
conjugating C1-3 to gliotoxin. Primary amine groups on C1-3 were thiolated by the addition of 
SATA. After a 1 hour incubation, excess SATA was removed by PD-10 filtration. C1-3-SATA 
conjugates were de-blocked in the presence of hydroxylamine for 1 hour. Whilst incubating, 
gliotoxin was conjugated by reaction with PMPI for 1hr. Once complete, gliotoxin-PMPI was 
reacted with the deblocked C1-3-SATA for a further 3 hours with excess compounds removed via 
PD-10 filtration.  
2.6 Protein Isolation and Analysis 
2.6.1 Preparation of whole cell extracts 
Medium was aspirated from the well and cells washed twice with 1xPBS. After 
washing, cells were scraped directly into either 100μl of reducing loading buffer 
(62.5mM Tris Buffer pH 6.8, 10% v/v glycerol, 2% w/v SDS, 100mM DL-
Dithiothreitol (DTT) and 0.02% w/v bromophenol blue) or 500μl of 1xPBS (per 
well of a 24 well plate).  The PBS/cell suspension was transferred to a sterile 
eppendorf and centrifuged at 3000g for 15 minutes.  The supernatant was then 
carefully removed and the cell pellet resuspended in a known volume of 20mM 
Tris pH 7.4. 5μl of the sample was removed and used for the determination of 
protein concentration via the Lowry method (2.6.4). Samples were frozen and 
stored short term at -20°C or long term at -80°C. 
47 
2.6.2 Preparation of whole tissue samples 
Tissue samples were removed from mice and snap frozen in liquid nitrogen. 
Samples were weighed and homogenised in 20% w/v TKMS buffer (50mM Tris, 
25mM potassium chloride, 5mM magnesium chloride and 250mM sucrose 
pH7.4). 5μl of the sample was removed and used for the determination of protein 
concentration via a Lowry assay (2.6.4). Samples were frozen and stored short 
term at -20°C or long term at -80°C. 
2.6.3 Preparation of bacterial lysates and scAb samples 
Osmotic shock solution for SDS-PAGE analysis was filtered through a 0.2μm 
filter to remove contaminating bacterial DNA. Samples were diluted 1:5 with 
reducing loading buffer. 
Unless specified otherwise, scAb samples for SDS-PAGE analysis were diluted 
1:1 with reducing loading buffer. Samples were frozen and stored short term at -
20°Cor long term at -80°C. 
2.6.4 Lowry Assay 
Protein concentration was determined by using a modified version of the Lowry 
assay described in 1951 [240]. It relies on the principle that under alkaline 
conditions copper complexes with protein and upon the addition and binding of 
Folin-phenol reagent, the complex is reduced and a blue colouration formed.  
Buffer ABC was prepared immediately prior to use and was composed of Lowry 
A (2% w/v Na2CO3 /4% w/v NaOH), B (2% w/v sodium tartrate) and C (1% w/v 
copper sulphate) mixed at a ratio of 100:1:1 (v:v:v).  
Bovine serum albumin (BSA) standards were prepared ranging from 0-20μg/μl 
from a 20mg/ml (20μg/μl) stock of BSA diluted in dH2O. 5μl of each standard or 
sample was aliquoted into an eppendorf, diluted with 50μl of dH2O and 1ml buffer 
ABC and left for 10 minutes at room temperature before the addition of 100μl of 
Folins reagent (Fluca, Switzerland, diluted 1:1 with dH2O). Samples were 
incubated for a further 30 minutes at room temperature to allow colour 
development. Samples were then transferred into plastic cuvettes and 
absorbance at 750nm was determined spectro-photometrically. A calibration 
curve was plotted using the absorbence of standards. The equation of the line 
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was used to calculate the protein concentration of the unknown samples by 
measuring their absorbance and rearranging the equation of the straight line in 
terms of x. (y = mx + c where y represents the absorbance, m represents the 
gradient of the line and c represents intercept with the axis). 
2.6.5 SDS-PAGE 
The use of sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) to analyse proteins is based on the original method of Laemmli in 1970 
[241]. When using an electrical current to drive macro-molecules through a fixed 
pore size gel, three factors influence the rate of movement – size, charge and 
degree of folding. SDS is an anionic detergent that denatures proteins by binding 
to the polypeptide backbone. When used in conjunction with reducing agents 
such as DTT, it converts highly folded heterogeneously charged proteins to linear 
structures with negative charge that varies per unit length. Thus the proteins will 
now migrate through the gel, from negative to positive, according to size. Proteins 
are run alongside a marker of known molecular weight (Invitrogen) in order to 
allow an estimation of the molecular weight of a certain band. 
A separating gel (375mM Tris buffer pH8.8, 0.1% w/v SDS, 0.05% w/v 
ammonium persulphate (APS) and 0.05% v/v TEMED) containing either 7.5, 9 or 
12% acrylamide was cast between two plates set 1mm apart. The gel was 
covered with a thin layer of isopropanol to ensure a level interface. Once 
polymerisation had occurred, the isopropanol was removed and the gel washed 
with water. A 4% stacking gel (4% w/v acrylamide in 125mM Tris buffer pH 6.8, 
0.1% w/v SDS, 0.05% APS and 0.1% TEMED) was carefully poured on top and 
wells created using combs. 
The protein samples were heated to 90°C for approximately 5 minutes to ensure 
that all structure was removed and 10μl of sample (concentration dependent 
upon protein of interest, typically 10-20μg) loaded per well. The gels were placed 
in the tank with electrophoresis running buffer ((ERB) 20mM Tris, 160mM glycine 
and 0.08% w/v SDS, pH 8.3)  and were run at 100V initially, ensuring that the 
protein formed a linear band at the interface. Following this the voltage was 
increased to 150V and left until the dye had reached the bottom of the gel. 
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Once the dye front had reached the end of the separating gel, the gels were 
removed and either stained (2.6.6) or total protein was electro-transferred onto 
nitrocellulose membrane for immunodetection of specific proteins (2.6.7). 
2.6.6 Gel staining 
Gels were removed from the electrophoresis equipment and washed briefly in 
water. Following washing, the gel was stained with coomassie blue (0.5% w/v 
coomassie blue in 25% v/v isopropanol / 10% v/v acetic acid) for 1 hour and 
destained for a further 4-24 hours depending upon the number of washes. 
Destaining solution consists of 10% acetic acid and 10% methanol in deionised 
water. Coomassie blue weakly binds to histidine and arginine as well as aromatic 
amino acids via weak Van der Waals forces (physisorption).  
2.6.7 Western Blotting 
Following separation of the proteins according to size, it was necessary to 
transfer them onto a nitrocellulose membrane (Amersham) for analysis by 
Western blotting. The membrane was placed on top of the resolved gel and 
sandwiched between filter paper and scotchbrite pads in a cassette, all of which 
had been pre-soaked in transfer buffer for 5 minutes. This was then submerged 
in transfer buffer (0.025M Tris, 0.19M Glycine, 20% v/v methanol pH 8.3) and 
subjected to 100V for one hour. 
Once transferred, non specific binding sites were blocked by incubation with 3% 
marvel (w/v) dissolved in TBS (20mM Tris, 200mM sodium chloride pH7.4)+ 
0.05% tween 20 (v/v) for one hour at room temperature. The membranes were 
subsequently washed with TBS-T and incubated with the primary antibody, 
diluted in 0.3% marvel in TBS-T, for 1 hour at room temperature. The bound 
antibody was detected using species specific IgG secondary antibodies directly 
conjugated to HRP (Horse-radish peroxidase). This enzyme catalyses the 
oxidation of luminol, present in the ECL reagents (Amersham), resulting in the 
production of light which is detectable on hyperfilm (Amersham). Antibody 
dilutions in table 2-1. 
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Antibody Dilution 
Goat anti Human Cκ Light Chain-HRP 
(Sigma) 
1:1000 
Rabbit anti gliotoxin 1:3000 
Goat anti Rabbit-HRP (Dako) 1:3000 
Mouse anti actin (Millipore) 1:3000 
Goat anti Mouse-HRP (Dako) 1:3000 
Rabbit anti Synaptophysin (Chemicon) 1:1000 
Mouse anti Synaptophysin (Dako) 1:1000 
Table 2-1 Dilutions of primary and secondary antibodies used for Western blotting 
2.7 Cell Culture 
2.7.1 Isolation of Mouse Hepatic Myofibroblasts 
3-4 C57Bl6 mice were schedule 1 killed and the whole liver removed. Liver tissue 
was mashed through a sterile tea strainer with the addition of 140mg pronase 
(Roche, Hertfordshire, UK) and 2mg DNAse in 40ml of Hanks balanced salt 
solution (HBSS) [0.14M NaCl, 5.4mM KCl. 0.34mM Na2HPO4.7H20, 0.44mM 
KH2PO4, 5.6mM D-glucose and 15.7mM NaHCO3, pH7.4] containing 6mM sterile 
Hepes, 1mM CaCl2 and 0.035% (w/v) NaHCO3.  A further 10ml of HBSS+ 
supplemented with 25mg collagenase B (Roche) was added to the liver pureé 
and left at 37°Cto digest for 30 minutes. The cell suspension was filtered through 
sterile 125μm nylon mesh and centrifuged at 1100g for 7 minutes. Pellets were 
resuspended in 40ml fresh HBSS+ supplemented with 30mg pronase (Roche) 
and 2mg DNAse and incubated for a further 30 minutes at 37°C. The cell 
suspension was centrifuged as previously described and resuspended in 60ml 
HBSS+ and 13ml optiprep. This mixture was equally divided between two 50ml 
falcon tubes, carefully overlayed with a further 1ml HBSS+ per tube and 
subjected to density gradient centrifugation at 1400g for 20 minutes. The HSC 
rich upper phase was carefully removed and mixed with at least 1:2 HBSS+ and 
centrifuged for 7 minutes at 1100g. Pellets were resuspended in culture medium 
(Dulbecco’s modification of Eagle’s medium (DMEM) supplemented with 16% 
foetal calf serum (FCS) and 80U/ml penicillin/streptomycin) and seeded into 6 
well plates.   
2.7.2 Isolation of Human Hepatic Myofibroblasts 
Explant liver tissue, obtained with full ethical consent from patients undergoing 
partial hepatectomy (Freeman Hospital, Newcastle, UK), was perfused using a 
51 
continuous flow pump system through manual insertion of perfusion tubing into 
available vessels at the cut surface with calcium free HBSS containing 6mM 
Hepes and 0.035% (w/v) NaHCO3 to clear blood from the tissue. The tissue was 
then perfused with HBSS+ supplemented with 30mg collagenase B (Roche) and 
235mg Pronase until the tissue was pliable to touch. The tissue was then 
dispersed in 100ml HBSS+ containing 35mg pronase (Roche) and 2mg DNAse, 
filtered through sterile 125μm nylon mesh and centrifuged at 1100g for 7 minutes. 
Pellets were resuspended in fresh HBSS+ containing 1mg DNAse and re-pelleted 
as previously described and repeated a further two times. After the three washes, 
the pellets were resuspended in 60ml HBSS+, 1mg DNAse and 13ml optiprep, 
carefully overlayed with a further 1ml of HBSS+ and subjected to density gradient 
centrifugation at 1400g for 20 minutes. The HSC rich upper phase was carefully 
removed and mixed with at least 1:2 HBSS+ and centrifuged for 7 minutes at 
1100g. Pellets were resuspended in culture medium (DMEM supplemented with 
16% foetal calf serum (FCS) and 80U/ml penicillin/streptomycin) and seeded into 
6 well plates 
2.7.3 Maintenance of Cells 
Cos 7 cells were routinely maintained at 37°C in a humidified atmosphere of 95% 
air and 5% CO2 in 75cm2 plastic culture vessels. Cells were cultured in DMEM 
containing 1g/l of glucose supplemented with 10% (v/v) FCS, 80U/ml penicillin 
and 80U/ml streptomycin. Human and mouse hepatic myofibroblasts were 
cultured in DMEM containing 4.5g/l of glucose supplemented with 16% (v/v) FCS, 
80U/ml penicillin and 80U/ml streptomycin. Culture medium was changed every 
2-3 days. 
2.7.4 Passage of Cells 
All cells were anchorage dependent and grown as a monolayer until 80-100% 
confluence and then passaged. Medium was aspirated from the cells and washed 
once in 1xPBS (4mls per 75cm2 flask) to remove any remaining medium. Cells 
were detached by incubation with 1xTrypsin-EDTA diluted in 1xPBS for Cos 7 
cells or 5xTrypsin-EDTA for hepatic myofibroblasts (4ml per 75cm2 flask) in the 
conditions described in 2.7.3 for 10 minutes. Gentle tapping of the culture vessel 
encouraged detachment of cells. Following detachment, 4ml of fresh media was 
added to the trypsin to inhibit its activity and the suspension transferred to a 50ml 
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falcon tube for centrifugation at 1000g for 3 minutes. The supernatant was 
discarded and the pellet resuspended in appropriate fresh culture medium. Cells 
were then seeded accordingly for cell maintenance or experimental protocol as 
detailed throughout.  
2.7.5 Cell Storage 
Cell stocks for all cell lines were routinely frozen down and stored in liquid 
nitrogen for long-term storage. Cells were detached and pelleted as previously 
described in 2.7.4 and resuspended in 90% FCS + 10% DMSO, typically 2ml per 
pellet harvested from a confluent 75cm2 flask. The suspension was aliquoted into 
sterile cryovials (1ml per cyrovial) and placed in an isopropanol filled cooling aid 
(Mr Frosty™, Nalgene) and left in the -80°C freezer overnight. Cells were cooled 
at a rate of approximately 1°C per hour and then transferred to liquid nitrogen for 
long-term storage. 
2.7.6 Revival of cells stocks 
Cells were removed from liquid nitrogen and rapidly thawed at 37°C, transferred 
to a 50ml falcon tube and re-suspended in 10ml of fresh warmed medium. The 
cell suspension was then centrifuged for 4 minutes at 500g and the supernatant 
was discarded. The pelleted cells were then resuspended in 10ml of fresh 
medium, added to a 25cm2 flask and allowed to attach overnight. Once 
confluence was reached cells were subcultured as previously described and 
transferred to a 75cm2 flask. 
2.7.7 Assessment of cell viability and number 
Cell viability was determined using trypan blue exclusion. Freshly isolated cells 
were resuspended in 10ml fresh medium, a 100μl aliquot of this was added to 
200μl fresh medium and 100μl 0.4% trypan blue solution (Gibco). 10μl of the cell 
suspension was added to an Improved Neubauer Haemocytometer and viable 
and non-viable cells counted. Viable cells have an intact membrane and are able 
to exclude the dye whereas non-viable cells take up the dye and are blue. Total 
cell number and the number of non-viable cells in a known volume of cell 
suspension were calculated and used to determine the percentage viability of the 
freshly isolated cells along with the total cell number. 
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2.7.8 C1-3 uptake  
The ability of C1-3 to bind to its target receptor synaptophysin was assessed by 
the incubation of the antibody with mouse hepatic myofibroblasts. Cells were 
detached as described in 2.7.4 and total cell number determined as described 
above. Cells were resuspended to a density of 1.33*105/ml and seeded in a fresh 
well (1.5ml/well of a 6 well plate). Cells were incubated overnight under standard 
conditions (37°Cin a humidified atmosphere of 95% air and 5% CO2.) The 
following day the medium was aspirated and cells washed in 1xPBS. A specified 
concentration of C1-3 antibody was added to the total medium required for all 
wells and once mixed the medium was distributed evenly between the wells. 
Once incubation was complete, the medium was removed and cells gently 
washed in 1xPBS. Cells were directly harvested into 100μl/well reducing loading 
buffer ready for Western blot analysis. 
2.7.9 In vitro assessment of gliotoxin activity 
Mouse hepatic myofibroblasts, between passages 1-4, were seeded into 24 well 
plates at a density of 0.5x105 per well and left for 24 hours to adhere and 
proliferate. Following this, C1-3 (4.5μg/ml), C1-3-GT (4.5μg/ml), free gliotoxin in 
DMSO (1.5μM) and DMSO were added to the cells in 300μl serum-free media 
and treated for 24 hours. Adherent cells, as a measure of cell viability, were 
counted from 5 random fields of view before the addition of treatment and 
subsequently at 1, 2, 4, 6 and 24 hours. Cell viability is expressed as a 
percentage of remaining adherent cells relative to time zero. All experiments 
performed in triplicate.  
2.7.10   Cell transfection 
Cells were transfected essentially as detailed in the manufacturer’s protocol and 
cultured under standard conditions (37°C in a humidified atmosphere of 95% air 
and 5% CO2).   
Briefly, cos-7 cells were resuspended at a density of 1.5*105/ml and seeded in 6 
well plates (1.5ml/well of a 6 well plate). Cells were left for 24 hours to adhere to 
culture plate before transfection. Genejuice transfection reagent (Merck, 
Nottingham, UK) was added to 100μl of serum free media in a sterile eppendorf 
at a ratio of 3μl Genejuice to 1μg plasmid DNA and incubated at room 
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temperature for 5 minutes. Plasmid DNA was added to the mixture and left to 
incubate for a further 15 minutes at room temperature. The entire volume of 
transfection medium was added drop wise to the cells in 1.5ml of complete 
medium and gently rocked to ensure even distribution. 
2.7.11 Assessment of transfection efficiency  
To assess transfection efficiency, cells were transfected as outlined in 2.7.9 with 
different concentrations of the eGFP (pEGF-N1, Stratagene) reporter construct 
for 24 hours. The number of positive cells were counted and expressed as a 
percentage of the total number of cells per field of view. 
2.8 Plasmid DNA constructs 
2.8.1 Synaptophysin constructs 
Mouse and human synaptophysin plasmids were purchased from Invitrogen 
(Paisley, UK). The sequences were transferred from the ORF prokaryote vector 
to the pTREX-DEST30 vector (Invitrogen) via site specific recombination 
mediated by LR Clonase II enzyme (Invitrogen) as outlined in the manufacturer’s 
protocol. Briefly, 150ng of the entry clone (3μl) and destination vector (1μl) were 
incubated with 4μl  TE buffer (10mM Tris, 1mM EDTA, pH 8 with HCl) and 2μl LR 
Clonase II for 1 hour at 25°C. The reaction was terminated by the addition of 
40μg of proteinase K and incubating the samples at 37°C for 10 minutes. 
Successful recombination was confirmed via PCR using synaptophysin US and 
DS 2,3 and 4 primers detailed in table 2-5. 
2.8.2 TOPO Cloning of Blunt-End PCR Products 
To confirm PCR results, PCR products were routinely cloned into the PCR®-Blunt 
TOPO® vector (Invitrogen) according to the manufacturer’s instructions. In brief, 
25ng (1μl) of PCR®-Blunt was added to 100ng (5μl) of blunt PCR product, 1μl 10x 
ligation buffer (60mM Tris-HCl pH 75, 60mM MgCl2, 50mM NaCl, 1mg/ml BSA, 
70mM β-mercaptoethanol, 1mM ATP, 20mM dithiothreitol and 10mM 
spermidine), 2μl sterile H2O and 1μl (4 Units) of T4 DNA ligase. For control 
reactions, the PCR product was replaced with 5μl sterile water. All reactions were 
incubated at 16°C for 1 hour. 2μl of the ligation reaction was transformed into 
TOP10 competent cells, as detailed in 2.8.3, and selected for kanamycin 
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resistance (50μg/ml). Plasmids were isolated by miniprep (2.8.5) and subjected to 
EcoRI restriction digest (2μl plasmid DNA, 1μl BSA 1mg/ml, 2μl buffer H, 4μl 
sterile H2O and 1μl (12 Units) EcoRI) for 1 hour at 37°C to confirm PCR product 
insertion. To analyse, samples were mixed with loading dye and run on an 
agarose gel (2.12.7). 
2.8.3 Competent cell transformation 
Constructs were routinely propagated in TOP10 E.coli cells (Invitrogen) for 
synaptophysin plasmids or XL-1 blue E.coli cells (Stratagene) for PIMS147 C1-3 
plasmid according to the manufacturer’s protocol. Briefly, 50-100ng of plasmid 
DNA was added to 50μl of competent cells and incubated on ice for 30 minutes, 
causing the DNA to condense on the surface of the bacteria. The solution was 
then heat shocked at 42°C for 45 seconds and 250μl of sterile LB media added. 
The E. coli were incubated for 1 hour at 37°C (250rpm) to recover followed by 
plating out. 50-200µl of the bacterial suspension was spread onto the surface of 
100mm petri dishes filled with solidified LB-agar with antibiotics (Synaptophysin: 
100μg/ml ampicillin C1-3: 50μg/ml ampicillin and 15μg/ml tetracycline) to select 
for cells which had successfully been transformed. 
The dishes were given 10 minutes to absorb the liquid and then incubated upside 
down at 37°C overnight (16 hours). Dishes were inspected for growth the 
following morning and well defined individual colonies were selected and used to 
inoculate 5ml of LB medium containing the appropriate antibiotic overnight at 
37°C. Following overnight incubation the culture was either used for miniprep or 
used to inoculate LB for a large scale expression and maxi prepped as described 
in 2.8.5 and 2.8.6. 
2.8.4 Storage of plasmid stocks 
Glycerol stocks were prepared for plasmid DNA constructs by adding 500μl of the 
overnight culture to 500μl of sterile LB containing 30% glycerol. This was then 
immediately stored at -80°C.  
When required, this stock was then used to produce more plasmid DNA by 
streaking out a small amount onto an agar plate with the appropriate antibiotic 
and grown overnight at 37°C. A single colony was then picked and used to 
inoculate liquid cultures, typically 1 colony was added to 5ml LB supplemented 
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with the appropriate antibiotic and incubated at 37°C overnight and then used for 
miniprep. Alternatively, the 5ml overnight culture was used to inoculate LB for a 
large scale expression with plasmid DNA being purified by maxiprep.  
2.8.5 Miniprep of plasmid DNA 
The purification process is based upon an alkaline lysis procedure followed by 
salt and pH dependent binding of plasmid DNA to the anion-exchange resin. The 
miniprep kit, provided by Qiagen (Southampton, UK), is designed for the 
purification of a maximum of 20μg plasmid DNA from 1-5ml of overnight culture. 
Briefly, bacteria from 1ml of the overnight culture were pelleted by centrifugation 
at 3000g for fifteen minutes at 4°C and the supernatant discarded. The bacterial 
cell pellet was then re-suspended in 250μl of buffer P1 (containing RNase), 250μl 
of buffer P2 (alkaline salt buffer containing SDS) was added and mixed by gentle 
inversion until the solution became clear and viscous. 350μl of buffer N3 was 
added to neutralise the solution and cause contaminating genomic DNA and 
membrane to precipitate. The precipitate was pelleted by further centrifugation at 
10000g for 10 minutes and the supernatant applied to a Qiaprep spin column and 
centrifuged at 10000g for 1 minute.  The flow through was discarded and the 
column was washed in 500μl of buffer PB and centrifuged for another minute. 
Any remaining contaminants were removed by a final wash step with 750μl of 
buffer PE and centrifugation at 10000g for 1 minute. Any flow through was 
discarded and the Qiaspin columns centrifuged for a further minute to ensure all 
residue was removed. The Qiaspin column was transferred to a sterile RNase-
free eppendorf and 50μl of sterile H2O was applied to the column and incubated 
for 1 minute before being centrifuged for 1 minute at 10000g to elute the DNA. 
2.8.6 Maxiprep of plasmid DNA 
Maxiprep kits, provided by Qiagen, are designed for the purification of plasmid 
DNA, maximum of 100μg, from 100-500ml overnight culture of transformed E.coli 
cells. In brief, 100ml of bacteria from an overnight culture were pelleted by 
centrifugation at 6000g for 15 minutes at 4°C. The supernatant was discarded 
and the pellet re-suspend in 10ml of Buffer P1 (containing RNase), 10ml of buffer 
P2 (alkaline salt buffer containing SDS) was then added and mixed by inversion. 
The mix was incubated at room temperature for 5 minutes and then 10ml of 
chilled buffer P3 was added, mixed immediately and incubated on ice for 20 
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minutes whilst contaminating genomic DNA and membranes precipitated. The 
precipitate was pelleted by centrifugation at 20000g for 30 minutes at 4°C and the 
supernatant applied to an Qiagen maxi column equilibrated with 10ml buffer QBT. 
Any contaminating RNA, proteins and low molecular weight impurities were 
removed by a medium salt wash, i.e. two 30ml washes with buffer QC, and any 
flow through discarded. DNA was removed from the column under high salt 
conditions by the addition of 15ml of buffer QF (containing isopropanol) to the 
column and flow through collected. DNA was then precipitated out of the solution 
by adding 10ml of 100% sterile isopropanol and pelleted by centrifugation at 
15000g for 30 minutes at 4°C and the supernatant discarded. 5ml of 70% EtOH 
was added to the pellet to remove precipitated salt and centrifuged for a further 
10 minutes at 15000g. The supernatant was removed and the pellet allowed to air 
dry. Upon drying the DNA pellet was resuspended in sterile ddH2O and quantified 
using a spectrophotometer (2.8.7). 
2.8.7 DNA quantification 
The concentration of the DNA isolated was determined using UV 
spectrophotometry at 260nm. The DNA was diluted 1:100 with sterile water and 
added to a cuvette. The absorbance at 260nm was used to determine the 
concentration on the basis that an absorbance of 1.0 corresponds to 50μg/ml 
double stranded DNA. 
The purity of the DNA was determined by measuring the absorbance values at 
260nm and 280nm, DNA maximally absorbs at 260nm whereas protein absorbs 
at 280nm. These values are typically expressed as a ratio, with a pure DNA 
sample having a ratio value of 1.8 or greater. 
2.9 Animal Work 
2.9.1 Mice 
C57Bl6 mice were purchased from Charles River and housed in the Comparative 
Biology Centre at Newcastle University. Mice were housed in an air conditioned 
environment at 20°C± 3oC and a humidity of 50 ± 10% with a 12 hour light/dark 
cycle.  Animals were cared for as per Home Office regulations. 
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Corticotrophin releasing hormone (Crh) transgenic mice were purchased from 
Jackson laboratories, St Louis and housed in the Comparative Biology Centre at 
Newcastle University. The rat Crh gene was expressed under the control of the 
metallothionine promoter in transgenic mice resulting in a mouse model of 
chronic pituitary activation. Mice developed symptoms characteristic of Cushing’s 
syndrome with excess fat accumulation, muscle atrophy, thinning of the skin and 
alopecia. 
2.9.2 Carbon tetrachloride-induced liver injury 
To cause centrilobular damage which typically represents liver disease in 
humans the chemical CCl4 was used. CCl4 was diluted 1:1 with olive oil and given 
twice a week via intraperitoneal injection at a dose of 1ml/kg of body weight. This 
was carried out for up to a maximum of 12 weeks.  
2.9.3 Partial Hepatectomy 
This technique was based upon the two thirds PHx methods first proposed by 
Higgins and Anderson in 1931 [128]. 
Mice were anesthetized with a mixture of isoflurane/oxygen, and right medial, left 
medial, and left lateral lobes were excised and weighed after separate ligations 
resulting in removal of ~70% of the hepatic mass. At each time point, livers were 
harvested, weighed, and processed for subsequent analysis. Preoperative and 
regenerated liver weight was expressed as liver-to-body-weight ratio and used to 
calculate the relative growth of residual liver lobes. All surgical work was 
performed by Dr Fiona Oakley (Newcastle University). 
2.9.4 Monitoring cellular proliferation 
Bromodeoxyuridine (BrDU), an analogue of thymidine, is incorporated into the 
DNA of replicating cells and is a useful monitor of cellular proliferation. BrDU, 
prepared at 20mg/ml in an isotonic buffer (typically PBS), was administered via 
i.p. injection to mice (200mg/kg) 4 hours prior to sacrifice.  
2.9.5  Serum enzyme assay 
Serum samples were collected by tail bleeding and terminal bleed after autopsy. 
Blood was allowed to clot and then centrifuged at 10000g for 10 minutes, the 
59 
serum was collected and analysed by the Clinical Biochemistry Department at the 
Royal Victoria Infirmary, Newcastle. 
2.10 Imaging 
2.10.1 OPT Imaging 
Optical projection tomography (OPT) allows the three dimensional imaging of 
fixed biological specimens typically over 1cm across. It has been generated to fill 
the gap between confocal microscopy and MRI imaging and is typically used to 
visualise gene expression patterns in human embryos. 
2.10.2 Sample Preparation 
One lobe from the liver was perfused with HBSS+ and stored in 10% formalin. 
The formalin fixed liver samples were embedded in 1% low melting point agarose 
and left to set overnight. The agarose plug was then dehydrated in increasing 
concentrations of methanol (10%, 25%, 50%, 75%, 90%, 100%), followed by four 
final washes with 100% methanol to ensure all water had been removed. The 
samples were finally cleared in three 1 hour washes of BABB (1:2 v/v Benzyl 
Alcohol:Benzyl Benzoate) followed by 1 final overnight incubation in BABB. 
2.10.3 Sample Scanning 
The first sample to be scanned was removed from BABB solution and blotted dry. 
The bottom of the agarose plug was attached to a small metal stub and placed 
onto the microscope. The samples were suspended in BABB whilst scanning to 
reduce light scattering and reduces heterogeneities of refractive index throughout 
the specimen. 
Each sample was rotated 1º and subjected to excitation at wavelengths of 488nm 
and 543nm. All data were written to a CD and manipulated post scanning to 
create a 3D image. Figure 2-2 illustrates how OPT works. 
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Figure 2-2: Overview of OPT. Light passes through the diffuser (blue) converting it into an even 
illumination and then through the specimen. The light is focused by the optics onto a CCD 
imaging chip (row of black dots). The intensity of the light at each position is recorded on the CCD 
chip which then approximates a projection through the focused part of the specimen.  
2.10.4 IVIS Imaging 
In vivo imaging system (IVIS) allows the non-invasive visualisation of 
fluorophores and luminescence present in the body of a rodent. All procedures 
adhered to the strict guidelines detailed by the Home Office. Animals were 
anaesthetised with isoflurane/oxygen mix and their stomach, abdomen and lower 
body regions shaved to prevent the fur blocking the visualisation of the 
fluorescence. Anaesthesia was maintained during the imaging procedure with up 
to 5 animals being imaged at any one time.  
Typically, a background picture was taken with an automatic, 1 second and 10 
second exposure time before any antibody was injected. Once this had been 
completed animals were either injected intraperitoneally or intraveneously with 
the C1-3-AF antibody with a specified dose of 8mg/kg and imaged immediately 
(i.p. injection only), 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour and 2 
hours following injection at the exposures stated previously. Once imaging 
studies were complete, all animals were sacrificed and their organs excised and 
imaged as previously described. 
2.11 Immunohistochemistry and Immunocytochemistry 
2.11.1 Immunohistochemistry 
All tissues were fixed in 10% formalin diluted in 1 x PBS for a minimum of twenty 
fours hours before processing. Once processed (sequentially through increasing 
concentrations of ethanol), tissue was mounted in paraffin and 4μm sections 
were cut and mounted onto super frost plus slides. Sections were de-waxed in 
xylene for 10 minutes and then re-hydrated through 5 minute incubations in 100% 
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ethanol followed by 90% ethanol. Tissue sections were then incubated with 
0.45% H2O2 in methanol for 10 minutes at room temperature to quench 
endogenous peroxide activity and washed for 5 minutes in 1 x PBS. Antigen 
retrieval was carried out using either 0.01M citrate buffer (see section 2.11.2) or 
10μg/ml proteinase K digestion (see section 2.11.3). Non-specific binding of 
antibodies was prevented by incubating tissue sections in 20% (v/v) FCS in 1 x 
PBS for 20 minutes prior to incubation with primary antibody diluted in 0.05% 
FCS in PBS (for dilutions see table 2-2) for 1 hour at room temperature or at 4°C 
overnight. Sections were then washed three times for 5 minutes in 1 x PBS and 
incubated with the appropriate HRP conjugated secondary antibody diluted in 
0.05% (v/v) FCS in 1 x PBS (see table 2.11.1) for 1 hour at room temperature 
followed by three 5 minute washes in 1 x PBS. HRP activity was visualised using 
diaminobenzidine (DAB) chromogen (Dako) to develop colour essentially as 
outlined in the manufacturer’s instructions. DAB was applied to the slide and 
incubated for 5 minutes, or as optimised for individual antibodies. In all cases 
control sections were stained without primary antibody incubation for each 
individual antibody used. After incubation with DAB slides were washed briefly in 
water and then counterstained for 30 seconds in haematoxylin and washed in 
acidified water for 10 seconds. Finally, the slides were sequentially dehydrated 
through 50%, 75%, 95%, 2x100% ethanol and finally into xylene before mounting 
in Depex. 
2.11.2 Citrate buffer pressure cooker antigen retrieval 
Slides were added to 0.01M citrate buffer vigorously boiling in a pressure cooker. 
When full pressure had been reached, the slides were timed for 1 minute before 
removing from the heat and rapidly cooled whilst the pressure was released. 
Slides were washed twice in 1xPBS before continuing with the staining protocol. 
2.11.3 Proteinase K antigen retrieval 
Tissue sections were digested in 10μg/ml proteinase K diluted in 1 x PBS for 25 
minutes at 37°C. Slides were rinsed in 1 x PBS before commencing with 
immunostaining protocol.  
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2.11.4 Vector Laboratories ABC method 
To increase staining sensitivity, an ABC kit produced by vector laboratories 
(Peterborough, UK) was used. The kit relies on the high binding affinity that 
avidin has for biotin, in addition to its four binding sites for biotin. These 
properties allow macromolecular (avidin:biotin complexes (ABC)) complexes to 
be formed between avidin and the biotinylated secondary antibody thus 
amplifying the bound antibody.  
Before the ABC complex can be applied, endogenous avidin/biotin activity in the 
liver tissue was blocked using the avidin/biotin blocking kit (Vector Labs). Briefly, 
slides were incubated with reagent A for 15 minutes, washed twice in 1 x PBS, 
and incubated with reagent B for a further 15 minutes. Slides were rinsed with 1 x 
PBS before continuing the staining protocol. This step was typically carried out 
prior to the FCS block. 
After primary antibody incubation, slides were washed and incubated with a 
biotinylated secondary antibody, see table 2-2 for dilutions, for 1 hour at room 
temperature. After two washes in PBS, slides were incubated with RTU 
Vectastain Elite ABC peroxidase reagent for 30 minutes at room temperature 
followed by three washes in 1xPBS. HRP activity was visualised, counterstained 
and mounted as described in 2.11.1. 
2.11.5 Picro-sirius red staining 
Picro-sirius red stain specifically binds to collagens [242, 243] thus can be used 
to monitor collagen deposition during fibrosis. Slides were dewaxed and 
rehydrated, as detailed in 2.11.1, and placed in the picro-sirius red stain 
(0.036mM in saturated picric acid) for 2 hours at room temperature. Excess stain 
was removed by 2 washes in acidified H20 (0.5% v/v acetic acid in deionised 
H20), then slides were dehydrated in 2 changes of 100% ethanol, cleared in 
xylene before mounting in Depex. 
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Antigen Dilution Antigen Retrieval 
Comments and Source RT=incubate 
at room temperature O/N= Overnight 
incubation 
α SMA-FITC 
1:1000 
IHC 
1:200 ICC 
Citrate 
Buffer 
Mouse monoclonal (Sigma) directly 
conjugated to FITC. RT 
Synaptophysin  1:5000 IHC 
Citrate 
Buffer Rabbit polyclonal from Abcam. O/N 
BrDU 1:10 IHC Citrate Buffer 
Mouse monoclonal from BD 
Biosciences, no FCS block required 
O/N 
NIMP 1:200 IHC Proteinase K 
Rat polyclonal from AbD Serotec 
(Kidlington, UK)  Requires ABC 
staining O/N 
C1-3-AF 60μg/ml ICC N/A Native staining only RT 
IL-6 1:50 IHC Citrate Buffer 
Rabbit polyclonal from Santa Cruz  
(USA) O/N 
Rabbit anti 
FITC HRP 1:200 IHC N/A Rabbit polyclonal from Dako RT 
Rabbit Anti Rat 
IgG 
Biotinylated 
1:200 IHC N/A AbD Serotec RT 
Goat anti 
Mouse HRP 1:300 IHC N/A Goat polyclonal from Dako RT 
Goat anti 
Rabbit HRP 1:300 IHC N/A Goat polyclonal from Dako RT 
Table 2-2 Antibody dilutions for IHC and ICC 
 
2.11.6 Immunocytochemistry 
For hepatic myofibroblast staining only, cells were seeded on to 22mm2 square 
coverslips that had been sterilised with 70% ethanol prior to placement in one 
well of a 6 well plate.  
Plates were removed from incubator, medium aspirated, washed in 1 x PBS and 
60μg/ml C1-3-AF added in Hepes/HBSS solution. Cells were left for 2 hours at 
37°C/5% CO2. Following incubation the antibody was removed and cells were 
washed twice in 1 x PBS. 2ml of fixative (2% v/v formaldehyde/ 0.2% v/v 
glutaraldehyde in 1 x PBS pH 7.4) was added to each well and cells were 
incubated for 15 minutes at room temperature. Fixative was removed and cells 
were washed twice for 5 minutes in 1 x PBS. For myofibroblast staining, non-
specific protein binding was blocked by incubation with 2ml 20% (v/v) FCS in 1 x 
PBS per well for 20 minutes at room temperature whilst being gently rocked.  The 
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blocking solution was then discarded and αSMA-FITC added at the required 
dilution (as detailed in table 2-2) in 0.05% (v/v) FCS in 1 x PBS.  Cells were 
incubated in αSMA-FITC for 1 hour at room temperature with gentle agitation. 
Primary antibody was then removed and cells were washed two times for 5 
minutes in 1 x PBS. Cell nuclei were stained with 6μg/ml 4',6-diamidino-2-
phenylindole (DAPI, a fluorescent stain which strongly binds DNA) in deionised 
H2O (2ml per well) and either visualised immediately using confocal microscopy 
(transfected cells) or mounted on super frost plus slides (myofibroblasts) in 
vectashield (Vector Labs) anti fade.  
2.12   Isolation and Quantification of RNA 
2.12.1 Trizol RNA purification 
Medium was removed and cells were washed twice in sterile 1 X PBS. For a 6 
well plate 1ml of Trizol was added to each well and placed on rotating plate at 
high speed for 5 minutes to disrupt cells. Trizol was then removed and put into an 
RNase/DNase free eppendorf. For whole tissue samples, a small portion of the 
tissue was placed into a RNase/DNase free eppendorf and was homogenised in 
1ml of Trizol.  
RNA was extracted from sample by the addition of 200μl of chloroform to the 
Trizol solution and mixed well using a vortex. Samples were centrifuged for 15 
minutes at 10000g at 4°C. The upper aqueous layer was removed and placed 
into a fresh eppendorf, 500μl of cold isopropanol was added and incubated on ice 
for 10 minutes.  Samples were then centrifuged at 10000g for 15 minutes at 4°C.  
The supernatant was discarded, the pellet dislodged and washed in 70% ethanol 
before centrifugation at 10000g for 15 minutes at 4°C. The supernatant was 
discarded and the pellet was allowed dry in air before being re-suspended in 
sterile pharmacy grade H2O. RNA was aliqouted and stored at –80°C with freeze 
thaw being avoided as much as feasibily possible.  
2.12.2 Determining RNA integrity and concentration  
RNA was quantified at 260nm, and purity determined by the ratio of absorbance 
at 260nm and 280nm readings.  RNA was diluted in 200μl of sterile H2O and 
transferred into a quartz cuvette, the absorbance was scanned between 260 and 
280nm versus 200μl of H2O to correct for background. RNA concentration was 
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then calculated based on 1 x 260nm being equivalent to 25μg RNA/ml. RNA 
integrity was routinely checked on an agarose gel containing ethidium bromide 
and viewed under UV light; two distinct bands were visualised, 28S and 18S 
respectively. Assessment of RNA purity was made by determining the 260/280 
ratio which should be 2.0 for pure RNA. Ratios lower than 2.0 may indicate 
protein or DNA contamination.  
2.12.3 DNase treatment of RNA (Promega) 
RNA was DNase treated to remove any genomic DNA contamination.  RNA was 
diluted in 50μl of sterile H2O; 0.1 Volume of RQ1 10x DNase I Reaction Buffer 
and 0.1 Volume DNase I and was then added to the sample (e.g. If resuspended 
in 50μl H2O then add 5μl DNase I Buffer and 5μL (5 Units) DNase I). The sample 
was mixed gently and incubated at 37°C for 30 minutes, the reaction was 
stopped by adding 0.1 volume of RQ1 DNase stop solution (5μl). The sample 
was mixed and then incubated at 65°C for 10 minutes to terminate reaction.  
2.12.4 1st strand cDNA synthesis 
Moloney murine leukaemia virus (MMLV) reverse transcriptase RNase H minus 
point mutant is an RNA dependent DNA polymerase used for the synthesis of 
cDNA. The point  -H mutant  lacks RNase H activity allowing optimal conditions 
for the generation of full length cDNA from long RNA templates. MMLV (-H); is 
thermostable, reducing any problems associated with secondary structure and 
gives higher yields of cDNA than MMLV. RNA was diluted to a starting 
concentration of 200ng/μl. 
First strand cDNA was produced by adding 400ng RNA (typically 2 μl) to 2 μl 
water and 1μl of oligo dT (stock concentration of 50 μg/ml). The reaction was 
heated to 85ºc for 3 minutes to remove secondary RNA structure, followed by 
rapid cooling on ice and 15 μl of megamix added to each tube (table 2-3). 
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 μl/tube  
5x MMLV buffer (Promega) 
250mM Tris-HCl (pH 8.3 at 25°C), 375mM KCl, 15mM MgCl2, 50mM 
DTT 
4 
Pharmacy Grade Water 7.5 
10mM dNTPs 2 
MMLV Reverse Transcriptase RNase H minus (Promega) 1 (50 Units) 
Table 2-3 Components of mastermix required for 1st cDNA synthesis 
The reaction was incubated for a further 1 hour at 42ºC. Typically 2-5μl of cDNA 
was used directly for PCR, or frozen and stored at -20°Cfor later use. 
2.12.5 PCR 
PCR is a very important tool in molecular biology and is used to amplify specific 
DNA sequences. Phusion high fidelity DNA polymerase uses a novel pyrococcus 
like enzyme with a processivity-enhancing domain catalysing the polymerisation 
of nucleotides into duplex DNA in the 5’   3’ direction in the presence of 
magnesium and has proof reading capability 3’  5’ which permits the removal of 
base misinsertions resulting in the products generated having fewer errors.  2μl of 
the first strand cDNA was added to 18μl of megamix containing the following 
components (Table 2-4): 
 μl/tube 
5 x Phusion HF Buffer (New England Biolabs) 4 
10mM dNTPs 0.4 
0.5μM upstream primer stock 2 
0.5μM downstream primer stock 2 
Pharmacy grade water 9.4 
Phusion high fidelity DNA polymerase 0.2 (0.4 Units) 
Table 2-4 Mastermix components required for PCR. 
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The reaction (illustrated in Figure 2-3) was initially heated to 98ºC for 30 seconds, 
followed by 35 cycles of 98ºC for 10 seconds, annealing temperature for 30 
seconds and 72ºC for 30 seconds. After the 35 cycles there was a final 
elongation step for 10 minutes at 72ºC. The annealing temperature varied 
according to the primer being used, but was typically 3ºC higher than the lowest 
primer melting point.  
 
Figure 2-3: Schematic diagram of PCR reaction. The cDNA is initially denatured at 98°Cfor 30 
seconds followed by 35 cycles of denature (10 seconds), annealing (30 seconds) and elongation 
(30 seconds). To complete the reaction, a final elongation step is carried out at 72°Cfor 10 
minutes. 
Primers 
Nucleotides 
5’ 3’ 
3’ 5’ 
5’ 3’ 
3’ 5’ 
5’ 3’ 
3’ 5’ 
5’ 3’ 
3’ 5’ 
5’ 5’ 
5’ 
5’ 
3’ 3’ 
3’ 
3’ 
1: Denature:  98°C 
2: Annealing:60-65°C  
3: Elongation: 72°C 
5’ 
 
1 
 
 
 
 
2 
 
 
 
 
 
3 
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The PCR program was optimised for each individual set of primers as detailed in 
table 2-5. 
Primer Name Sequence Melting Point 
Annealing 
temperature 
Synaptophysin 
upstream 1 ATGGACGTGGTGAATCAGCTGGT 
67.20 ºC  
Synaptophysin 
downstream 2 GCCCCCATGGAGTAGAGGAA 
59.97 ºC 62.9ºC 
Synaptophysin 
downstream 3 CATCTGATTGGAGAAGGAGGTGGG   
60.40 ºC 63.4ºC 
Synaptophysin 
downstream 4 GGGTGCATCAAAGTACACTTGG     
60.69 ºC 63.6ºC 
GAPDH 
upstream TGACATCAAGAAGGTGGTGAAG 42.1ºC  
GAPDH 
downstream 2 TCTTACTCCTTGGAGGCCATGT 44.9ºc 42ºc 
Table 2-5 DNA oligonucleotide sequences used in PCR. 
2.12.6 Primer Design 
Primer pairs were routinely designed to amplify specific DNA sequences of 
interest. DNA sequences were acquired from the NCBI database 
(www.ncbi.nlm.nih.gov). BLAST was then used to check the specificity of chosen 
primer sequences and also to assess the possibility of dimerisation. The following 
guidelines were generally followed: primers should contain 40-60% G and C and 
have a length of approx 18-30 bases, the G and C content of each primer should 
be similar in order to keep the Tm values within the same region and primers 
pairs were not complementary to one another to avoid the formation of primer 
dimmers. Tm = 2°C x (A + T) + 4°C x (G + C). 
2.12.7 Agarose gel electrophoresis 
This technique allows the separation of DNA fragments according to size. 
Agarose, a polysaccharide extracted from seaweed, is dissolved in a heated 
buffer which upon cooling forms a solid matrix. If a current is applied using a 
conducting buffer, DNA loaded onto the gel will migrate according to size and 
degree of folding. Due to the negative charge of the sugar-phosphate backbone 
of nucleic acids they migrate towards the positive electrode. The migration 
process is monitored by using ethidium bromide.  
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Agarose powder was dissolved in 1x TAE buffer by boiling the solution until all 
traces of powder were gone. 50x TAE stock consisted of 242g Tris base, 57.1ml 
acetic acid, 100ml 0.5M EDTA, and water to 1 litre. The percentage of agarose 
gel used was dependent upon the size of the nucleic fragment that was to be 
analysed. High percentage gels are used for small fragments and low percentage 
for large fragments. Ethidium bromide was added to the gel solution to intercalate 
into the DNA backbone and fluoresce, meaning that the bands can be visualized 
when viewed under UV light. Once the solution had cooled slightly, it was poured 
into a casting stand and allowed to set for thirty minutes. The set gel was 
transferred to an electrophoresis tank and submerged in 1x TAE buffer. 10μl of a 
100bp DNA ladder (Promega) was loaded to allow size approximation of DNA 
bands. 10μl of DNA was added to 2μl of 6x loading dye (Promega) and added to 
the wells. 
The gel was run at 80V for approximately 45 minutes and visualized using a 
Fluorchem (Alpha Innotech) gel doc system.  
2.12.8 Real-time PCR using TaqMan 
All cDNA samples were diluted to 10ng/μl, 5μl (50ng) of which was added to each 
well in a 96 well plate (Applied Biosystems, Warrington, UK) with samples run in 
duplicate. 8μl of TaqMan mastermix (Applied Biosystems: 6.5μl 2x TaqMan 
universal mastermix, 0.65μl 20x primer/probe and 0.85μl pharmacy grade sterile 
water) to each well, with control wells containing mastermix only. All TaqMan 
primers used are detailed in table 2-6. 
Gene Name Applied 
Biosystems Assay 
ID Number 
Gene Group 
18S HS99999901_s1 Eukaryotic 18S rRNA 
α smooth muscle actin Mm01546133_m1 Cytoskeletal protein 
Synaptophysin Mm00436850_m1 Membrane traffic regulatory 
protein 
Collagen 1a1 Mm00801666_g1 Extracellular matrix structural 
protein 
Interleukin 6 Mm00446190_m1 Cytokine 
Interleukin 1β Mm00434228_m1 Cytokine 
Epidermal growth factor Mm00438696_m1 Growth factor 
Hepatocyte growth factor Mm01135185_m1 Growth factor 
Tumour necrosis factor α Mm00443258_m1 Cytokine 
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Transforming growth factor 
β 
Mm03024053_m1 Cytokine 
Cyclin D1 Mm00432359_m1 Kinase modulator 
Cyclin E1 Mm01266311_m1 Kinase modulator 
Cyclin-dependent kinase 2 Mm00443947_m1 Protein kinase 
Tissue inhibitor of 
metalloproteinases 1 
Mm00441818_m1 Protease inhibitor 
Table 2-6 Summary of TaqMan primers 
All primers used for TaqMan were conjugated to the fluorescent dye FAM and 
analysed using FAM detector settings on an Applied Biosystems 7500 PCR 
machine. The programme used was as follows: 
1. 50°Cfor 2 minutes 
2. 95°C for 10 minutes 
3. 40 cycles of 95°C for 15 seconds and 60°C for 1 minute 
To calculate CT values, threshold limits were manually adjusted to represent the 
exponential phase of amplification. Relative quantitation of gene expression 
relative to an endogenous control 18S, were calculated using the comparative CT 
method as described in the Applied Biosystems RT-PCR guide and as validated 
in [244]. Briefly, the mean and standard deviation (SD) of the CT values were 
calculated for each target gene and 18S. The ΔCT was calculated by subtracting 
the 18S CT from the target gene CT. The SD for the ΔCT was calculated as 
follows: SD= (SD12 + SD22)1/2 where SD1/2 are the SD of 18S and the target gene. 
The ΔΔCT was calculated by subtracting the average ΔCT of the designated 
control (i.e. olive oil/ sham mice) from the ΔCT of the remaining values. Fold 
change, relative to the designated control was calculated using the following 
equation: fold change = 2-ΔΔCT with SD range calculated by SD plus = (2-ΔΔCT-SD) – 
Fold change and SD minus = Fold change - (2-ΔΔCT+SD). 
2.13 Statistical Analysis 
Data between treatment groups were tested for statistical significance using the 
Student’s two tailed t Test. Data were considered significant when p<0.05 unless 
otherwise stated. Sample power calculations based on a previous model of 
myofibroblast depletion [126] suggest that animal group sizes of 6 are sufficient 
to obtain statistical significance. 
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Chapter 3. Production of a recombinant single chain antibody 
fragment, C1-3, and analysis of the expression of its antigen 
synaptophysin 
3.1 Introduction 
Single chain antibody fragments (scAbs) are fusion proteins of the variable region 
of the heavy (VH) and light (VL) immunoglobulin chain and are connected by a 
short linker peptide. They are typically produced by phage display, where an 
antigen of interest is immobilised on the surface of a well and a phage antibody 
specific for that sequence remains bound whilst the rest are washed away. 
Bound antibodies are eluted and are further enriched and purified by numerous 
rounds of panning [125]. The sequence of the desired phage-antibody can be sub 
cloned into an expression vector and expressed in bacterial cells, allowing for 
unlimited production. 
C1-3, a scAb with a human constant kappa domain, was generated by the Wright 
lab in 2005 and shown to specifically target and bind hepatic myofibroblasts in 
vitro [125] via the synaptophysin protein. Furthermore, the group demonstrated 
that conjugation of the scAb to the toxin tributyl-tin was able to induce apoptosis 
of cultured hepatic myofibroblasts. 
Synaptophysin is a 38kDa transmembrane glycoprotein found on neural and 
neuroendocrine cells and is associated with neurotransmitter release and control 
of exocytosis [120]. Cassiman et al [124] established that synaptophysin was a 
unique marker in the liver, with the protein expressed on the surface of quiescent 
hepatic stellate cells and hepatic myofibroblasts. 
The use of scAbs as imaging agents and for delivering therapeutics is continually 
increasing as their small size allows rapid distribution and excretion throughout 
the body. In liver disease, research to date has established that the hepatic 
myofibroblast is the key cell involved in liver fibrosis, with its survival determining 
fibrosis progression or resolution. The generation of a scAb which specifically 
targets this cell has the potential to revolutionise the diagnosis and treatment of 
liver fibrosis, however in order to investigate this large quantities of the scAb 
need to be produced and the interactions with its receptor analysed.  
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3.2 Results 
3.2.1 C1-3 Production 
C1-3 production was induced by the addition of Isopropyl-β-D-thiogalactosidase 
(IPTG) to proliferating XL-1 blue cells containing the PIMS147 expression vector, 
as described in the methods chapter. IPTG cannot be metabolised by E.coli cells 
thus the concentration remains constant allowing for maximal production of the 
scAb. To isolate the scAb, the bacterial cells were lysed via enzymatic and 
chemical means allowing final purification via the hexahistidine tag by 
immobilised metal ion chelate affinity chromatography (IMAC). 
Non-specifically bound proteins were removed from the column with a 10mM 
imidazole wash, a compound able to displace the bond between proteins and 
nickel sepharose. A higher concentration of imidazole was used to elute the C1-3 
from the column, with excess imidazole removed by overnight dialysis in PBS. 
Samples from the osmotic shock solution before and after incubation with the 
nickel sepharose were routinely run on an SDS-PAGE gel alongside the binding 
buffer wash and eluted C1-3. Figure 3-1 is an example of a typical SDS page gel, 
the arrow shows a decrease in the C1-3 in the osmotic shock solution following 
incubation with the nickel sepharose indicating that all C1-3 was bound to the 
sepharose in the column. The majority of the bands present in the osmotic shock 
solution are reduced following incubation with the nickel sepharose. This 
suggests that these proteins are binding in a non specific manner to the nickel 
sepharose as they are removed in the binding buffer wash. Furthermore, the 
binding buffer wash shows that little C1-3 was removed from the column during 
this stage and was eluted with the higher concentration of imidazole. This can be 
more clearly seen using Western blot analysis with the antibody Goat anti human 
Cκ light chain (Sigma) which specifically binds to the C1-3 scAb. Both the 
western blot and the SDS-PAGE gel reveal two distinct bands which are smaller 
than the expected weight for the C1-3 and are likely degradation products of the 
C1-3 protein. 
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Figure 3-1 SDS-PAGE and WB analysis of osmotic shock solution and eluted C1-3. A:  
Osmotic shocked solution (OSS) before and after incubation with nickel sepharose, as well as 
binding buffer wash and eluted C1-3 were diluted 1:5 in reducing loading buffer and denatured at 
90°Cfor 5mins. 10μl of each sample was loaded onto a 9% SDS-PAGE gel and separated 
according to size. To visualise proteins, gels were stained for 1hr with coomassie blue, destined 
by numerous washes with 10% v/v methanol and acetic acid in deionised H2O. B: Following 
electrophoresis proteins were transferred to nitrocellulose membrane, blocked with 3% milk 
marvel solution and probed with goat anti human Cκ light chain antibody.  Results are typical of 5 
different C1-3 preparations.  
To be able to use the scAb in downstream applications it was important to 
confirm that it was capable of binding to its target antigen, peptide 2. To do this a 
binding ELISA was conducted using peptide 1, as a negative control, alongside 
peptide 2. 
Figure 3-2 shows that C1-3 was able to bind to its receptor peptide 2 with little 
binding to peptide 1. 
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Figure 3-2 Peptide 1 and 2 binding ELISA for C1-3. 96 well plates were coated with BSA-
conjugated peptide 1 or peptide 2. ScAb samples of unknown concentrations were initially diluted 
1:10 with PBS then serially diluted across the plate. Bound antibody was detected using a 
secondary HRP conjugated goat-anti human Cκ light chain antibody and quantified by measuring 
a colorimetric reaction by the addition of TMB and the absorbance at 450nm noted. All 
experiments were performed in triplicate and the absorbance at dilution 5 (1/160) plotted. Data 
presented are the mean and SD of three well replicates and are representative of 5 separate C1-3 
preparations. 
To determine the concentration of the C1-3 antibody, two methods were used. 
The simplest was running diluted C1-3 on an SDS page gel alongside known 
concentrations of BSA protein standards however this is subject to user error in 
the estimation of band size. Figure 3-3 is an example of a typical SDS page gel, it 
shows that the C1-3 protein sample is of a similar concentration to BSA standard 
0.5μg/μl, thus when the 1:1 dilution of C1-3 to loading buffer is taken into 
consideration this gives the C1-3 a concentration of 1μg/μl. 
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Figure 3-3 SDS-PAGE analysis of C1-3 vs. BSA standards. 20mg/ml BSA was diluted to the 
following concentrations in reducing loading buffer: 0.01μg/μl, 0.5μg/μl, 1μg/μl and 2μg/μl. C1-3 
was diluted 1:1 in reducing loading buffer. All samples were denatured at 90°Cfor 5 minutes prior 
to loading of 10μl onto a 9% SDS-PAGE gel. To visualise proteins, gels were stained for 1hr with 
coomassie blue, destined by numerous washes with 10% v/v methanol and acetic acid in 
deionised H2O.  Data are representative of 5 different C1-3 preparations. 
A more accurate method of quantification could be achieved by performing a 
capture ELISA (Figure 3-4). C1-3, of an unknown concentration, was initially 
diluted 1/10 and then serially diluted across a plate alongside known 
concentrations of human IgG. C1-3 concentration was determined from the linear 
portion of the curve and corrected for dilution factor and for the presence of an 
extra human kappa light chain domain on the human IgG antibody. The corrected 
concentration of C1-3 is shown in table 3-1. However this method also has the 
potential for error as multiple dilutions of C1-3 may have similar absorbency 
values in the liner portion of the IgG concentration curve leading to different C1-3 
concentrations. Ideally both SDS-PAGE and ELISA methods should be used to 
ensure accurate quantification.  
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Figure 3-4 Quantification of C1-3 using a capture ELISA. 96 well plates were coated with goat 
anti human Cκ light chain antibody and blocked with 2% milk marvel solution. C1-3, of an 
unknown concentration, was initially diluted 1:10 then serially diluted across the plate.  IgG with 
an initial concentration of 1.25mg/ml was serially diluted as previously described. Bound antibody 
was detected by using a secondary HRP conjugated goat-anti human Cκ light chain antibody and 
quantified by measuring a colorimetric reaction by the addition of TMB and the absorbance at 
450nm noted. All experiments were performed in triplicate and the data plotted are the mean and 
SD for each dilution.  Data are representative of 5 different C1-3 preparations.  
 
 
Table 3-1 Adjusted concentration of C1-3. C1-3 concentration was determined from the linear 
portion of the curve and corrected for dilution factor and for the presence of an extra human 
kappa light chain domain on the human IgG antibody. For example dilution 11 of C1-3 is equal to 
dilution 7 of IgG with a concentration of 19.53ng/ml. To correct for dilution this number is 
multiplied by 211 and finally by 10 to account for initial 1:10 dilution. Finally the value is adjusted 
for the presence of 2 human Cκ light binding domains by multiplying by 2. 
 
Sample Concentration Determined by Capture ELISA 
Corrected for Sample 
Dilution 
Adjusted for 
IgG 
C1-3 19.53ng/ml 0.4mg/ml 0.8mg/ml 
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3.2.2 Synaptophysin  
To investigate whether the synaptophysin protein was expressed by both human 
and mouse hepatic myofibroblasts, primers were designed to 4 conserved 
regions of the synaptophysin mRNA sequence forming 1 upstream and 3 
downstream primers (Figure 3-5). 
 
 
 
 
Figure 3-5 Conserved regions in rat/human/mouse synaptophysin sequence. Rat, human 
and mouse cDNA sequences were aligned and conserved regions identified. US primer contains 
ATG start codon and the three further sequences identified were reverse complemented for use 
as downstream primers. DS4 is part of the peptide 2 cDNA sequence and DS3 amplifies the 
whole transcribed cDNA sequence. 
PCR confirmed partial 5’ synaptophysin gene expression in myofibroblast 
samples since the full length of the gene could not be amplified. Full length 
synaptophysin mRNA was only present in samples from mouse brain and a 
human neural cell line, SY5Y, which were being used as positive controls since 
both are known to express the synaptophysin protein [245] (Figure 3-6).  
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Figure 3-6 Synaptophysin expression in neural and hepatic myofibroblast samples. RNA 
was isolated from brain, SY5Y cells and hepatic myofibroblast cells using Trizol, quantified and 
reverse transcribed using oligo dT. 40ng were added to PCR mastermix containing 0.5μM 
required primers.  Samples separated according to size on an agarose gel containing ethidium 
bromide to allow visualisation of the PCR products. GAPDH is a housekeeping gene and is used 
to confirm cDNA integrity. Data are representative of 3 technical replicates and of 5 different cell 
protein samples.  
  
To ensure that the bands amplified were in fact synaptophysin, the PCR products 
were cloned into the Zero Blunt TOPO vector (Invitrogen) and sent away for 
sequencing. Table 3-2 shows the results obtained. 
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Synaptophysin mRNA Expression 
 
SYN1US – 
SYN4 DS 
237bp 
 
SYN1US – 
SYN2 DS 
347bp 
 
SYN1US – 
SYN3 DS 
924bp 
Mouse Brain N/D 
100% 
alignment with 
synaptophysin 
sequence 
N/D 
Mouse Hepatic 
Myofibroblasts 
100% 
alignment with 
synaptophysin 
sequence 
96% alignment 
with 
synaptophysin 
sequence 
N/D 
Human SY5Y 
99% alignment 
with 
synaptophysin 
sequence 
100% 
alignment with 
synaptophysin 
sequence 
99% alignment 
with 
synaptophysin 
sequence 
Human Hepatic 
Myofibroblasts 
100% 
alignment with 
synaptophysin 
sequence 
100% 
alignment with 
synaptophysin 
sequence 
N/D 
Table 3-2 Synaptophysin sequencing results. Blunt end PCR products were cloned into Zero 
Blunt TOPO vector (Invitrogen) as detailed in 2.8.2. Results were inputted into a BLAST search to 
determine alignment with synaptophysin sequence. N/D= not detected. Data are representative of 
3 sequencing attempts. 
The table shows that the approximately 1/3 of the synaptophysin sequence could 
be cloned for mouse brain, human SY5Y and human hepatic myofibroblast 
samples with only 96% sequence alignment achieved with mouse hepatic 
myofibroblast samples. This difference could reflect a genuine difference in the 
synaptophysin sequence or a mutation introduced by the high fidelity DNA 
polymerase. However, since the full sequence for synaptophysin could not be 
cloned from either hepatic myofibroblast samples it is unknown whether genuine 
differences occur. The full synaptophysin sequence could only be cloned from the 
human SY5Y sample. 
Matching protein samples were used to confirm protein expression by Western 
blot analysis (Figure 3-7). 
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Figure 3-7 Western blot analysis of synaptophysin expression. Protein concentration from 
whole cell lysates was determined by Lowry analysis and samples diluted to 1.5μg/μl in reducing 
loading buffer. Samples were denatured by heating to 90°Cfor 5 minutes with 10μl loaded onto a 
9% SDS-PAGE gel and separated according to size alongside a prestained protein marker 
(PPM). Proteins were transferred to nitrocellulose membrane, blocked with 3% milk marvel 
solution and probed with rabbit anti synaptophysin or mouse anti βactin primary antibodies. βactin 
is an internal housekeeping gene and serves as a loading control for Western blots. Data are 
representative of 3 technical repeats and are typical of 5 different cell protein samples. 
No synaptophysin protein could be detected in the human hepatic myofibroblast 
sample and only a slight band at approximately 30KDa was present in the mouse 
hepatic myofibroblast sample using commercially available antibodies which bind 
to the C terminal region of the protein. Furthermore, the bands present in mouse 
brain and human SY5Y samples appear to be different sizes suggesting that 
synaptophysin may be modified post translation, e.g. glycosylation. The smaller 
band in the mouse hepatic myofibroblast sample would indicate that the 
synaptophysin protein has been decreased in size, possibly the result of a splice 
variant.  
To confirm that C1-3 was capable of binding to its target cell in vitro, it was 
conjugated to alexa fluorophore 594 and incubated with hepatic myofibroblasts 
isolated from healthy mouse and human livers. To confirm myofibroblast 
phenotype, cells were dual labelled with C1-3-AF in combination with αSMA 
(figures 3-8 and 3-9). 
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Figure 3-8 Mouse hepatic myofibroblasts incubated with C1-3-AF594 and αSMA Cells were 
isolated from C75Bl6 murine livers and cultured on tissue culture plastic causing cellular 
activation into a hepatic myofibroblast phenotype. Myofibroblasts were used for ICC staining 
between passages 1-4. Briefly, 22mmx22mm coverslips were sterilised with 70% ethanol and 
placed into a well of a 6 well plate. Cell numbers were determined using a haemocytometer and 
an equal number of cells seeded per well. Once confluency was reached, cells were incubated 
with 60μg/ml C1-3-AF for 2hrs in HEPES/HBSS for 2hrs at 37°C. Following this cells were fixed 
with 2% formaldehyde/0.2% glutaraldehyde in PBS and permeabilised with ice cold methanol. 
Cells were co-stained with aSMA-FITC. Finally, cell nuclei were stained with DAPI, mounted on 
slides and visualised using a Zeiss fluorescent microscope. Images taken at x200 magnification. 
Images are representative of staining from 3 different cell preparations. 
Figures 3-8 and 3-9 show representative images of the dual ICC staining and 
demonstrates co-localisation of the C1-3-AF with hepatic myofibroblasts 
expressing αSMA. 
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Figure 3-9 Human hepatic myofibroblasts incubated with C1-3-AF594 and αSMA Cells were 
isolated from human explant livers and cultured on tissue culture plastic causing cellular activation 
into a hepatic myofibroblast phenotype. Myofibroblasts were used for ICC staining between 
passages 1-4. Briefly, 22mmx22mm coverslips were sterilised with 70% ethanol and placed into a 
well of a 6 well plate. Cell numbers were determined using a haemocytometer and an equal 
number of cells seeded per well. Once confluency was reached, cells were incubated with 
60μg/ml C1-3-AF for 2hrs in HEPES/HBSS for 2hrs at 37°C. Following this cells were fixed with 
2% formaldehyde/0.2% glutaraldehyde in PBS and permeabilised with ice cold methanol. Cells 
were co-stained with aSMA-FITC. Finally, cell nuclei were stained with DAPI, mounted on slides 
and visualised using a Zeiss fluorescent microscope. Images taken at x200 magnification. Images 
are representative of 2 different cell preparations. 
Whilst the images in figures 3-8 and 3-9 illustrate C1-3 binding to hepatic 
myofibroblasts, it does not confirm that the scAb is specifically binding to 
synaptophysin. To demonstrate this, cos-7 cells were transfected with plasmid 
DNA containing mouse and human synaptophysin expression sequences. To 
determine optimal transfection conditions, cos-7 cells were initially transfected 
with 2 concentrations of the pEgfp-N1 reporter construct (Figure 3-10A) and the 
number of green cells counted to determine transfection efficiency (Figure 3-
10B). The data showed that 2μg of pEgfp-N1 plasmid DNA provided the highest 
transfection efficiency and this was confirmed with the mouse and human 
synaptophysin plasmid DNA (Figure 3-10C). The Western blot probed with a 
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commercial synaptophysin primary antibody revealed multiple bands at the 
predicted protein size suggesting that synaptophysin may be modified post 
translation, e.g. glycosylation.  
Following transfection, the binding of C1-3-AF to synaptophysin was investigated. 
Since previous studies have shown that C1-3 staining works best under native 
conditions, i.e. no fixation, cells were incubated with either C1-3-AF or a 
commercially available synaptophysin antibody (chemicon, CCN) conjugated to 
alexa fluorophore AF594 under both native and fixed conditions. Representative 
images are shown in figure 3-11. 
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Figure 3-10 Transfection of cos-7 cells with eGFP and synaptophysin. A: Cos-7 cells were 
equally seeded into 6 well plates and transfected with two different concentrations of pEgfp-N1 
plasmid DNA vector. Images are representative of fixed untransfected cells and cells transfected 
with 2μg of mouse synaptophysin (mSYN) and human synaptophysin (hSYN). Cell nuclei stained 
with DAPI. Pictures taken at x60 magnification, Scale bar=47.62μm. B: For quantification, the 
number of eGFP positive cells were counted in 5 random fields of view at x400 magnification and 
expressed as a percentage of the total cell number per field of view. C: Untransfected and 
transfected cells were harvested into 100μl of reducing loading buffer, 10μl of which was loaded 
onto a 9% SDS-PAGE gel. Separated proteins were transferred onto a nitrocellulose membrane, 
blocked with 3% milk marvel solution and probed with Chemicon rabbit anti synaptophysin 
primary antibody.  Data are representative of 3 individual experimental repeats.  
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Figure 3-11 C1-3-AF and CCN-AF staining of transfected cos-7 cells under native and fixed 
conditions. Cos-7 cells were equally seeded into 6 well plates and transfected with 2μg of human 
and mouse synaptophysin plasmids for 24hrs at 37°C, 5% CO2. Following this cells were 
incubated with C1-3-AF or CCN-AF in HEPES/HBSS for 2hrs under native conditions before or 
after fixation. Cell nuclei were stained with DAPI and pictures taken at x60 magnification. 
Transfection control represents untransfected cells incubated with specified antibodies. Data are 
representative images of staining observed and are typical of 3 individual experimental repeats. 
Scale bar=20μm. 
The data in figure 3-10 show that C1-3-AF can bind to synaptophysin transfected 
cells under native conditions only whereas the chemicon synaptophysin antibody 
(CCN-AF) can only bind after cell fixation and permeabilisation. This is due to the 
location of the antigen to which the antibody binds, for example peptide 2 is 
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expressed on the cell surface thus C1-3-AF can bind under native conditions 
whereas CCN-AF binds to the C terminal region of the synaptophysin protein 
thus can only bind after permeabilisation. To verify that C1-3-AF is specifically 
targeting and binding synaptophysin positive cells, peptide 2 could be added to 
the culture medium as a competitor for the C1-3 binding site and has previously 
been shown to reduce C1-3 staining in a dose dependent manner [125]. 
The granular appearance of the C1-3-AF staining under native conditions 
suggests that the scAb is being actively taken up into the hepatic myofibroblast 
cell. To determine if this was the case, mouse hepatic myofibroblasts were 
incubated with increasing concentrations of C1-3 for 3 different time periods. 
After extensive washing, cells were harvested into reducing loading buffer and 
analysed by Western blot. Figure 3-12 shows that there is an increasing uptake 
of C1-3 by the cells with increasing C1-3 concentration. C1-3 incubation for 2hrs 
compared to 1hr resulted in increased uptake suggesting this was due to active 
uptake by receptor mediated endocytosis rather than non specific mechanisms. 
After overnight incubation, C1-3 concentration on the Western blot appears to be 
lower when directly compared to the 2hr incubation time point suggesting that 
C1-3 is being broken down by the cells.  
 
 
 
 
 
 
 
 
Figure 3-12 C1-3 uptake by mouse hepatic myofibroblasts. Equal number of mouse hepatic 
myofibroblasts were seeded into 6 well plates and allowed to adhere to the plastic. Specified 
amounts of C1-3 were added to the cells in HEPES/HBSS and allowed to incubate for the 
required time. Following this, cells were thoroughly washed in PBS and directly harvested into 
100μl reducing loading buffer. 10μl of each sample was loaded onto a 9% SDS-PAGE gel and 
separated proteins transferred onto nitrocellulose membrane. Membranes were blocked and 
probed with Goat anti human Cκ light chain.   Data are representative of 3 experimental repeats. 
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The problems associated with the current diagnostic protocols for liver disease 
have led to a surge in publications proposing novel serum markers which exploit 
the changes in matrix deposition however to date non are liver specific. Little 
information is known about synaptophysin expression and function on quiescent 
HSCs and hepatic myofibroblasts thus a binding ELISA was used to detect the 
presence of synaptophysin in serum isolated from fibrotic and non fibrotic mice. 
Figure 3-13 represents the absorbance mean and SD obtained at a serum 
dilution of 1/160. The data show low absorbance readings for wells probed with 
C1-3 to detect synaptophysin, with no differences observed between the 
treatment groups. If synaptophysin was a serum marker of fibrosis, absorbance 
levels would be expected to significantly increase in comparison to the olive oil 
controls. Albumin detection in all treatment groups confirmed that the assay was 
working efficiently. 
 
 
 
 
 
 
 
Figure 3-13 C1-3 ELISA to detect synaptophysin in the serum of fibrotic and non fibrotic 
mice. Whole blood was extracted following schedule 1 termination from olive oil control mice and 
mice treated for 4, 8 and 12wks with CCl4. Isolated serum was initially diluted 1/10 then serially 
diluted across a 96well plate. Serum was incubated with either C1-3, to detect synaptophysin, or 
rat anti albumin, as a positive control since it is the most abundant plasma protein in the blood. All 
experiments performed in triplicate. Data are the mean and SD of absorbance values obtained at 
a serum dilution of 1/160 of triplicate samples and are representative of 3 experimental repeats. 
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3.3 Discussion 
Hepatic myofibroblasts have been identified as the pivotal cell type involved in 
liver fibrogenesis, dictating disease progression or regression. A vast amount of 
research has been dedicated to investigating the mechanistic actions of hepatic 
myofibroblasts in an effort to develop targeted therapeutics which act as a ‘magic 
bullet’ to slow liver fibrosis progression or even stimulate liver regeneration 
following chronic injury.  Targeted therapeutics have many advantages over 
untargeted ones, such as reduced chance of adverse side effects and lower 
levels of therapeutic dose required. However it is essential that the target antigen 
is tissue/cell specific since presence of the antigen outside of the disease site 
could have unprecedented consequences.  
Single chain recombinant antibodies are currently used in clinical practice to 
image tumours [246], target drugs [247] and neutralise cytokines in diseases 
associated with cytokine dysregulation [248]. Advances in recombinant DNA 
technology have allowed the production of recombinant antibodies where the 
target antigen can be designed to user specification allowing unlimited potential 
as clinical therapeutics. 
In 2005, Elrick, Leel et al published a novel method for targeting hepatic 
myofibroblasts using a recombinant scAb developed by the group and was 
termed C1-3. In vitro studies showed that C1-3-FITC was capable of specifically 
binding hepatic myofibroblasts, even when co cultured with other cell types e.g. 
hepatocytes. Furthermore binding of C1-3-FITC to hepatic myofibroblasts was 
blocked upon the addition of extracellular synaptophysin to the cell culture 
medium. The group also demonstrated that C1-3 could be successfully 
conjugated to apoptosis inducing agents, such as tributyl tin isothiocyanate and 
gliotoxin, to successfully deplete hepatic myofibroblasts in vitro and in in vivo 
models of liver fibrosis [125, 126, 249].  
C1-3 specifically binds a region of the synaptophysin protein expressed on the 
surface of hepatic myofibroblasts, termed peptide 2. Synaptophysin was 
identified as a novel marker of human and rat hepatic myofibroblasts in 1999 
[124], and whilst its function on neural cells involves neurotransmitter exocytosis, 
its function for quiescent HSCs and hepatic myofibroblasts is unknown. In order 
to utilise this scAb in further studies, large quantities of the antibody need to be 
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produced for further conjugation reactions. Typically, 1 litre of bacterial culture 
yielded 5-8mg of C1-3 and over 150mg was produced over two years. This 
chapter investigated the production of C1-3 and the binding to its antigen, 
synaptophysin.  
The data in this chapter show that C1-3 could be produced in large quantities 
with further analysis confirming antigen binding ability and purity. Once produced, 
its binding to synaptophysin was further investigated.  
Primers designed to four conserved regions of the mouse/rat/human 
synaptophysin cDNA sequences were used to confirm synaptophysin expression 
in both mouse and human hepatic myofibroblast samples, with neural samples 
from mouse brain and the human cell line SY5Y being used as positive controls. 
PCR products were subcloned into a commercial sequencing vector to ensure 
that the correct product had been amplified. The sequencing results verified 
synaptophysin mRNA expression in all hepatic myofibroblast and neural samples 
however the full sequence could only be successfully cloned from the human 
neural cell line SY5Y. Two thirds of the sequence, which incorporates the peptide 
2 binding site, was successfully amplified from all samples using downstream 
primer 2 (as detailed in table 2-5). To determine if a splice variant of 
synaptophysin is expressed by hepatic myofibroblasts, a poly T primer could be 
used in conjunction with the upstream synaptophysin primer. This would amplify 
the whole synaptophysin sequence and allow for further sequencing analysis.  
Matching protein samples were analysed for synaptophysin protein expression by 
Western blotting. Bands of slightly different sizes were observed in human and 
mouse neural samples, with the differences possibly reflecting post translational 
modifications. However a much smaller band was observed in mouse hepatic 
myofibroblast samples suggesting a splice variant of the synaptophysin sequence 
exists that may possibly create a functionally distinct protein. Interestingly, no 
protein expression was detected in human hepatic myofibroblast samples. This 
result was obtained for two commercially available anti synaptophysin antibodies 
which bind to the C terminal region of the protein. Future work would involve the 
optimisation of C1-3 antibody for use in Western blotting as it has been 
previously shown to detect the peptide 2 synaptophysin sequence [125]. 
90 
Immunocytochemistry (ICC) confirmed that C1-3 was capable of binding to both 
mouse and human hepatic myofibroblasts in vitro as previously described [125, 
249], with hepatic myofibroblast phenotype verified by αSMA staining. Similarly, 
ICC of synaptophysin transfected cells has shown for the first time that C1-3 
actually binds the synaptophysin protein and is internalised, possibly by receptor 
mediated endocytosis, as demonstrated by the granular staining pattern and 
Western blotting, However further work is required to elucidate the precise 
mechanisms involved in C1-3 uptake.  
Currently, there are no published scientific studies which have investigated 
synaptophysin function on quiescent HSCs and hepatic myofibroblasts. With a 
growing interest in serum markers for diagnosing liver fibrosis, serum samples 
from fibrotic and non fibrotic mice were analysed by binding ELISA for 
synaptophysin presence. The studies revealed that synaptophysin could not be 
detected in serum, confirming that synaptophysin could not be used as a serum 
marker of liver fibrosis.  
Whilst the data in this chapter confirm that C1-3 binds to synaptophysin and that 
mRNA expression can be detected by PCR, further work needs to be carried out 
to determine if splice variants of synaptophysin are expressed by hepatic 
myofibroblasts.  
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Chapter 4. The use of C1-3 as an imaging agent 
4.1 Introduction 
Liver disease is a leading cause of morbidity and mortality in the Western world 
and, with an ever increasing incidence, is placing a huge burden on the health 
system. Liver fibrosis is the result of the body’s wound healing response to injury 
which can be triggered by numerous aetiologies. It is a carefully balanced ‘see-
saw’, for example if the insult is removed the balance tips in favour of 
regeneration however if it persists the body tries to encapsulate the injury and the 
deposition of ECM results in the disruption of normal tissue architecture resulting 
in organ functional impairment [15].  
Due to the huge compensatory ability of the liver, liver disease is typically not 
detected until the end stages however it can be detected at earlier stages using 
routine blood tests which detect serum concentrations of amino transferases 
such as ALT and AST [190]. It is crucial to be able to accurately quantify and 
stage fibrosis in order to monitor disease progression and the effects of any 
treatment, especially for viral hepatitis that require constant monitoring to check 
treatment regimes [250]. Currently, the gold standard for disease staging is using 
a liver biopsy, however many clinicians avoid this technique due to the small 
sample size of tissue in comparison to the liver making the result prone to error 
as well as a risk of bleeding and in rare cases results in death [183, 184, 189]. 
This problem has led to a surge in publications proposing novel serum markers 
and new imaging techniques [197], however the majority of serum markers are 
not organ specific and whilst the imaging techniques hold more promise, a lack of 
standardisation and normal results have prevented them being more widely used.  
This chapter investigates using C1-3 as an imaging agent to quantify and stage 
liver fibrosis. It is widely accepted that the hepatic myofibroblast is the key cell 
type involved in liver fibrosis [36] and are characteristically associated with the 
‘scar-regions’ of the liver tissue [251]. Our lab hypothesize that the number of 
hepatic myofibroblasts present is indicative of the stage of fibrosis, with more 
hepatic myofibroblasts being present in chronic liver disease. 
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4.2 Results 
C1-3 and CSDB9 (a control scAb which binds to microcystin, was kindly provided 
by Angela Douglass, Aberdeen University) were conjugated to alexa fluorophore 
594 (AF594). Conjugation was confirmed by SDS-PAGE analysis with a distinct 
increase in molecular weight observed in the C1-3-AF and CSBD9-AF lanes 
(Figure 4-1). 
 
 
 
 
 
Figure 4-1 SDS-PAGE analysis of C1-3 and CSBD9 before and after conjugation to AF594. 
Samples of unconjugated and conjugated antibody were diluted 1:1 with reducing loading buffer. 
Following denaturation, 10μl of each sample was loaded into a well of a 7.5% SDS-PAGE gel 
alongside a prestained protein marker (PPM) and separated according to size. To visualise the 
proteins, each gel was stained for 1hr with coomassie blue, destained for 24hr to remove excess 
stain. Results for C1-3-AF conjugation are typical of 5 separate conjugation reactions. SDS-PAGE 
analysis is typical of 3 technical and repeats.  
Prior to its use in vivo, C1-3-AF was checked to ensure it was capable of binding 
to its antigen using a binding ELISA and incubating it with mouse hepatic 
myofibroblasts. For the binding ELISA, C1-3 and C1-3-AF were initially diluted 
1/10 then serially diluted across a 96 well plate coated with antigens peptide 1 
and 2. Figure 4-2A is a typical representation of the data obtained and shows that 
both C1-3 and C1-3-AF bind to their antigen peptide 2 but not peptide 1. 
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Figure 4-2 Peptide 1 and 2 binding ELISA and ICC of mouse hepatic myofibroblasts to 
check binding ability of C1-3-AF. A: 96 well plates were coated with BSA-conjugated peptide 1 
or peptide 2. Antibody samples of unknown concentrations were initially diluted 1:10 with PBS 
then serially diluted across the plate. Bound antibody was detected using a secondary HRP 
conjugated goat-anti human Cκ light chain antibody and quantified by measuring a colorimetric 
reaction by the addition of TMB and the absorbance at 450nm noted. All experiments were 
performed in triplicate and the mean and SD of the absorbance at dilution 5 (1/160) plotted. Data 
are representative of 3 experimental repeats using different preparations of C1-3 and C1-3-AF. B: 
Following isolation from C75Bl6 mouse livers and subsequent activation on tissue culture plastic, 
mouse myofibroblasts were used for ICC staining between passages 1-4. Cells were incubated 
with 60μg/ml C1-3-AF for 2hrs in HEPES/HBSS for 2hrs at 37°C. Following this cells were fixed 
with 2% formaldehyde/0.2% glutaraldehyde in PBS and permeabilised with ice cold methanol. 
Cells were co-stained with aSMA-FITC. Finally, cell nuclei were stained with DAPI, mounted on 
slides and visualised using a Zeiss fluorescent microscope. Images taken at x200 magnification 
Results are typical of 3 individual experimental repeats.  
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Previous research by the Wright group has shown that synaptophysin expression 
increases following activation of a quiescent HSC to a myofibroblast phenotype 
(unpublished observations). Thus following isolation of mouse hepatic 
myofibroblasts, cells were cells were dual labelled with C1-3-AF and aSMA-FITC. 
Figure 4-2B shows that C1-3-AF colocalises with aSMA-FITC where as no 
staining was observed in the no antibody controls.  
To test C1-3-AF as an imaging agent in vivo, a CCl4 model of chronic liver injury 
was set up dosing C57Bl6 mice twice weekly for seven weeks. 24hr after the final 
dose on the eighth week, control and CCl4 mice were either injected with C1-3-
AF, CSBD9-AF (scab control) or PBS (vehicle control) and sacrificed 3hrs later 
(see Figure 4-3).  
 
 
 
Figure 4-3 Overview of OPT imaging study. Animals received twice weekly injections of CCl4 or 
olive oil for 8 weeks. 24hrs after the final dose the CCl4 and olive oil mice were further subdivided 
into 3 groups to receive either PBS, C1-3-AF or CSBD9-AF via i.p. injection. 3hrs after dosing all 
animals were schedule 1 killed and the livers removed along with a blood sample for serum 
analysis. Each liver was split into 3 samples and either perfused for OPT analysis, fixed in 
formalin or snap frozen in liquid nitrogen. Each treatment group is representative of 3 animals. 
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To ensure that CCl4 treatment had resulted in liver damage, whole blood was 
removed following schedule 1 termination and serum sent for ALP and ALT 
analysis. ALT, an enzyme associated with hepatocytes, is released into the 
circulation following hepatocyte cell death. ALP is an enzyme of hepatobiliary 
origin and is induced during cholestasis due to impaired bile flow. 
Figure 4-4 shows the mean and SD for ALT serum concentrations for each 
treatment group. Since CCl4 treatment does not tend to cause cholestasis [81], 
ALP levels were below the threshold limit which could be accurately detected. 
ALT levels were significantly higher in CCl4 treated mice than the control 
treatment group. 
A small portion of each liver (typically 1cm3) was perfused with an isotonic buffer 
and prepared for OPT analysis. OPT is typically used for investigating gene 
expression in embryos however it is able to show antibody distribution within a 
tissue. Each piece of liver tissue was subjected to both 488nm and 543nm 
wavelengths whilst being slowly rotated and images captured. Exposure to 
488nm was essential to determine tissue morphology as the liver is very 
autofluorescent in this spectrum 
 
 
 
 
 
 
 
 
 
Figure 4-4 Serum concentration of ALT in control and CCl4 treated mice. Mice were schedule 
1 killed and whole blood was removed and allowed to clot at room temperature for 1hr. Serum 
was removed following centrifugation and diluted in 0.9% (w/v) sodium chloride. All serum 
samples were analysed by Newcastle Clinical Biochemistry Department. Data are the mean and 
SD for each treatment group (n=9) and were tested for statistical significance using the Student’s 
two tailed t test. Serum ALT levels in 8wk CCl4 animals were significantly higher than the control 
treatment group (p<0.05).  
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Figure 4-5 Images of control and CCl4 liver scanned with 488nm wavelength using OPT 
setup. Perfused liver samples were fixed in formalin for 48hrs and embedded in low melting point 
agarose. The agarose plug was dehydrated in increasing concentrations of methanol and cleared 
in BABB (1:2 v/v Benzyl Alcohol:Benzyl Benzoate). For OPT analysis, each agarose plug was 
glued to a metal holder and placed onto the microscope. The sample was suspended in BABB 
and an image captured at every 1° rotation using the specified 488nm wavelength. A: Image from 
a control liver from a PBS injected animal B: Images from a fibrotic liver from a PBS injected 
animal. 
Figure 4-5 is a snapshot of the liver tissue scanned from a PBS olive oil control 
mouse and a CCl4 treated mouse. The differences in tissue architecture are quite 
dramatic, blood vessels which can be clearly seen in the olive oil controls (Figure 
4-5A) are lost in the CCl4 treated mice (Figure 4-5B) due to the deposition of 
extracellular matrix. 
To visualise distribution of the labelled antibodies, the tissue was also subjected 
to a wavelength scan at 543nm. Figure 4-6 shows representative images from 
XYZ planes of olive oil control injected with C1-3-AF and CCl4 animals injected 
with PBS, C1-3-AF and CSBD9-AF.  
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Figure 4-6 OPT images from XYZ planes of olive oil control injected with C1-3-AF and CCl4 
animals injected with PBS, C1-3-AF and CSBD9-AF (A-D respectively). Samples were 
scanned, as previously described, using both 488nm and 543nm wavelengths to visualise tissue 
structure and bound antibody. Images from each 1° rotation were manipulated post scanning to 
generate a 3D model of the tissue sample allowing images to be taken throughout the XYZ 
planes. All images are grey scales with bound antibody represented by the lighter pixels. Images 
are representative of data obtained per treatment group (n=3). 
All images are grey scale with lighter pixels representing bound antibody, 
however it is important to note that the technique results in ‘noise’ around the 
edge of the tissue and should not be mistaken for bound antibody. Figure 4-6A 
and C show bound antibody in non fibrotic and fibrotic tissue respectively. Whilst 
a small amount of bound C1-3-AF can be visualised in the non fibrotic tissue, 
there is a large increase in pixel intensity in the fibrotic tissue which seems to be 
in the ‘scar-associated’ regions. There are no lighter pixels in the scar regions in 
the liver samples from CCl4 mice injected with PBS or CSBD9-AF (Figure 4-6 
B&D) confirming that there is no bound antibody 
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To emphasize bound C1-3-AF antibody, images could be manipulated post 
scanning to colour pixels above a certain threshold (Figure 4-7) allowing the 
distribution of hepatic myofibroblasts to be easily visualised within the tissue.  
 
 
 
 
 
 
 
 
 
 
Figure 4-7 OPT images manipulated to emphasise positive staining. All images generated by 
the OPT software are grey scale with bound antibody represented by lighter pixels. The OPT 
software designed by Edinburgh University allows the user to measure individual pixel intensity 
and set a threshold level meaning anything above that intensity represents bound antibody and is 
coloured red. Following analysis the images could be edited to remove ‘noise’ generated by light 
scattering around the edge of the tissue so it was not mistaken as bound antibody. The data 
shown are typical before and after images following pixel manipulation. 
Whilst the data provide proof of concept that a recombinant antibody can be used 
to visualise fibrosis, a major limitation with OPT is sample size. Specimens over 
1cm3 in size have poor resolution therefore this technique could not be used for 
whole liver samples. Furthermore, due to the ‘noise’ the amount of bound 
antibody cannot be accurately quantified thus the technique cannot be used to 
stage and grade fibrosis. 
Recent advances in scientific equipment have led to the development of an in 
vivo imaging system (IVIS) capable of live animal imaging. To ensure that C1-3-
AF was suitable for this system a mouse and its organs were scanned at all pre-
set wavelengths to look at tissue autofluorescence (figure 4-8). 
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Figure 4-8 Autofluorescence scan of whole body and organs. A C57Bl6 mouse was 
anaesthetised and scanned at all pre-set wavelengths available on the IVIS/Living Image system. 
Following this the mouse was schedule 1 killed and its organs (brain, heart, lung, liver, kidney, 
spleen, stomach & pancreas) removed and imaged as before. All data generated using set 
exposure time of 1 second. Regions of interest were drawn around the upper abdominal area and 
excised liver and the total flux measured. The arrow on the bar chart represents the total flux for 
AF594 excitation/emission filter wavelengths.  
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The arrow on the bar chart illustrates the autofluorescence of the whole body and 
liver tissue expected for AF594 in comparison to all other wavelengths pre-set on 
the machine. Whilst the longer wavelengths have reduced autofluorescence in 
the whole body scans there is an increase in the autofluorescence of the excised 
liver tissue. Thus the chosen fluorophore, AF594, should be suitable for animal 
imaging. 
An animal study was set up to determine if IVIS, in combination with C1-3-AF, 
could be utilised to quantify different stages of fibrosis of the whole liver tissue. 
C57Bl6 mice were dosed for either 4, 8 or 12 weeks with CCl4 to induce different 
grades of liver injury whilst controls received olive oil (Figure 4-9). 
 
 
 
 
Figure 4-9 Overview of imaging animal study. Animals were subjected to twice weekly doses 
of CCl4 to induce centrilobular liver fibrosis for either three, seven or eleven weeks. Dosing was 
staggered so that all mice received their final dose of CCl4 during the same week. 24hrs following 
the final dose animals were anaesthetised and a background fluorescence scan taken at the 
appropriate wavelength. Mice were injected via i.v. or i.p. injection and imaged immediately after 
(i.p. only), 10min, 20min, 30min, 45min, 60min and 120min (i.p. only) following injection. After the 
final image, mice were schedule 1 killed and organs (brain, heart, lung, liver, kidney, spleen, 
stomach & pancreas) removed and imaged as before. Auto, 1 second and 10 second exposure 
setting were used at each time point.  
Figure 4-10 to 4-13 are the images for each of the treatment groups over the 1hr 
time course and were generated using a manually set 10 second exposure time. 
Both whole body scans and organ scan were deemed necessary to determine if 
the total flux value in vivo was representative of organ flux since tissues have 
different absorption properties and autofluorescence. 
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Figure 4-10 Whole body and organ scan from control mice which have received C1-3-AF 
via i.v. injection. Images generated with a 10 second exposure since both auto and 1 second 
setting revealed little fluorescence. All images (both body and organ scan) were manipulated post 
scanning to be on the same radiance scale so data can be directly compared. All 4 mice (labelled 
1-4 in the live scans and with respective organs) were injected with 8mg/kg or C1-3-AF and the 
antibody distribution monitored over time. 
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Figure 4-11 Whole body and organ scan from 4wk CCl4 mice which have received C1-3-AF 
via i.v. injection. Images generated with a 10 second exposure since both auto and 1 second 
setting revealed little fluorescence. All images (both body and organ scan) were manipulated post 
scanning to be on the same radiance scale so data can be directly compared. All 4 mice (labelled 
1-4 in the live scans and with respective organs) were injected with 8mg/kg or C1-3-AF and the 
antibody distribution monitored over time. 
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Figure 4-12 Whole body and organ scan from 8wk CCl4 mice which have received C1-3-AF 
via i.v. injection. Images generated with a 10 second exposure since both auto and 1 second 
setting revealed little fluorescence. All images (both body and organ scan) were manipulated post 
scanning to be on the same radiance scale so data can be directly compared. All 4 mice (labelled 
1-4 in the live scans and with respective organs) were injected with 8mg/kg or C1-3-AF and the 
antibody distribution monitored over time. 
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Figure 4-13 Whole body and organ scan from 12wk CCl4 mice which have received C1-3-AF 
via i.v. injection. Images generated with a 10 second exposure since both auto and 1 second 
setting revealed little fluorescence. All images (both body and organ scan) were manipulated post 
scanning to be on the same radiance scale so data can be directly compared. All 4 mice (labelled 
1-4 in the live scans and with respective organs) were injected with 8mg/kg or C1-3-AF and the 
antibody distribution monitored over time. 
For analysis, images from each treatment group were set to the same radiance 
scale so that fluorescence could be visually compared between the images over 
the study time course. Regions of interest (ROI) were manually drawn around the 
upper abdominal area, bladder and each individual excised organ to allow for 
total flux calculation (Figure 4-14). 
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Figure 4-14 Example of the regions of interest used to calculate total flux. Images were 
manipulated post scanning using Living Image 4.0 software using the analysis tools to draw ROI 
around the areas where total flux measurements were required. For the whole body scans total 
flux was measured in the upper abdominal region (for C1-3-AF uptake) and the bladder (for C1-3-
AF excretion). 
Figure 4-15 shows the average total flux for the upper abdominal and bladder 
regions for each treatment group over the time course. Interestingly Figure 4-15A 
shows that there were no significant differences in the upper abdominal total flux 
readings over the time course however it is difficult to interpret the finding since 
some i.v. injections were unsuccessful and remained within the tail sheath, as 
represented by the highly fluorescent tails in figures 4-10 to 4-13. Antibody which 
did enter the circulation was increasingly excreted from the body over the 1hr 
time course as shown by the increase in bladder total flux (Figure 4-15). 
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Figure 4-15 Total flux readings for both upper abdominal and bladder region for each 
treatment group during the 1hr time course. Images were manipulated post scanning using 
Living Image 4.0 software using the analysis tools to draw ROI around the areas where total flux 
measurements were required. Data are mean total flux for each treatment group over the time 
course. SD not plotted for clarity. 
The data from figure 4-15 agree with figure 4-16 which show the total flux from 
the organs excised following imaging. There were no significant differences 
observed in the total liver flux between the treatment groups. The kidneys also 
show a high amount of flux which demonstrates that C1-3-AF is being excreted 
from the body, correlating with the increasing bladder flux in figure 4-15. The 
stomach has a high flux value which may be explained by the autofluorescence 
of chlorophyll in the mouse diet. 
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Figure 4-16 Total flux for all treatment group organs excised following imaging. Images 
were manipulated post scanning using Living Image 4.0 software using the analysis tools to draw 
ROI around the areas where total flux measurements were required. Data are the mean and SD 
of the total flux for each treatment group (n=4 per group) over the time course 
Whilst i.v. injection of C1-3-AF is representative of the current clinical situation, 
the difficulty of the injection increases the chances of the C1-3-AF antibody 
missing the mouse tail vein and remaining in the tail sheath. This presents a 
major problem when trying to investigate whether C1-3-AF can be used as a non 
invasive in vivo measure of liver fibrosis since it cannot be guaranteed that each 
animal receives the same dose of antibody. Therefore it was deemed necessary 
to repeat the experiment and inject the C1-3-AF antibody directly into the 
intraperitoneal cavity.  
Figure 4-17 to 4-20 represent images taken at the specified time points for 
control, 4 wk, 8wk and 12wk CCl4 mice respectively which received C1-3-AF via 
intraperitoneal injection. Data presented are from 1 second exposure only, 
settings auto and 10 second resulted in either too little or a saturated signal. An 
uninjected control mouse was included for each treatment group to provide a 
reference point for tissue and organ autofluorescence. 
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Figure 4-17 Whole body and organ scan from control mice which have received C1-3-AF 
via i.p. injection. Images generated with a 1 second exposure since both auto and 10 second 
setting revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
Mice 1-3 were injected i.p. with 8mg/kg C1-3-AF. 
 
109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-18 Whole body and organ scan from 4wks CCl4 mice which have received C1-3-AF 
via i.p. injection. Images generated with a 1 second exposure since both auto and 10 second 
setting revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
Mice 1-3 were injected i.p. with 8mg/kg C1-3-AF. 
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Figure 4-19 Whole body and organ scan from 8wks CCl4 mice which have received C1-3-AF 
via i.p. injection. Images generated with a 1 second exposure since both auto and 10 second 
setting revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
Mice 1-3 were injected i.p. with 8mg/kg C1-3-AF. 
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Figure 4-20 Whole body and organ scan from 12wks CCl4 mice which have received C1-3-
AF via i.p. injection. Images generated with a 1 second exposure since both auto and 10 second 
setting revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
Mice 1-4 were injected i.p. with 8mg/kg C1-3-AF. 
 
112 
 As described previously, total flux was measured over the time course by 
drawing a box around the upper abdominal region to measure liver fluorescence 
and around the bladder to measure excretion of the fluorophore from the body. 
The data in figure 4-21 show that there is a significantly higher total flux value in 
the upper abdominal region of CCl4 treated mice (at selected time points) in 
comparison to the control and uninjected mice. Furthermore, this value is higher 
in the 4wk CCl4 mice in comparison with the 8wk and 12wk CCl4 mice. 
The total flux in the bladder region follows a different pattern, an initial peak 
between 0-20 minutes suggests quick excretion of excess fluorophore from the 
body followed by a gradual increase between 45 minutes to 2 hours where 
remaining fluorophore is removed. 
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Figure 4-21 Total flux readings for both upper abdominal and bladder region for each 
treatment group during the 2hr time course. Images were manipulated post scanning using 
Living Image 4.0 software using the analysis tools to draw ROI around the areas where total flux 
measurements were required. Data are mean total flux for each treatment group over the time 
course. SD not plotted for clarity. Data tested for statistical significance using the Student’s two 
tailed T test, * represent significance between 4wk CCl4 and control £ represent significance 
between 8wk CCl4 and control and $ represent significance between 12wk CCl4 and control 
(p<0.05). Animal group numbers: Uninjected control n=4, Control/4wks CCl4/8wks CCl4 n=3; 
12wks CCl4 n=4. 
 
Following time course completion, the major organs were excised from each 
animal and total flux measured as previously described. 
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Figure 4-22 Total flux for all i.p. injected treatment group organs excised following 
imaging. Images were manipulated post scanning using Living Image 4.0 software using the 
analysis tools to draw ROI around the areas where total flux measurements were required. Data 
are the mean total flux for each treatment group (n=3 per group 4,8 CCl4 and control injected 
groups, n=4 12wk CCl4 and uninjected controls) over the time course. . Data tested for statistical 
significance using the Student’s two tailed T test; * illustrates significantly lower total flux in brain 
tissue from injected animals in comparison to the liver (p<0.0001); kidney (p<0.0001); stomach 
(p<0.0005); pancreas (p<0.0001) from injected animals. £ illustrates significantly lower total flux in 
the hearts from injected animals in comparison to the liver (p<0.00001); kidney (p<0.0005); 
stomach (p<0.0005); pancreas (p<0.0001) from injected animals. & illustrates significantly lower 
total flux in the lungs from injected animals in comparison to the liver (p<0.0001); kidney 
(p<0.001); stomach (p<0.00001); pancreas (p<0.00001) from injected animals. $ illustrates 
significantly lower total flux in the spleen from injected animals in comparison to the liver 
(p<0.0001); kidney (p<0.005); stomach (p<0.0005); pancreas (p<0.0001) from injected animals. 
#,!,@ and ? represent significantly lower total flux in the organs from the uninjected animals 
compared with the injected animals (# p<005; !,@ ? p<0.05).  
The bar chart in figure 4-22 shows that total flux are significantly higher in the 
liver, kidney, stomach and pancreas of injected animals in comparison to the 
other organs. This shows that the C1-3-AF antibody is binding to synaptophysin 
positive cells in the liver and pancreas as the total flux in these organs is 
significantly higher than the uninjected controls. The high total flux in the kidney, 
combined with the increasing total flux in the bladder regions (figure 4-21) would 
suggest that the antibody is being actively excreted, since the total flux is 
significantly higher in the injected animals compared to the uninjected controls. 
Interestingly, the total stomach flux is higher in the injected animals in 
comparison to the uninjected controls. Whilst some of this is due to the presence 
of autofluorescence compounds in the diet, the data would suggest that C1-3-AF 
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is binding to synaptophysin positive cells in this organ. However, there is no 
evidence in the literature that synaptophysin is expressed by cells in the stomach. 
Figure 4-23 illustrates total liver flux for both i.v. and i.p. injected animals. Whilst 
no change in liver flux is seen in the i.v. injected animals, probably due to the 
difficulty of injection, a clear increase can be seen in the liver of the CCl4 
compared to the injected controls. More importantly this increase is significantly 
higher in mice treated 12 weeks with CCl4 in comparison to the controls.  
 
 
 
 
 
 
 
 
Figure 4-23 Total flux of the excised liver from all treatment groups. Images were 
manipulated post scanning using Living Image 4.0 software using the analysis tools to draw ROI 
around the areas where total flux measurements were required. Data are the mean total flux for 
each treatment group (I.V. n=4 per treatment group, I.P.n=3 per 4,8 CCl4 and control injected 
groups, n=4 12wk CCl4 and uninjected controls) over the time course Data tested for statistical 
significance using Student’s two tailed T test $ represents significance between 12wks CCl4 and 
control (p<0.01); * represent significantly lower total flux in the uninjected controls in comparison 
to the injected animals (p<0.005). 
To confirm that the CCl4 treatment had resulted in liver damage, whole blood was 
removed from each animal following schedule 1 termination and serum sent for 
ALT/ALP analysis. As expected, ALP levels were below the threshold level for 
accurate quantification since CCl4 is not known to cause cholestasis. ALT 
analysis showed a significant increase in serum ALT concentrations in the CCl4 
treated mice in comparison to the controls indicating liver damage had occurred 
(Figure 4-24).  
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Figure 4-24: Serum ALT concentration for all treatment groups. Mice were schedule 1 killed 
and whole blood was removed and allowed to clot at room temperature for 1hr. Serum was 
removed following centrifugation and diluted in 0.9% sodium chloride. All serum samples were 
analysed by Newcastle Clinical Biochemistry Department. Data are the mean and SD for each 
treatment group and were tested for statistical significance using the Student’s two tailed. * 
represent significance between 4wk CCl4 (p<0.001) and control £ represent significance between 
8wk CCl4 and control (p<0.001) and $ represent significance between 12wk CCl4 and control 
(p<0.001). 
To determine if this result reflected the number of hepatic myofibroblasts present 
in the liver tissue, formalin fixed liver tissue was stained with α-SMA-antibody. For 
quantification, slides were examined at x200 magnification and the percentage 
area of positive staining per field of view was determined using Leica software 
and is shown in figure 4-25. 
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Figure 4-25 α-SMA IHC staining and quantification. A: Formalin fixed paraffin embedded 
tissue samples from each animal were cut into 4μm sections. Sections were dewaxed, subjected 
to heat induced antigen retrieval, blocked and incubated for 1hr with Mouse anti αSMA-FITC 
antibody. After extensive washing, bound antibody was detected with Rabbit anti FITC-HRP 
secondary antibody and visualised with DAB chromagen. Finally, sections were counterstained 
with haematoxylin and mounted. All images taken at x200 magnification. B: For quantification, 
pictures were taken around 10 random CLV at x200 magnification and subjected to analysis using 
Leica software to determine the percentage area of the αSMA stain. Data are the mean and SD of 
percentage area of the αSMA stain for each treatment group and were tested for statistical 
significance using Student’s two tailed T test. * represent significance between 4wk CCl4 
(p<0.001) and control; £ represent significance between 8wk CCl4 and 4wk CCl4 (p<0.05); $ 
represent significance between 12wk CCl4 and 8wk CCl4 (p<0.001). Scale bar = 100μm. 
Quantification of the α-SMA stain in figure 4-25 reveals that there is a significant 
increase in the percentage area of positive staining in the CCl4 mice in 
comparison with the control which significantly increases with treatment time.  
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Sections of the liver tissue were also stained with picro-sirius red to allow 
quantification of collagen deposited in response to injury. Upon inspection under 
the light microscope at x200 magnification, CLV were located and moved to the 
corner of the field of view so the band of collagen could be quantified by software 
analysis as previously described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-26 Picro-Sirius red staining and quantification. A: Formalin fixed paraffin embedded 
tissue samples from each animal were cut into 4μm sections. Sections were dewaxed and 
incubated in picro-sirius red stain for 2hrs at room temperature. Excess stain was removed by 2 
washes in acidified H2O (0.5% acetic acid in deionised water) and sections dehydrated in two 
changes of 100% ethanol. Sections were mounted and images taken at x200 magnification. B: 
For quantification 10 random CLV were located and moved to the corner of the field of view to 
allow quantification of the band of collagen by Leica software analysis. Data are mean and SD of 
percentage area of picro-sirius red stain and were tested for statistical significance using 
Student’s two tailed T test. * represent significance between 4wk CCl4 (p<0.001) and control; £ 
represent significance between 8wk CCl4 and 4wk CCl4 (p<0.001). Scale bar = 100μm. 
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Images in figure 4-26A are typical representations of picro-sirius staining 
observed in all treatment groups. Quantification of the collagen staining (figure 4-
26B) revealed a significant increase in the percentage of area stained in all CCl4 
treated mice in comparison with the controls. Initially there is a significant 
increase in positive staining between control-4wks CCl4 and 4-8wks CCl4, 
however no difference is observed between 8 -12wks of CCl4 treatment.  
Whilst the αSMA and picro-sirius red staining show an increase in αSMA staining 
and collagen deposition with increasing treatment time, the organ flux data 
revealed a significant increase in the 12wk CCl4 liver in comparison to the 
injected controls.  However, the upper abdominal flux during the whole body scan 
is somewhat different, with 4 wk CCl4 treatment resulting in a higher flux than the 
two other CCl4 groups. One possible explanation which may account for this is 
the liver tissue itself quenching the fluorescence. A simple experiment was setup 
to test this theory which involved imaging a dose of C1-3-AF fluorophore next to 
and under an uninjected liver.  As anticipated, the placing of the fluorophore tube 
under the liver resulted in 99% quenching of the fluorophore signal (Figure 4-27) 
suggesting that the flux values obtained throughout the experiment may not be 
representative of the true values.  
 
 
 
 
 
 
Figure 4-27 Quenching of C1-3-AF fluorescence by the liver. A: A liver from an uninjected 
C57Bl6 mouse was imaged alongside a 100μl dose of C1-3-AF antibody (0.2mg) using manually 
set 1 second exposure. The fluorophore tube was placed underneath the excised liver and 
imaged as before. The total flux for each of the three regions was determined using Living Images 
4.0 software. B: The arrows on the bar chart highlight the quenching of the fluorophore signal by 
the liver.  
Since the pilot IVIS data revealed the high binding capacity of C1-3-AF in the 
pancreas as well as the liver, a second animal study was set up to investigate 
whether it was able to distinguish pancreatic islet cell mass. Tg (CRH) mice, 
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which appear cusingoid by 21 weeks of age, are known to have increased β cell 
mass to compensate for their insulin resistance and are therefore predicted to 
have a higher pancreatic flux value than C57Bl6 controls [252]. The study was 
set up as before, with the animals being imaged immediately before injection to 
measure background fluorescence, then at 1minute, 10 minutes, 20 minutes, 30 
minutes, 1hr and 2hrs following i.p. injection. An uninjected C57Bl6 mouse was 
imaged alongside the CRH to provide a background reference point for the whole 
body and organ scans. It was decided not to inject the antibody intravenously 
since this had proved difficult in the previous study.  
Figure 4-28 and 4-29 are images taken at the specified time points for CRH and 
control mice respectively. Data presented are from 1 second exposure only since 
auto and 10 second exposures resulted in too little or too much fluorescence. The 
images in both figures show an increase in fluorescence in the upper abdominal 
and bladder regions after C1-3-AF injection. In some mice there appears to be a 
large amount of fluorescence in the lower abdominal region which may be the 
result of some antibody accidentally entering the intestines due to a bad injection. 
Figure 4-29 shows 5 mice being imaged over the experiment time course 
however it is clearly visible that mice 1 and 2 have received a bad injection with 
the antibody being injected subcutaneous instead of into the intraperitoneal 
cavity. As a result of this, it was decided to exclude their organs from the final 
organ scan since it would be difficult to calculate the exact dosage that these 
mice received and in turn normalise the data.  
Upper abdominal and bladder flux were calculated for the CRH mice and the 3 
injected female C57Bl6 controls as previously described. The average total flux 
for each region and treatment group is illustrated in figure 4-30. A significantly 
higher flux was observed in the upper abdominal region of the CRH mice in 
comparison to the controls at 1 and 2hr time points following injection. 
Interestingly, the total flux in the bladder region was significantly higher in CRH 
mice in comparison to the C57Bl6 controls suggesting that either the CRH mice 
excrete the antibody more rapidly than the controls or that the control mice 
received a lower dose of C1-3-AF due to some antibody going subcutaneous. 
However, due to the lack of CRH mice available at the time of the study it was not 
possible to repeat this experiment. 
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Figure 4-28 Whole body and organ scan from CRH mice which have received C1-3-AF via 
i.p. injection. Images generated with a 1 second exposure since both auto and 10 second setting 
revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
 
 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-29 Whole body and organ scan from control mice which have received C1-3-AF 
via i.p. injection. Images generated with a 1 second exposure since both auto and 10 second 
setting revealed too little or too much fluorescence. All images (both body and organ scan) were 
manipulated post scanning to be on the same radiance scale so data can be directly compared. 
Both mice 1 & 2 injections went subcutaneous instead of intraperitoneal thus organs have been 
excluded from the final scan. 
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Figure 4-30 Total flux readings for both upper abdominal and bladder region for each 
treatment group during the 2hr time course. Images were manipulated post scanning using 
Living Image 4.0 software using the analysis tools to draw ROI around the areas where total flux 
measurements were required. Data are the mean total flux for each treatment group over the time 
course (n=3 per treatment group). Data tested for statistical significance using the Student’s two 
tailed T test, * represent significance between C57Bl6 and CRH (p<0.05). 
Previous work by Wallace et al [252] has shown that pancreata in CRH mice are 
significantly smaller compared to C57Bl6 wild type controls. Thus total flux was 
expressed per gram of pancreas weight for each group and is illustrated in figure 
4-31. The data show that CRH mice had a significantly higher total flux value per 
gram of pancreatic weight compared to C57Bl6 controls.  This correlates with 
previous data published [252] and shows that an increase in islet cell mass in 
CRH can be quantified by C1-3-AF imaging.  
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Figure 4-31 Pancreatic flux for each group. Images were manipulated post scanning using 
Living Image 4.0 software using the analysis tools to draw ROI around the areas where total flux 
measurements were required. Uninjected control represents female C57Bl6 mouse. Tg(CRH) and 
C57Bl6 were injected with 8mg/kg C1-3-AF. Data are the mean total flux for the pancreata. Data 
tested for statistical significance using the Student’s two tailed T test, * represent significance 
between C57Bl6 and CRH (p<0.05). 
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4.3 Discussion 
Recent advances in scientific research have led to a greater understanding of the 
mechanisms involved during fibrosis and the proposal that fibrosis may in fact be 
reversible [126, 253]. Therefore if diagnosed during the early stages therapeutic 
strategies could be implemented to halt or even reverse disease progression 
before end stage liver failure is reached.  
C1-3, a single chain antibody fragment, was generated by the Wright group in 
2005 and was shown to specifically target synaptophysin positive hepatic 
myofibroblasts in the liver [125]. Since hepatic myofibroblasts have been shown 
to be the principal cell type involved in fibrosis progression and matrix deposition 
[36, 91] it has been postulated that the number of hepatic myofibroblasts present 
within the tissue may be indicative of the stage of fibrosis.  
Single chain antibodies are being increasingly used in clinical practice to target 
therapies [247] and image tumours [246] due to their specificity, ability to 
penetrate tissue and fast excretion from the body. Therefore this chapter set out 
to investigate whether C1-3 would be a suitable imaging agent to successfully 
distinguish between the stages of fibrosis. 
In order to address this question, C1-3 was successfully conjugated to alexa 
fluorophore 594 and its binding activity tested in vitro. In vivo function was tested 
in an animal model of liver fibrosis, where mice had been treated with CCl4 to 
induce centrilobular damage due to hepatocyte apoptosis and necrosis. OPT 
analysis showed clear distribution of C1-3-AF in the fibrotic liver, particularly in 
scar regions around CLV. As expected, C1-3-AF was also present in the control 
non fibrotic livers, albeit to a lesser extent. This is because synaptophysin is 
expressed by both quiescent HSCs and hepatic myofibroblasts thus under 
normal conditions there are a few quiescent HSCs which reside in the space of 
Dissé, sensing the microenvironment [124]. Bound antibody could be easily 
visualised by colouring pixels above a threshold limit, as determined by analysis 
of control samples. Whilst this highlighted the difference in antibody distribution 
between the treatment groups, the lack of ability to actually quantify the number 
of coloured pixels and normalise for ‘noise’ makes it impossible to conclude if any 
significant differences were observed. 
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Whilst the data provide proof of concept that single chain antibodies can be used 
to successfully image liver fibrosis, as with many of the new detections methods 
recently proposed there are major limitations with regard to OPT technology. 
OPT has been developed to fill the gap between confocal microscopy and MRI 
imaging and is typically used to map gene expression pathways in embryos over 
1cm across [254]. The technique relies on shadows generated when light is 
shone at the sample and the intensity at each point recorded. A computer 
programme translates the data into a 3D image which can be further manipulated 
with imaging software. The liver samples used for analysis were approximately 
1cm3 and even at this size there was poor resolution within the centre of the 
tissue due to insufficient lighting. To compensate for this, threshold values could 
be altered post-scanning to increase pixel intensity however this tended to 
increase the noise surrounding the tissue thus a compromise had to be made. 
More importantly, however, OPT is subject to the same complications and 
sampling errors as a needle biopsy and whilst it provides a novel method for 
assessing hepatic myofibroblast numbers it is unlikely that this technique will be 
used in a clinical setting.  
The emergence of a highly sensitive, non invasive imaging system that allows the 
visualisation and tracking of fluorophores in the body and tissue of live animals 
led to the novel proposal that C1-3-AF could be used as a non invasive measure 
of liver fibrosis. To test this theory, three different stages of liver fibrosis were 
generated in mice by dosing for 4, 8 and 12 weeks with CCl4 whilst control mice 
received olive oil. After their final dose of CCl4 or olive oil, each treatment group 
was injected with C1-3-AF and its distribution monitored over time using 
Xenogen’s IVIS® 200 series imager. To replicate a clinical setting, C1-3-AF was 
injected into mice via two routes, either intravenously or in the intraperitoneal 
cavity. It was predicted that i.v. injection would provide the most useful data since 
distribution of the antibody to the liver would be much quicker in the circulatory 
system and would reduce the possibility of non specific background fluorescence. 
However, injection of the antibody into the tail vein was more difficult than first 
thought and on many occasions a substantial proportion of the dose remained 
within the tail sheath thus no difference in upper abdominal and organ flux was 
observed between the fibrotic stages.  
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I.P. injection proved much more successful and showed that at specific time 
points (particularly 45 and 60 minutes after injection) there was a significantly 
higher upper abdominal total flux in comparison with the injected control animals. 
Interestingly, the upper abdominal flux was highest in the mice treated for 4 
weeks with CCl4 suggesting that there are a higher number of synaptophysin 
positive hepatic myofibroblasts involved during the early stages of liver disease. 
To determine if this is an accurate representation of the number of synaptophysin 
positive hepatic myofibroblast it would be necessary to quantify cell number by 
IHC staining and RT-PCR analysis. 
To determine if the whole body readings actually reflected the fluorescence of the 
organ, following completion of the time course the mice were schedule 1 killed 
and organs removed. In order to fully account for the whole body readings, it was 
deemed necessary to remove the brain, heart, lungs, kidney, pancreas, spleen 
and stomach as well as the liver to ensure that C1-3-AF was specifically targeting 
its antigen. The data revealed an increase in liver total flux with increasing CCl4 
treatment time however this difference was only significant for the 12wk CCl4 
mice in comparison to the olive oil controls. This suggests that there is an 
increasing number of synaptophysin positive hepatic myofibroblasts throughout 
disease progression and that this number corresponds to the stage of fibrosis.  
Immunohistochemical staining revealed a similar trend with collagen deposition 
significantly increasing during treatment time due to the significant increase in the 
number of αSMA positive myofibroblasts. This work agrees with a previous study 
which similarly demonstrated that αSMA could be used a marker to stage fibrosis 
and to monitor therapeutic treatments since the number of  αSMA cells reflected 
the disease status [251].  
Whilst the liver organ flux values provide proof of concept that C1-3-AF can be 
detect advanced fibrosis, it should be noted that these values were not reflective 
of the upper abdominal flux values in the whole body scans. The organ scan 
revealed significantly higher total flux in the liver, kidney, stomach and spleen in 
comparison to the brain, heart, lungs and spleen of injected animals. A high total 
flux in the kidney was due to excretion of the excess antibody, as shown by the 
increase in total flux in the bladder regions during the liver animal imaging. 
Interestingly, quantification revealed that animals injected C1-3-AF had a 
significantly higher stomach total flux compared to the uninjected controls. Whilst 
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the autofluorescence of chlorophyll in the mouse diet contributes to the total 
value, the data suggest that C1-3-AF is binding to cells within the stomach. As 
there is no evidence in the literature that the stomach contains synaptophysin 
positive cells, it would be necessary to carry out synaptophysin IHC on stomach 
tissue to investigate this further. The high total flux reading for the pancreas can 
be accounted for by the expression of synaptophysin in the islet cells [255]. It is 
therefore possible that the slight difference in total flux readings in the whole body 
scan may be enhanced or accounted for by the fluorescence of the pancreas and 
the stomach.  
A simple experiment, where an uninjected liver was placed over a dose of C1-3-
AF, proved that the liver was capable of quenching up to 99% of the fluorescent 
signal therefore an animal experiment was set up to determine if the total flux 
readings in the upper abdominal region were dependent upon the expression of 
synaptophysin in the pancreas. Total flux in the upper abdominal region of CRH 
mice, known to have increased islet cell mass due to insulin resistance [252], was 
significantly higher than C57Bl6 wild type controls. Furthermore, they had a 
significantly higher total flux per gram of pancreas weight than the controls 
indicating that C1-3-AF was a useful tool in measuring islet cell mass. However, 
due to the difference in bladder total flux suggesting different dosing of C1-3-AF 
fluorophore and lack of animals, it would be necessary to repeat this experiment 
to confirm the result. 
This chapter shows that C1-3-AF may be useful in quantifying the number of 
synaptophysin positive hepatic myofibroblasts in explant liver tissue, with the 
number of hepatic myofibroblasts increasing with disease progression. However 
its use as a non invasive marker of liver fibrosis may be limited due to the 
expression of synaptophysin in the pancreas which in turn affects the total flux 
measurement of the upper abdominal region as well as the quenching of the 
fluorescent signal by the liver. One way to overcome this may be to use a 
fluorophore which emits near the infrared end of the spectrum, since the 
absorbance spectra of the body fluids and tissues are much lower in the near 
infrared region [256]. Ideally, 3D scans would be conducted on each individual 
mouse to map the fluorescence to a particular organ allowing for more accurate 
flux values to be calculated; however with the technology currently available 
during this pilot study this was not feasibly possible.  
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Finally, it is important to note another limitation of C1-3-AF as an imaging agent. 
Immunohistochemical studies of the fibrogenic response during liver disease 
caused by different aetiological agents have revealed that there are functionally 
and morphologically distinct populations of myofibroblasts present during fibrosis 
[52, 53]. More importantly however, studies have shown that during portal 
fibrosis, for example, the portal fibroblast is dominant and is closely associated 
with scar regions [55]. Unfortunately, these cells do not express synaptophysin 
[124] therefore an animal study of obstructive cholestasis would be necessary to 
determine the involvement of synaptophysin positive hepatic myofibroblasts 
during disease progression.  
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Chapter 5. Use of C1-3-GT to investigate the role of hepatic 
myofibroblasts in liver regeneration 
5.1 Introduction 
The liver has a remarkable ability to regenerate following injury or loss of tissue.  
It is generally mediated by replication of existing hepatocytes although a 
progenitor cell repopulation can occur if hepatocyte replication is inhibited [129, 
257]. The complex pathways governing the initiation and termination of liver 
regeneration have been under investigation for years yet many areas are still not 
well understood.  
Although the stimulus for the initiation of liver regeneration is unclear, it is widely 
accepted that hepatic myofibroblasts and macrophages are the main source of 
IL-6 and TNFα [131-133, 135, 138], the two cytokines responsible for priming 
hepatocytes to respond to the mitogens HGF and EGF [160, 258]. Once primed, 
the hepatocytes undergo 2-3 rounds of cell division to restore liver mass after 
70% hepatectomy. 
Hepatic myofibroblasts are thought to play a key role in liver regeneration, not 
only providing the key cytokines responsible for priming hepatocytes but are also 
a source of serotonin [146], a neurotransmitter which is believed to play a pivotal 
role in regeneration. However, researchers investigating the possible reversal of 
liver fibrosis have shown that the induced apoptosis of these cells results in 
degradation of the collagen scar and an improvement in tissue function [100, 102, 
249].  
C1-3-GT has been shown to target hepatic myofibroblasts in vivo and 
significantly reduce fibrosis severity in a recovery model [126].  Thus, this 
antibody will therefore be used in a two thirds partial hepatectomy (PHx) model to 
investigate the role hepatic myofibroblasts in liver regeneration. 
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5.2 Results 
Prior to the investigation, C1-3 was conjugated to gliotoxin as described in the 
materials and methods sections. Successful conjugation was confirmed by SDS-
PAGE (figure 5-1), where a distinct increase in molecular weight could be seen in 
the C1-3-GT sample in comparison to C1-3. Western blotting using rabbit anti 
gliotoxin antibody proved that this increase was due to gliotoxin conjugation. 
 
 
 
 
 
 
 
Figure 5-1 SDS-PAGE and Western blot analysis of samples from the C1-3-GT conjugation 
process. Samples were taken throughout the conjugation process and diluted 1:1 with reducing 
loading buffer. After denaturation, 10μl of each sample was loaded onto a 9% SDS-PAGE gel 
alongside a prestained protein marker and separated according to its size. To visualise the 
proteins, each gel was stained for 1hr with coomassie blue, destained for 24hr to remove excess 
stain. For Western blot analysis, proteins were transferred to a nitrocellulose membrane, blocked 
with 3% milk marvel solution, and probed with rabbit anti gliotoxin. Results are typical of 5 
individual antibody conjugation reactions. 
To ensure that conjugation of gliotoxin had not resulted in functional impairment 
of the antibody a binding ELISA was used. Figure 5-2 shows that C1-3-GT is able 
to bind to its antigen peptide 2 with C1-3 being used as a positive control. 
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Figure 5-2 Peptide 1 and 2 binding ELISA for C1-3 and C1-3-GT. 96 well plates were coated 
with BSA-conjugated peptide 1 or peptide 2. Antibody samples of unknown concentrations were 
initially diluted 1:10 with PBS then serially diluted across the plate. Bound antibody was detected 
using a secondary HRP conjugated goat-anti human Cκ light chain antibody and quantified by 
measuring a colorimetric reaction by the addition of TMB and the absorbance at 450nm noted. All 
experiments were performed in triplicate and the absorbance at dilution 5 (1/160) plotted. Results 
are typical of 5 separate antibody conjugation reactions. 
Following confirmation of binding ability, C1-3-GT was routinely checked by 
addition to cultures of activated human and mouse hepatic myofibroblasts. Figure 
5-3 is an example of the results obtained from in vitro cell detachment assays. 
Adherent cells were counted from 5 random fields of view per treatment group 
and expressed as a percentage of cells attached using the average cell number 
from time zero. Both C1-3 and DMSO (vehicle control for free gliotoxin) did not 
affect cell attachment however the addition of free gliotoxin rapidly induced cell 
apoptosis and detachment. C1-3-GT caused a much slower detachment of cells, 
possibly due to the process required for the uptake and processing of the C1-3 
antibody itself. Even after 24 hours, approx 35% remained attached in the C1-3-
GT treatment group compared to those treated with free GT which may be 
explained by the heterogeneity of synaptophysin expression on hepatic 
myofibroblasts. Whilst cell detachment is not a direct measure of apoptosis in 
itself, it provides a very quick and crude measurement to confirm that the C1-3-
GT is working.  To confirm apoptosis, it would be necessary to measure caspase 
3 activity in the live cell cultures using commercially available kits. 
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Figure 5-3 In vitro assessment of C1-3 & C1-3-GT activity. Hepatic myofibroblasts were 
isolated from C57Bl6 mouse livers and cultured on plastic for 1-2 weeks until fully activated. Cells 
were seeded at equal densities into 24 well plates and incubated with either 4.5μg C1-3, 4.5μg 
C1-3-GT (to give approximately 450 pmol GT/well), DMSO or GT (450pmol GT/well) in serum free 
medium for up to 24hrs. The number of adherent cells were counted in 5 random fields of view at 
the specified time points and expressed as a percentage of cells attached. Experiments were 
performed in triplicate and data at each time point are the mean and SD per treatment group. 
Data are representative of 2 experimental repeats.   
An animal study to investigate the role of hepatic myofibroblasts in liver 
regeneration was set up using the two thirds PHx model. This is a popular model 
used to investigate liver regeneration as tissue is easily removed due to the multi 
lobular structure of the liver thus the regenerative process is not influenced by 
outside factors e.g. necrosis or inflammation. Mice were dosed with C1-3-GT at 
critical time points to ensure hepatic myofibroblast depletion before and after 
surgery whilst control animals received C1-3. Each mouse was weighed before 
surgery and the amount of liver removed recorded. Sham hepatectomies were 
performed to ensure that the surgical procedure itself did not have any impact on 
the regenerative process, where the mice were subjected to the same procedure 
except that the liver was not removed. This is outlined by the schematic diagram 
in Figure 5-4. 
 
134 
 
 
 
 
 
 
 
Figure 5-4 Overview of partial hepatectomy animal study. Male C57Bl6 mice were injected 
with 4mg/kg of C1-3+/-GT 1 hr prior to and at 1, 12, 24 and 36hrs following two thirds PHx 
surgery. Mice were schedule 1 killed at 4, 36 and 72hrs following surgery which were key time 
points identified in the liver regeneration process. Sham hepatectomies were performed to ensure 
the results were not due to the procedure itself and were subjected to the same surgery except no 
liver tissue was removed. Animals were weighed prior to and after surgery. Liver tissue removed 
at the time of surgery and following sacrifice was recorded as a measure of liver regeneration. 
Whole blood samples were taken at the time of sacrifice for serum analysis of liver enzyme 
markers. Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr n=3; 
72hr n=4. Sham n=3 per treatment group and time point.  
 
At each time point the mice were sacrificed and their livers removed and 
weighed.  To verify that the remaining liver weight could be used as a measure of 
liver regeneration between the treatment groups, the liver removed during 
surgery was expressed as a percentage of the total body weight. As shown in 
figure 5-5A, there is no significant difference in the percentage of liver removed 
between treatment groups. 
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Figure 5-5 Assessment of liver regeneration using liver weight. A:  Animals were weighed 
prior to surgery and the amount of liver removed during surgery recorded. Data are the mean and 
SD of the percentage of total liver removed with respect to (wrt) body weight for all C1-3 and C1-
3-GT treatment groups. Average liver weight is the mean and SD from 5 wild type C57Bl6 mice 
which were weighed prior to schedule 1 killing and their liver weights noted. B: At each time point, 
animals were weighed prior to schedule 1 sacrifice and the remaining liver removed and weighed. 
Data represent the remaining liver weight wrt body weight. Data are the mean and SD for each 
treatment group at each specified time point. Animal group numbers: C1-3 4hr n=5; 36hr n=6; 
72hr n=4. C1-3-GT 4hr n=4; 36hr n=3; 72hr n=4. Sham n=4 per treatment group and time point. 
Figure 5-5B displays the remaining liver weight, once the animal has been 
sacrificed, as a percentage of body weight. The graph shows that whilst the liver 
of the sham mice remains relatively stable, there is a sharp decrease in liver 
weight in mice subjected to PHx at 4hr followed by a gradual increase in weight 
over 36-72hrs. This clearly demonstrates that the livers in these mice are 
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regenerating however no significant differences were observed between the 
treatment groups. 
Following sacrifice serum was sent for analysis of the liver enzymes ALT and 
ALP. These enzymes are markers of hepatocyte damage and cholestasis 
respectively, however since PHx does not incur much damage to the liver or 
blockage of bile flow it was expected that there should be no difference in these 
enzymes between the treatment groups. The results are shown in figure 5-6. 
 
 
 
 
 
 
 
 
 
 
Figure 5-6 ALT serum concentration in partial hepatectomy and sham mice. Mice were 
schedule 1 killed and whole blood was removed and allowed to clot at room temperature for 1hr. 
Serum was removed following centrifugation and diluted in 0.9% sodium chloride. All serum 
samples were analysed by Newcastle Clinical Biochemistry Department. Data are the mean and 
SD for each treatment group. Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 
4hr n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time point. 
Interestingly, ALT levels rose in both sham and PHx groups at 4hrs (Figure 5-6), 
possibly the result of the surgical procedure itself, nevertheless there were no 
significant differences between groups. As expected, ALP remained below 
threshold limits thus could not be accurately measured.  
To investigate whether the hepatic myofibroblasts had in fact been targeted and 
depleted by C1-3-GT, portions of the liver from each group were stained for the 
presence of αSMA positive myofibroblasts. Slides from olive oil control and 4wk 
CCl4 mice were included as staining controls since it is widely known that CCl4 
treatment elicits hepatic myofibroblast proliferation, representative images are 
shown in figure 5-7. Upon inspection of the tissue under the light microscope, it 
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was discovered that α-SMA positive cells were present in specific regions of the 
tissue, and more importantly they were surrounding either the centrilobular veins 
or the portal tracts. Thus, for quantification 10 random PT regions and 10 random 
CLV regions were photographed at x200 magnification and the number of 
positive cells counted. An image representing each treatment group and time 
points are shown in figures 5-8 to 5-9. The images show that 4wk CCl4 treatment 
resulted in an increase in the number of αSMA positive hepatic myofibroblasts 
surrounding the CLV only. However, only a few αSMA positive hepatic 
myofibroblasts are observed surrounding the PT and CLV in PHx mice 
suggesting that they are not a major cell involved in the response to PHx unlike 
CCl4 treatment. Quantification of αSMA positive cells is shown in figure 5-10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7 Immunohistochemical staining of αSMA cells in olive oil control and 4wk CCl4 
liver tissue. Formalin fixed paraffin embedded tissue samples from each animal were cut into 
4μm sections. Sections were dewaxed, subjected to heat induced antigen retrieval, blocked and 
incubated for 1hr with mouse anti αSMA-FITC antibody. After extensive washing, bound antibody 
was detected with rabbit anti FITC-HRP secondary antibody and visualised with DAB chromagen. 
Finally, sections were counterstained with haematoxylin and mounted. All images taken at x200 
magnification.  The images from the olive oil control and 4wk CCl4 groups are representative of 5 
individual animals. Images are representative of the 10 random PT and CLV photographed from 
each treatment group. Scale bar=100μm. 
 
 
 
 
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8 Immunohistochemical staining of α-SMA cells surrounding PT. Formalin fixed 
paraffin embedded tissue samples from each animal were cut into 4μm sections. Sections were 
dewaxed, subjected to heat induced antigen retrieval, blocked and incubated for 1hr with mouse 
anti αSMA-FITC antibody. After extensive washing, bound antibody was detected with rabbit anti 
FITC-HRP secondary antibody and visualised with DAB chromagen. Finally, sections were 
counterstained with haematoxylin and mounted. All images taken at x200 magnification. Images 
are representative of the 10 random PT photographed from each treatment group. Scale 
bar=100μm. Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr 
n=3; 72hr n=4. Sham n=3 per treatment group and time point. 
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Figure 5-9 Immunohistochemical staining of α-SMA cells surrounding CLV. Formalin fixed 
paraffin embedded tissue samples from each animal were cut into 4μm sections. Sections were 
dewaxed, subjected to heat induced antigen retrieval, blocked and incubated for 1hr with mouse 
anti αSMA-FITC antibody. After extensive washing, bound antibody was detected with rabbit anti 
FITC-HRP secondary antibody and visualised with DAB chromagen. Finally, sections were 
counterstained with haematoxylin and mounted. All images taken at x200 magnification. Images 
are representative of the 10 random CLV photographed from each treatment group. Scale 
bar=100μm. Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr 
n=3; 72hr n=4. Sham n=3 per treatment group and time point. 
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Figure 5-10 Quantification of αSMA cells around PT and CLV. For quantification, pictures 
were taken around 10 random PT (A) and CLV (B) at x20 magnification and the number of αSMA 
positive cells with clear nuclear staining counted. Data are the mean and SD of the number of 
αSMA cells for each treatment group at each time point and were tested for statistical significance 
using Student’s two tailed T test. * represents significance between C1-3-GT PHX in comparison 
to C1-3 PHX (p<0.001); £ represent statistical significance between no treatment and 4wk CCl4 
(p<0.0001). The data from the no treatment and 4wk CCl4 groups are representative of 5 
individual animals and 10 random fields of view for both PT and CLV. PHx animal group numbers: 
C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr n=3; 72hr n=4. Sham n=3 per 
treatment group and time point. 
Treatment of mice with C1-3-GT resulted is a significant increase in the number 
of αSMA positive cells surrounding portal tracts at 36 and 72hrs (Figure 5-10A) 
whereas no significant difference was observed between the treatment groups of 
αSMA positive cells around centrilobular veins (Figure 5-10B). The αSMA counts 
in the 4 wk CCl4 treated animals show that liver regeneration following PHx 
invokes the proliferation of hepatic myofibroblasts surrounding PT rather than the 
CLV. 
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Next, RT-PCR was used to quantify total gene expression of αSMA in liver 
samples from each treatment group and normalised to an 18S rRNA standard. 
The data in figure 5-11 show a significant increase in expression of the αSMA 
gene 4hrs after surgery in C1-3-GT treated PHx mice in comparison to the C1-3 
PHx controls. This increase is mirrored by an increase in the number of αSMA 
positive cells at 36 and 72hr in C1-3-GT PHx mice (figure 5-10). 
 
 
 
 
 
 
 
 
 
 
Figure 5-11 Relative gene expression levels of α-SMA sham and PHx mice. RNA was 
isolated from each mouse liver using Trizol, quantified and reverse transcribed using oligo dT. 
RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan software. 
Data are the mean and SD of the fold change relative to 18S standard and normalised to αSMA 
expression in C1-3 SHAM operated mice at 4hrs. Data tested for statistical significance using 
Student’s two tailed T test, * represent significance between C1-3-GT PHX and C1-3 PHX 
(p<0.01). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr n=3; 
72hr n=4. Sham n=3 per treatment group and time point. All samples performed in duplicate. 
To determine if the increase in αSMA gene expression and cell number was 
reflective of the number of synaptophysin expressing hepatic myofibroblasts, liver 
tissue from all animals was stained for the presence of synaptophysin and the 
number of positive cells surrounding PT and CLV counted at x400 magnification. 
Mouse pancreatic tissue, used as a positive control to ensure the antibody was 
working correctly, shows staining of synaptophysin positive beta cells in the 
pancreatic islets (figure 5-12). Liver tissue from olive oil controls and 4wk CCl4 
mice were included as a positive control since previous work by our group has 
demonstrated successful C1-3-GT mediated hepatic myofibroblast depletion in 
8wk CCl4 mice [126]. Representative images from these two treatment groups 
are shown in figure 5-13. Representative images from each treatment group and 
time point are illustrated in figures 5-14 and 5-15, and quantified in figure 5-16. 
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Figure 5-12 Immunohistochemical staining of synaptophysin in mouse pancreatic tissue. 
Formalin fixed paraffin embedded tissue samples from each animal were cut into 4μm sections. 
Sections were dewaxed, subjected to heat induced antigen retrieval, blocked and incubated 
overnight with rabbit anti synaptophysin antibody. After extensive washing, bound antibody was 
detected with goat anti rabbit HRP secondary antibody and visualised with DAB chromagen. 
Finally, sections were counterstained with haematoxylin and mounted. All images taken at x 400 
magnification and are representative of the staining observed in the pancreatic tissue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-13 Immunohistochemical staining of synaptophysin cells in untreated and 4wk 
CCl4 liver tissue. Formalin fixed paraffin embedded tissue samples from each animal were cut 
into 4μm sections. Sections were dewaxed, subjected to heat induced antigen retrieval, blocked 
and incubated overnight with Rabbit anti Synaptophysin antibody. After extensive washing, bound 
antibody was detected with Goat anti Rabbit HRP secondary antibody and visualised with DAB 
chromagen. Finally, sections were counterstained with haematoxylin and mounted. All images 
taken at x 400 magnification. The images from the olive oil controls and 4wk CCl4 groups are 
representative of 5 individual animals. Images are representative of the 10 random PT and CLV 
photographed from each treatment group. Scale bar=50μm. 
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Figure 5-14 Immunohistochemical staining of synaptophysin around PT. Formalin fixed 
paraffin embedded tissue samples from each animal were cut into 4μm sections. Sections were 
dewaxed, subjected to heat induced antigen retrieval, blocked and incubated overnight with rabbit 
anti synaptophysin antibody. After extensive washing, bound antibody was detected with goat anti 
rabbit HRP secondary antibody and visualised with DAB chromagen. Finally, sections were 
counterstained with haematoxylin and mounted. All images taken at x 400 magnification. Images 
are representative of the 10 random PT photographed from each treatment group. Scale 
bar=50μm. 
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Figure 5-15 Immunohistochemical staining of synaptophysin around CLV. Formalin fixed 
paraffin embedded tissue samples from each animal were cut into 4μm sections. Sections were 
dewaxed, subjected to heat induced antigen retrieval, blocked and incubated overnight with rabbit 
anti synaptophysin antibody. After extensive washing, bound antibody was detected with goat anti 
rabbit HRP secondary antibody and visualised with DAB chromagen. Finally, sections were 
counterstained with haematoxylin and mounted. All images taken at x 40 magnification. Images 
are representative of the 10 random CLV photographed from each treatment group. Scale bar 
=50μm. 
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Figure 5-16 Quantification of synaptophysin cells around PT and CLV. For quantification, 
pictures were taken around 10 random PT (A) and CLV (B) at x400 magnification and the number 
of synaptophysin positive cells with clear nuclear staining counted. Data are the mean and SD of 
the number of synaptophysin cells for each treatment group at each time point and were tested 
for statistical significance using Student’s two tailed T test, * represents significance between C1-
3-GT PHX in comparison to C1-3 PHX (A: p<0.005) (B: p<0.0005); £ represents significance 
between olive oil control and 4wk CCl4 (p<0.0001); $ represents a significant increase in 
synaptophysin positive cells surrounding CLV in sham mice in comparison to olive oil control 
(p<0.0001); & represents a significant increase in synaptophysin positive cells surrounding CLV in 
PHx mice in comparison to olive oil control (p<0.0001). 
Quantification revealed a significant increase in the number of synaptophysin 
positive cells surrounding both PT and CLV in C1-3-GT PHx mice at 72hrs in 
comparison to C1-3 controls. No significant differences were observed at other 
time points (Figure 5-16).  Synaptophysin counts from olive oil control and 4wk 
CCl4 mice revealed that the number of synaptophysin positive cells surrounding 
CLV was significantly higher in CCl4, sham and PHx mice in comparison to the no 
treatment controls. This suggests that the surgical procedure itself causes the 
proliferation of a few synaptophysin positive hepatic myofibroblast. 
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Synaptophysin gene expression was further quantified using RT-PCR and the 
data (figure 5-17). 
 
 
 
 
 
 
 
 
Figure 5-17 Relative gene expression levels of synaptophysin in sham and PHx mice. RNA 
was isolated from each mouse liver using Trizol, quantified and reverse transcribed using oligo 
dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software. Data are the mean and SD of the fold change relative to 18S standard and normalised 
to synaptophysin expression in C1-3 SHAM operated mice at 4hrs. Data tested for statistical 
significance using Student’s two tailed T test, * represents significance between C1-3-GT SHAM 
and C1-3 SHAM (p<0.05). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 
4hr n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time point. All samples 
performed in duplicate. 
Whilst C1-3-GT caused a significant decrease in synaptophysin gene expression 
in sham mice at 4hrs (Figure 5-17), no significant difference were observed in the 
PHx groups at any of the time points. Furthermore, at 36hrs there are no 
significant differences in synaptophysin gene expression between the treatment 
groups which are reflective of the quantified IHC staining in figure 5-16. 
Liver regeneration begins with the priming of hepatocytes to respond to growth 
factors in order to begin the 2-3 rounds of proliferation required to restore liver 
mass. The two key cytokines implicated in this process are TNFα and IL-6, which 
are produced by kupffer cells and hepatic myofibroblasts, were quantified by RT-
PCR and are shown in figure 5-18. 
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Figure 5-18 Relative gene expression levels of TNFα and IL-6 in sham and PHx mice. RNA 
was isolated from each mouse liver using Trizol, quantified and reverse transcribed using oligo 
dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software.  Data are the mean and SD of the fold change relative to 18S standard and normalised 
to TNFα (A) or IL-6 expression (B) in C1-3 SHAM operated mice at 4hrs. Data tested for statistical 
significance using Student’s two tailed T test, * represents significance between C1-3-GT PHX 
and C1-3 PHX (p<0.001). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr 
n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time point. All samples performed in 
duplicate. 
As demonstrated in figure 5-18, PHx mice treated with C1-3-GT had a significant 
increase in TNFα gene expression at 4hr in comparison to mice treated with C1-
3. An increase in IL-6 gene was also observed at the same point in the same 
treatment group however this difference was not significant. TNFα and IL-6 
cytokines are only necessary during the initial stages of liver regeneration to 
prime the hepatocytes to respond to growth factors which may explain why gene 
expression levels fell dramatically at 36 and 72hrs. IL-6 protein expression was 
also quantified by immunohistochemistry using an anti-IL6 antibody. Positive cells 
were counted using the same guidelines set up for the αSMA staining. Figures 5-
19 and 5-20 are representative images from each treatment group at each time 
point. 
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Figure 5-19 Immunohistochemical staining of IL-6 around PT. Formalin fixed paraffin 
embedded tissue samples from each animal were cut into 4μm sections. Sections were dewaxed, 
subjected to heat induced antigen retrieval, blocked and incubated overnight with rabbit anti IL-6 
antibody. After extensive washing, bound antibody was detected with goat anti rabbit HRP 
secondary antibody and visualised with DAB chromagen. Finally, sections were counterstained 
with haematoxylin and mounted. All images taken at x 200 magnification. Images are 
representative of the 10 random PT photographed from each treatment group. Scale bar=100μm. 
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Figure 5-20 Immunohistochemical staining of IL-6 around CLV. Formalin fixed paraffin 
embedded tissue samples from each animal were cut into 4μm sections. Sections were dewaxed, 
subjected to heat induced antigen retrieval, blocked and incubated overnight with rabbit anti IL-6 
antibody. After extensive washing, bound antibody was detected with goat anti rabbit HRP 
secondary antibody and visualised with DAB chromagen. Finally, sections were counterstained 
with haematoxylin and mounted. All images taken at x 200 magnification. Images are 
representative of the 10 random CLV photographed from each treatment group. Scale 
bar=100μm. 
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Both groups treated with C1-3-GT saw a significant increase in the number of IL-
6 positive cells surrounding both portal tracts and CLV at 4hr (Figure 5-21). No 
differences were seen between the groups at any further time points as IL-6 is 
only required for the priming phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-21 Quantification of IL-6 cells around PT and CLV. For quantification, pictures were 
taken around 10 random PT (A) and CLV (B) at x400 magnification and the number of IL-6 
positive cells with clear nuclear staining counted. Data are the mean and SD of the number of IL-6 
cells for each treatment group at each time point and were tested for statistical significance using 
Student’s two tailed T test, * represents significance between C1-3-GT in comparison to C1-3 
treatment groups (A: p<0.005) (B: p<0.0005). 
Researchers have demonstrated that hepatocyte growth factor, synthesised by 
non-parenchymal cells particularly the hepatic myofibroblast, and epidermal 
growth factor, are the two main growth factors involved in stimulating the 
hepatocytes to proliferate. These growth factors, which are found in the tissue in 
the first 4hrs following PHx, were quantified using RT-PCR (figure 5-22). 
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Figure 5-22 Relative gene expression levels of HGF and EGF in sham and PHx mice. RNA 
was isolated from each mouse liver using Trizol, quantified and reverse transcribed using oligo 
dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software. Data are the mean and SD of the fold change relative to 18S standard and normalised 
to HGF (A) or EGF (B) expression in C1-3 SHAM operated mice at 4hrs. Data tested for statistical 
significance using Student’s two tailed T test, B: * represents significance between C1-3-GT PHX 
and C1-3 PHX (p<0.05). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr 
n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time point. All samples performed in 
duplicate. 
Figure 5-22A shows that at 4hrs there was no difference in HGF gene expression 
between treatment groups which suggests that intracellular sources of HGF are 
being released to stimulate hepatocyte proliferation. At 36 and 72hr HGF gene 
expression was not significantly different when compared to the sham controls.  
EGF gene expression did not vary significantly at 36hr and 72hr post 
hepatectomy (Figure 5-22B). However, C1-3-GT treatment of PHx mice resulted 
in a significant increase in EGF gene expression at 4hrs in comparison to the C1-
3 PHx group. 
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To determine if the changes in growth factor and cytokine gene expression 
between the treatment groups had any significant effect on cellular proliferation, 
bromodeoxyuridine (BrDU) was injected into each animal 4 hours prior to 
sacrifice. BrDU is a synthetic nucleotide that is an analogue of thymidine and is 
incorporated into the newly synthesised DNA of proliferating cells. Images in 
figure 5-23 and 5-24 are typical representations of BrDU staining around CLV 
and PT at each time point and are quantified in figure 5-25 and 5-26. 
Quantification was carried out as previously described however the number of 
positive parenchymal (e.g. hepatocytes) and non parenchymal (e.g. hepatic 
myofibroblasts) cells, as distinguished by cell morphology, were counted 
separately. 
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Figure 5-23 Immunohistochemical staining of BrDU around PT. Formalin fixed paraffin 
embedded liver tissue from each animal were cut into 4μm sections. Slides were dewaxed, 
subjected to heat induced antigen retrieval and incubated with mouse anti BrDU primary antibody 
overnight at 4°C. After extensive washing, bound antibody was detected using a goat anti mouse-
HRP secondary antibody and visualised with DAB chromagen. Sections were lightly 
counterstained with haematoxylin and mounted with coverslips. All images taken at x200 
magnification and are representative of the 10 random PT photographed from each treatment 
group.  
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Figure 5-24 Immunohistochemical staining of BrDU around CLV. Formalin fixed paraffin 
embedded liver tissue from each animal were cut into 4μm sections. Slides were dewaxed, 
subjected to heat induced antigen retrieval and incubated with mouse anti BrDU primary antibody 
overnight at 4°C. After extensive washing, bound antibody was detected using a goat anti mouse-
HRP secondary antibody and visualised with DAB chromagen. Sections were lightly 
counterstained with haematoxylin and mounted with coverslips. All images taken at x200 
magnification and are representative of the 10 random CLV photographed from each treatment 
group. 
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Quantification of these cells shows that at 4hr there is a significant increase in the 
number of proliferating parenchymal cells surrounding both PT and CLV in PHx 
mice treated with C1-3-GT compared to the C1-3 PHx control (Figures 5-25A and 
5-26A). C1-3-GT treatment of sham operated mice resulted in a significant 
decrease in the number of proliferating non parenchymal cells surrounding the 
PT (Figure 5-25B) 
At 36hr, there is no difference in the number of BrDU positive parenchymal and 
non parenchymal cells in the sham groups however treatment of PHx mice with 
C1-3-GT results in a significant decrease in the number of BrDU positive 
parenchymal and non parenchymal cells surrounding both PT and CLV in 
comparison to the C1-3 controls (Figures 5-25 and 5-26). Finally, at 72hr there is 
only a significant increase in the number of non parenchymal cells surrounding 
PT in PHx mice treated with C1-3-GT (Figure 5-25B). 
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Figure 5-25 BrDU quantification of parenchymal and non parenchymal cells surrounding 
PT. For quantification, the number of parenchymal (A) and non parenchymal (B) cells with clear 
BrDU nuclear staining surrounding 10 random PT regions were counted at x200 magnification. 
Data presented are the mean and SD of the average number of cells for each treatment group at 
each time point. Statistical significance was tested using Student’s two tailed T test * represents 
significance between C1-3-GT PHX and its respective C1-3 PHx control £ represents significance 
between C1-3-GT SHAM and C1-3 SHAM control. (A: 4hr p<0.05 36hr p<0.005) (B £4hr p<0.05 
*36hr p<0.005 *72hr p<0.05). 
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Figure 5-26 BrDU quantification of parenchymal and non parenchymal cells surrounding 
CLV. For quantification, the number of parenchymal (A) and non parenchymal (B) cells with clear 
BrDU nuclear staining surrounding 10 random CLV regions were counted at x200 magnification. 
Data presented are the mean and SD of the average number of cells for each treatment group at 
each time point. Statistical significance was tested using Student’s two tailed T test, * represents 
significance between C1-3-GT PHX and its respective C1-3 PHX control (A: 4hr p<0.05 36hr 
p<0.0001) (B: 36hr p<0.05). 
Relative gene expression levels of the cellular markers of proliferation were 
quantified using TaqMan probes (figure 5-27). Cyclin D1, E1 and cyclin-
dependent kinase 2 (CDK2) are essential for the transition of cells from G1 
(growth) to S (synthesis) phase of the cell cycle. The data in figure 5-27A and C 
show that cyclin D1 and CDK2 expression is significantly higher in C1-3-GT PHx 
mice at 4hrs in comparison to the C1-3 control. Whilst levels of cyclin D1 remain 
relatively stable at 36 and 72hr in the PHx mice, there is a significant decrease in 
cyclin D1 expression in the sham operated mice at 36hr that correlates with the 
reduced number of BrDU positive parenchymal cells in figures 5-25A and 5-26A.  
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Figure 5-27 Relative gene expression levels of Cyclin D1, E1 and CDK2 in sham and PHx 
mice. RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed 
using oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems 
TaqMan software. Data are the mean and SD of the fold change of cyclin D1(A), cyclin E1(B) and 
CDK2 (C) relative to 18S standard and normalised to expression levels in C1-3 SHAM operated 
mice at 4hrs. Data tested for statistical significance using Student’s two tailed T test, A/C: * 
represents significance between C1-3-GT PHX vs. C1-3 PHX (p<0.005); $ represents significance 
between PHX vs. SHAM mice at 36hrs (p<0.0005). Animal group numbers: C1-3 4hr n=5; 36hr 
n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time 
point. All samples performed in duplicate. 
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The data in figure 5-27B and C follow a similar trend, with a significant increase in 
cyclin E1 and CDK2 gene expression at 36hr in the PHx mice in comparison to 
the sham operated controls. However, unlike the BrDU data in figures 5-25 and 
5-26, there are no significant differences in gene expression levels of the cellular 
proliferation markers between the C1-3 and C1-3-GT treatment groups.  
Collagen type I is a fibrillary collagen and is one of the common components of 
the interstitial ECM surrounding PT and CLV. Hepatic myofibroblasts are the 
principal cell type involved in collagen type I production and during centrilobular 
induced liver fibrosis the deposition of collagen type I disrupts the basement-
membrane like matrix resulting in functional impairment and organ failure. 
Relative expression levels of collagen type I was quantified using RT-PCR (figure 
5-28). Collagen 1a1 is the gene which encodes the major component of collagen 
type I. 
 
 
 
 
 
 
 
Figure 5-28 Relative gene expression levels of collagen 1a1 in sham and PHx mice. RNA 
was isolated from each mouse liver using Trizol, quantified and reverse transcribed using oligo 
dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software. Data are the mean and SD of the fold change relative to 18S standard and normalised 
to expression levels in C1-3 SHAM operated mice at 4hrs. Data tested for statistical significance 
using Student’s two tailed T test, $ represents significance between PHX vs. SHAM mice at 36hrs 
(p<0.001). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. C1-3-GT 4hr n=4; 36hr 
n=3; 72hr n=4. Sham n=3 per treatment group and time point. All samples performed in duplicate. 
The data in figure 5-28 show a significant increase in col1a1 expression in PHx 
mice at 36hr following surgery in comparison to sham controls which would 
correlate with the deposition of interstitial matrix around new PT and CLV. 
Although a significant increase in hepatic myofibroblasts around PT was 
observed in C1-3-GT PHx mice at 36 and 72hrs (figure 5-10), this was not 
associated with an increase in col1a1 gene expression.  
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Following PHx the liver grows back to its precise mass and does not exceed it 
with molecules such as TGFβ, IL-1β and Activin A implicated in controlling the 
process however their exact mechanisms still remain elusive. Relative expression 
levels of TGFβ1 and IL-1β were quantified by RT-PCR and are illustrated in 
figure 5-29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-29. Relative gene expression levels of TGFβ1 and IL-1β in sham and PHx mice. 
RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed using 
oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software. Data are the mean and SD of the fold change of TGFβ (A) and IL-1β (B) relative to 18S 
standard and normalised to expression levels in C1-3 SHAM operated mice at 4hrs. Data tested 
for statistical significance using Student’s two tailed T test, A/C: * represents significance between 
C1-3-GT PHX vs. C1-3 PHX (p<0.05). Animal group numbers: C1-3 4hr n=5; 36hr n=6; 72hr n=4. 
C1-3-GT 4hr n=4; 36hr n=3; 72hr n=4. Sham n=3 per treatment group and time point. All samples 
performed in duplicate. 
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It was predicted that the gene expression levels of these two cytokines would 
peak around 72hrs after PHx surgery since cellular proliferation would be almost 
completed and liver mass almost returned to normal. The data in figure 5-29A 
shows a significant increase in TGFβ gene expression in C1-3-GT mice at 4hrs in 
comparison to C1-3 controls. This may account for the decrease in cellular 
proliferation, as measured by BrDU incorporation, observed in the C1-3-GT mice 
at 36hrs (figures 5-25 and 5-26). However, PHx surgery did not affect the relative 
gene expression levels of both cytokines since expression remained relatively 
constant between all treatment groups at both 36 and 72hr time points. This does 
not necessarily mean that these cytokines are not involved in the inhibition of 
proliferation, for example IL-1β is intracellularly stored, thus it can be readily 
released without the need for gene transcription.  
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5.3 Discussion 
The liver has the remarkable ability to regenerate following injury or even when 
up to 75% of the tissue is lost, and it is this response which may be critical in 
determining the outcome of chronic disease. Typically, liver mass is restored by 
the proliferation of existing hepatocytes however oval cell proliferation can be 
induced if hepatocyte proliferation has been inhibited. 
The pathways governing liver regeneration have been under investigation for 
many years with the two thirds partial hepatectomy model, first proposed by 
Higgins and Anderson in 1931 [128], providing a useful paradigm for studying 
organ growth [180]. Although this model was slightly modified for use with mice, it 
has identified key components in the initiation, proliferation and termination of 
liver regenerative pathways. More importantly, however, this model has shown 
that the liver has many redundant pathways governing each phase of 
regeneration which are capable of compensating if key components are 
inhibited/removed and tend to only delay regeneration rather than preventing it 
altogether.  
The activation and transdifferentiation of the hepatic stellate cell into a hepatic 
myofibroblast has been shown to be a key event in fibrosis, furthermore its 
lifespan is thought to dictate the course of fibrosis leading to either cirrhosis or 
regression [36, 91, 100, 253]. Their role in liver regeneration is somewhat 
complex, since they produce key factors responsible for the priming and 
proliferation of hepatocytes e.g. IL-6, HGF and serotonin  [131, 138, 146] yet also 
secrete factors responsible for the termination of liver regeneration e.g. TGFβ 
[259].  
Few studies have actually investigated the outcome of hepatic myofibroblast 
depletion during liver regeneration yet many researchers are proposing that their 
depletion during fibrosis is crucial for disease reversal  [100-102, 126, 249] which 
may have severe consequences for liver function and patient well being. C1-3-GT 
has been shown to specifically target and deplete synaptophysin positive hepatic 
myofibroblasts during CCl4 induced liver injury in mice, with 60%  depletion of 
total myofibroblasts significantly reducing fibrosis severity [126]. This chapter 
utilises the targeted apoptotic effects of C1-3-GT to investigate the role of hepatic 
myofibroblasts during the regenerative process initiated by two thirds PHx.  
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After successful conjugation and functional testing in vitro, C1-3-GT was injected 
into the intraperitoneal cavity of mice at crucial time points during liver 
regeneration, as determined by the current scientific literature. The remaining 
liver weight was used as a measure of liver regeneration between the treatment 
groups since there were no significant differences observed in the average liver 
weight removed during surgery.  
Initial experiments set out to prove that C1-3-GT had specifically targeted and 
depleted synaptophysin positive hepatic myofibroblasts. Quantification of αSMA 
IHC staining showed a significant increase in the number of αSMA positive cells 
surrounding the PT at 36 and 72hrs in the PHx mice treated with C1-3-GT. This 
result was unexpected since previous studies have shown that C1-3-GT 
treatment resulted in a significant decrease in the number of αSMA positive cells 
[126, 249]. Interestingly, synaptophysin IHC revealed no significant differences in 
the number of synaptophysin cells in the first 36hrs after surgery for all treatment 
groups. The data suggest that the C1-3-GT has not worked in vivo since both the 
IHC and RT-PCR reveal no differences in the number of synaptophysin positive 
cells or any changes in gene expression at both 4 and 36hr. Furthermore, a 
significant increase in both αSMA and synaptophysin positive cells at 72hr would 
suggest that C1-3-GT treatment stimulated cellular proliferation.  
The inclusion of αSMA and synaptophysin counts from untreated and 4wk CCl4 
mice revealed that the number of hepatic myofibroblasts proliferating in response 
to the PHx stimulus is significantly lower than CCl4 treatment suggesting that 
hepatic myofibroblasts do not play a major role in liver regeneration. Furthermore, 
only a few synaptophysin positive cells were present in the liver tissue of the 
sham and PHx mice, which was similar to CCl4 treatment, thus if any cells had in 
fact been depleted it may be difficult to show this.  
Animal studies using knockout mice have implicated IL-6 and TNFα as the 
principal cytokines involved in the initiation of the regenerative process and are 
important in priming the resident hepatocytes to be responsive to growth factors 
[132, 136]. This process is believed to be instigated by TNFα, which upon binding 
to its receptor on non parenchymal cells in the liver stimulates the activation of 
the NFκB pathway and the subsequent production of IL-6. Hepatic myofibroblasts 
are a known source of IL-6 [131] thus it was predicted that their removal would 
reduce hepatocyte priming and subsequent proliferation. In this study, cytokine 
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levels were quantified by RT-PCR and once normalised, fold change in gene 
expression was calculated with respect to expression in sham C1-3 mice at 4hrs. 
As anticipated, the data showed a significant increase in TNFα gene expression 
in C1-3-GT PHx mice with respect to C1-3 PHx controls. This trend has been 
previously observed by our group when C1-3-GT has been administered to mice 
with acute CCl4 induced liver injury (unpublished observations). Whilst a similar 
trend was observed with IL-6 gene expression this difference was not significant. 
However when IL-6 was quantified using IHC staining a significant increase in the 
number of IL-6 positive cells around both PT and CLV was observed in C1-3-GT 
PHx  and sham mice at 4hrs following surgery.  
RT-PCR analysis of the two growth factors essential in stimulating hepatocyte 
proliferation, HGF and EGF, showed that hepatic myofibroblast depletion resulted 
in a significant increase in EGF gene expression in C1-3-GT PHx mice at 4hrs in 
comparison to C1-3 PHx control. EGF has been shown to be essential in liver 
regeneration since removal of the salivary gland prior to PHx prevented 
subsequent liver regrowth [160] however the relationship between EGF and 
hepatic myofibroblasts is unknown. No differences were observed in HGF 
expression between the treatment groups at any of the time points analysed, 
however research groups have shown that HGF is capable of binding matrix 
proteins thus the initial sources of HGF may be released by matrix remodelling 
rather than active secretion by hepatic myofibroblasts [154, 155].  
Whilst no differences in liver regeneration were observed at 4hrs, as determined 
by liver weight, BrDU incorporation was shown to be significantly higher at 4hrs in 
parenchymal cells surrounding both PT and CLV in C1-3-GT PHx mice 
suggesting that the increase in priming cytokines accelerated the proliferative 
response in response to the elevated EGF levels. This also correlated with a 
significant increase in the cellular markers of proliferation (cyclin D1, E1 and 
CDK2) in C1-3-GT PHx mice at 4hrs post surgery. Cyclin E1 binds CDK2, a 
component essential for the transition from G1 phase to S phase. This complex 
also binds cyclin A1 which is necessary for the completion of S phase. Cyclin D1, 
which forms a complex with and is a regulatory subunit of CDK4 or CDK6 is also 
required for the passage of the cell from the G1 phase of the cell cycle to the S 
phase.  
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Taken together, the data suggest that the depletion of hepatic myofibroblasts 
using C1-3-GT stimulates an increase in TNFα and IL-6 expression which could 
result in accelerated liver regeneration. However, analysis of cellular proliferation 
at 36hrs revealed that hepatic myofibroblast depletion resulted in a significant 
decrease in BrDU incorporation in parenchymal and non parenchymal cells 
surrounding both PT and CLV in C1-3-GT PHx mice. Whilst relative expression 
levels of cyclin D1, E1 and CDK2 were significantly higher in the PHx mice at 
36hr in comparison to the sham controls, there were no significant differences 
between the treatment groups of the PHx at 36 and 72hrs. It is possible that the 
decrease in BrDU incorporation at 36hrs is associated with the increase in αSMA 
positive myofibroblasts and suggests a possible regulatory role for hepatic 
myofibroblasts. To confirm this theory, it would be necessary to a dual label IHC 
stain for BrDU and αSMA to reveal any cellular proximity relationships.  
Analysis of TGFβ and IL-1β, two cytokines implicated in the termination of liver 
regeneration, revealed a significant increase in TGFβ expression in C1-3-GT PHx 
mice at 4hrs only with no differences in IL-1β observed between the treatment 
groups at any of the time points. It is therefore possible that the increase in TGFβ 
may account for the decreased proliferative response at 36hr since addition of 
TGFβ to hepatocytes in culture inhibited their proliferative response [167, 168]. In 
vivo inhibition of TGFβ signalling prior to PHx surgery resulted in an early peak in 
DNA proliferation and was associated with accelerated entry into the S phase of 
the cell cycle, as determined by an increase in cyclin D1 and E [171].  More 
importantly, the study showed that hepatocyte proliferation halted when the 
correct liver mass was reached suggesting that TGFβ signalling is not essential 
for the termination of liver regeneration. To investigate whether hepatic 
myofibroblast depletion affected the termination of proliferation, it would be 
interesting to extend the time course beyond 5 days, the normal time taken for 
liver regeneration to occur. 
At 72hrs, there were no differences in cellular proliferation markers between the 
treatment groups. Intriguingly, quantification of synaptophysin staining revealed a 
significant increase in the number of synaptophysin positive cells surrounding 
both PT and CLV at this time point in C1-3-GT treated mice. Whilst 
synaptophysin is a marker of quiescent HSCs and hepatic myofibroblasts, it is 
also expressed by oval cells which reside in the canals of herring and can 
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transdifferentiate into hepatocytes and biliary epithelial cells when required [260]. 
Therefore it is possible that the decrease in parenchymal and non parenchymal 
cell proliferation at 36hrs may be compensated for by the activation of the oval 
cell response. To investigate this possibility it would be necessary to do a dual 
label IHC stain of synaptophysin and another oval cell marker e.g. OV-6.  
The data generated by this study propose a complex role for hepatic 
myofibroblasts in liver regeneration. Following PHx, the data suggest that hepatic 
myofibroblasts exert a suppressive effect on kupffer cells restricting the 
expression of the priming cytokines and in turn controlling the number of 
hepatocytes undergoing cellular proliferation. In conjunction with this, hepatic 
myofibroblasts are known sources of hepatocyte growth factors, HGF and 
serotonin [146, 149], therefore are essential in ensuring that hepatocytes enter 
the cell cycle (Figure 5-30A). Depletion of hepatic myofibroblasts using C1-3-GT 
removes the inhibitory effect on the kupffer cells which leads to an increase in 
TNFα and IL-6 gene expression and stimulates accelerated entry into the cell 
cycle. However a reduction in parenchymal cell proliferation is also observed, and 
whilst the data show no significant changes in HGF expression between the 
treatment groups, this would suggest that hepatic myofibroblasts produce and 
express a key component involved in modulating hepatocyte proliferation, for 
example serotonin (Figure 5-30B). In conclusion, the data reveal that hepatic 
myofibroblasts have distinct, opposing roles during liver regeneration and further 
work is necessary to determine if hepatic myofibroblast depletion is a viable 
option during disease. 
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Figure 5-30 Proposed roles of hepatic myofibroblast during liver regeneration. A: Hepatic 
myofibroblasts exert a suppressive effect on kupffer cells and thus controls the release of TNFα. 
They also produce an unknown component which stimulates passage of hepatocytes into the G1 
phase of the cell cycle. B: Depletion of HM increases TNFα production by kupffer cells but 
decreases hepatocyte proliferation. 
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Chapter 6. Use of C1-3-GT to investigate the effect of hepatic 
myofibroblast depletion during sustained liver injury 
6.1 Introduction 
Hepatic fibrosis is a wound healing response to liver injury caused by a wide 
range of aetiologies. In the UK alone, liver disease is the 5th biggest killer (source 
British Liver Trust) and with a surge in alcohol consumption and obesity the 
incidence can only increase. With no treatments currently available, a vast 
majority of research is dedicated to the cells involved in the disease progression 
to try and discover new therapeutic options.  
The literature to date has provided convincing evidence that hepatic 
myofibroblasts are the key cell involved in fibrosis [102, 253]. More importantly, 
emerging evidence has shown that removal of hepatic myofibroblasts can 
stimulate the reversal of fibrosis in recovery models [126, 249]. However this is 
not a perfect clinical representation since it is not always possible to remove the 
damaging insult. This chapter aims to investigate the effect of C1-3-GT mediated 
hepatic myofibroblast depletion during sustained CCl4 induced liver injury. 
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6.2 Results 
It was decided to use C1-3-FITC as a conjugated antibody control, successful 
conjugation to FITC was confirmed by an increase in molecular weight on a 9% 
polyacrylamide gel (Figure 6-1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 SDS-PAGE and peptide a/2 binding ELISA to confirm C1-3-FITC conjugation and 
function A: Samples of C1-3, C1-3 endotoxin (ETX) free and C1-3-FITC were diluted 1:1 with 
reducing loading buffer and 10μl of each sample was loaded onto a SDS-PAGE gel. Results are 
typical of 3 separate conjugation reactions. B: 96 well plates were coated with BSA-conjugated 
peptide 1 or peptide 2. Antibody samples of unknown concentrations were initially diluted 1:10 
with PBS then serially diluted across the plate. Bound antibody was detected using a secondary 
HRP conjugated goat-anti human Cκ light chain antibody and quantified by measuring a 
colorimetric reaction by the addition of TMB and the absorbance at 450nm noted. All experiments 
were performed in triplicate and the mean absorbance and SD at dilution 5 (1/160) plotted. 
Results are typical of 3 experimental repeats. 
To check antibody binding ability, a binding ELISA was also carried out. Figure 6-
1B demonstrates that C1-3-FITC is capable of binding to its antigen peptide 2. 
C1-3 binding was measured at the same time as a positive control and although 
C1-3 has a slightly higher absorbance at dilution 5 this is likely due to slight 
differences in antibody concentration and not antibody affinity. C1-3-GT 
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functionality was tested as previously described in the methods section 2.4.3 and 
2.7.9 and was shown in figures 5-1 to 5-3. 
To test the effect of myofibroblast depletion during sustained liver injury a CCl4 
model of livery injury was set up (figure 6-2). 
 
  
 
 
 
 
 
 
 
Figure 6-2 Overview of animal study indicating C1-3 and CCl4 dosing times. Male C57Bl6 
mice were dosed for 4,6,10 or 12wks with CCl4 or with olive oil for 4 or 10wks. CCl4 and olive oil 
T=0 mice were schedule 1 killed following 4 and 10wks of treatment. The remaining mice received 
CCl4 treatment for a further 2 weeks with either C1-3-FITC/GT dosing every other day. Tail vein 
bleeds were taken at strategic time points during the final two weeks of treatment and serum sent 
for analysis of liver damage. Whole blood was extracted following schedule 1 killing and serum 
sent for analysis of liver damage markers. Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk 
n=6; 10wk n=5. C1-3-FITC 6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8. 
Two time points of 6 and 12 weeks of CCl4 treatment were chosen since they 
represent chronic injury and end stage cirrhosis. Although most liver disease is 
diagnosed at its end stages it is clinically relevant to know if therapeutic 
treatments would be effective at both the early and end stage time points. Tail 
bleeds were carried out at two strategic time points throughout the final two 
weeks of therapy to determine if the treatments were having any effect on the 
serum marker of liver fibrosis, ALT. 48hrs following the final dose of CCl4 and C1-
3, mice were killed and livers harvested. CCl4 and olive oil mice were also 
harvested at 4/10wks to serve as baseline controls for injury. Serum from each 
treatment group and time point was sent for ALT/ALP analysis as an indicator of 
liver injury (figure 6-3). 
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Figure 6-3 Assessment of liver damage using the serum marker ALT. Whole blood was 
extracted following either tail vein bleed or schedule 1 killing. Whole blood was allowed to clot at 
room temperature for 1hr. Serum was removed following centrifugation and diluted in 0.9% (w/v) 
sodium chloride. All serum samples were analysed by Newcastle Clinical Biochemistry 
Department. Data are the mean and SD for each treatment group. Animal group numbers: Olive 
oil 4/10wk n=3. CCl4 4wk n=6; 10wk n=5. C1-3-FITC 6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8. 
Figure 6-3 shows that there are no significant differences in ALT serum 
concentration after both tail bleeds and the final terminal bleeds. Serum ALT 
concentrations from the terminal bleeds are substantially lower than the tail vein 
bleeds however this is most likely due to the dosing of CCl4 two days before 
termination. Whilst the data would suggest that C1-3-GT is not having an affect 
on liver fibrosis, it is unlikely that serum ALT quantification would be sensitive 
enough to distinguish between the later stages of fibrosis. Since ALP is an 
enzyme released during cholestasis, levels were typically below an accurate 
threshold measurement thus have not been presented.  
To determine if C1-3-GT was successfully depleting hepatic myofibroblasts in 
vivo paraffin embedded liver tissue sections were stained for the presence of 
αSMA and the number of cells surrounding each CLV quantified using Leica 
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software analysis of the percentage area stained. Representative images and 
quantification are illustrated in figures 6-4 and 6-5. 
Quantification revealed that there is a significantly higher percentage of αSMA 
staining present in the CCl4 treated animals compared to the olive oil controls for 
both treatment times of CCl4 (figure 6-4B and 6-5B). However the number of 
hepatic myofibroblasts, as determined by the percentage of area stained since it 
is very difficult to accurately quantify cell number, remained relatively constant 
between 4-10wks of CCl4 (figure 6-4B and 6-5B) treatment suggesting that 
increased treatment time does not necessarily correlate with increased hepatic 
myofibroblast number. Ideally, hepatic myofibroblast number would be 
determined by counting the number of positive cells with clear nuclear staining 
however the dense staining pattern observed makes this task very difficult and 
error prone. Nevertheless, treatment with C1-3-GT for an additional 2 wks after 
4wks of CCl4 did not reduce αSMA stainig in comparison with the C1-3-FITC 
control (figure 6-4B). Interestingly, figure 6-5B shows a 12% significant reduction 
in αSMA staining (as determined by subtracting the percentage area of αSMA 
staining of C1-3-GT mice from those treated with C-1-3-FITC) in mice treated for 
12wks CCl4 plus two weeks of C1-3-GT in comparison to its C1-3-FITC control.  
 
 
 
 
 
 
 
 
 
 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4 αSMA staining and quantification following 4-6wks of CCl4 treatment. A: Formalin 
fixed paraffin embedded tissue samples from each animal were stained with mouse anti αSMA 
antibody. All images taken at x200 magnification. B: For quantification, pictures were taken 
around 10 random CLV at x200 magnification and subjected to analysis using Leica software to 
determine the percentage area of the αSMA stain. Data are the mean and SD of percentage area 
of the αSMA stain for each treatment group. Data tested for statistical significance using the 
Student’s two tailed T test; * represents significance between CCl4 and olive oil (p<0.0001). 
Animal group numbers: Olive oil 4wk n=3. CCl4 4wk n=6. C1-3-FITC 6wk n=7. C1-3-GT 6 n=8. 
Scale bar=100μm. 
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Figure 6-5 αSMA staining and quantification following 10-12wks of CCl4 treatment. A: 
Formalin fixed paraffin embedded tissue samples from each animal were stained with mouse anti 
αSMA antibody. All images taken at x200 magnification. B: For quantification, pictures were taken 
around 10 random CLV at x200 magnification and subjected to analysis using Leica software to 
determine the percentage area of the αSMA stain. Data are the mean and SD of percentage area 
of the αSMA stain for each treatment group. Animal group numbers: Olive oil 10wk n=3. CCl4 
10wk n=5. C1-3- 12wk n=8. C1-3-GT 12wk n=8. Data tested for statistical significance using the 
student’s two tailed T test, * represents significance between C1-3-GT vs. C1-3-FITC (p<0.01); £ 
represents significance between CCl4 and olive oil (p<0.0001). Scale bar=100μm. 
 
 
         £ 
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Sustained CCl4 injury during the final 2 weeks of C1-3 therapy provides a 
continuous stimulus for the proliferation of hepatic myofibroblasts thus it is 
possible that whilst there is little difference in αSMA IHC staining due to the 
dense staining patterns observed, C1-3-GT may be having a greater effect on the 
reduction of αSMA gene levels. To determine if this was the case, whole liver 
samples were analysed for αSMA gene expression by RT-PCR. As expected, 
following 4-6wks CCl4 treatment there is a significant increase in αSMA gene 
expression in both C1-3-FITC and C1-3-GT compared to the olive oil control 
however no significant differences were observed between the C1-3-GT and C1-
3-FITC treatment groups (Figure 6-6A). This agrees with the 
immunohistochemical data in figure 6-4. Intriguingly the data observed in figure 6-
6B is somewhat different from figure 6-5. Whilst a significant increase in αSMA 
gene expression is observed in mice treated for 12wks with CCl4, there appears 
to be no difference in αSMA gene expression between the 10wk CCl4 and olive 
oil mice. Interestingly, 2wks of C1-3-GT treatment resulted in a significant 
increase in expression of the αSMA gene compared to the C1-3-FITC control. 
This is the opposite of what would be expected as C1-3-GT would be expected to 
reduce αSMA gene expression and furthermore this does not correlate with the 
IHC quantification. However, αSMA is expressed by other myofibroblasts which 
are not derived from HSCs and this could account for the difference. 
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Figure 6-6 Relative gene expression levels of αSMA in CCl4 and olive oil treatment groups. 
RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed using 
oligo dTRT-PCR was carried out for 40 cycles and analysed using Applied Biosystems TaqMan 
software. All experiments were performed in duplicate and data are the mean and SD of the fold 
change relative to 18S and normalised to expression levels in the relative olive oil controls. 
Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk n=6; 10wk n=5. C1-3-FITC 6wk n=7; 12wk 
n=8. C1-3-GT 6/12wk n=8. Data tested for statistical significance using the Student’s two tailed T 
test. * represents significance between C1-3-GT and C1-3-FITC (A: p<0.05); £ represents 
significance between C1-3-FITC and olive oil (A: p<0.01; B: p<0.05); $ represents significance 
between C1-3-GT and olive oil (A:p<0.01; B: p<0.0001). 
Since C1-3-GT only targets hepatic myofibroblasts expressing synaptophysin, it 
was necessary to determine if the αSMA protein and gene levels reflected the 
presence of synaptophysin positive hepatic myofibroblasts. Paraffin embedded 
liver tissue sections were stained for the presence of synaptophysin as detailed in 
the materials and methods sections. Analysis of the synaptophysin staining 
revealed populations of positive cells surrounding both PT and CLV thus images 
were taken around 10 random PT and CLV and the number of positive cells 
quantified. Figures 6-7 to 6-10 are typical representations of staining patterns 
observed for each time point and treatment group. 
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Figure 6-7 Synaptophysin IHC staining and quantification around PT following 4-6wks of 
CCl4/olive oil treatment. A: 4μm sections were incubated with rabbit anti synaptophysin 
antibody. Images were taken at x400 magnification and are representative of each treatment 
group. Scale bar=50μm. B: For quantification, pictures were taken around 10 random PT at x400 
magnification and the number of positive cells with clear nuclear staining counted. Data presented 
are the mean and SD of the number of cells per treatment group. Animal group numbers: Olive oil 
4wk n=3. CCl4 4wk n=6. C1-3-FITC 6wk n=7. C1-3-GT 6 n=8.  
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Figure 6-8 Synaptophysin IHC staining and quantification around CLV following 4-6wks of 
CCl4/olive oil treatment. A: 4μm sections were incubated with rabbit anti synaptophysin 
antibody. Images were taken at x400 magnification and are representative of each treatment 
group. Scale bar=50μm.B: For quantification, pictures were taken around 10 random PT at x400 
magnification and the number of positive cells with clear nuclear staining counted. Data presented 
are the mean and SD of the number of cells per treatment group. Animal group numbers: Olive oil 
4wk n=3. CCl4 4wk n=6. C1-3-FITC 6wk n=7. C1-3-GT 6 n=8. Data tested for statistical 
significance using Student’s two tailed T test; * represents significance between 4wk CCl4 and 4 
wk olive oil (p<0.0001); $ represents significance between C1-3-FITC and 4wk olive oil (p<0.005); 
£ represents significance between C1-3-GT and 4wk olive oil (p<0.005). 
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Figure 6-9  Synaptophysin IHC staining and quantification around PT following 10-12wks 
of CCl4/olive oil treatment. A: 4μm sections were incubated with rabbit anti synaptophysin 
antibody. Images were taken at x400 magnification and are representative of each treatment 
group. Scale bar=50μm. B: For quantification, pictures were taken around 10 random PT at x400 
magnification and the number of positive cells with clear nuclear staining counted. Data presented 
are the mean and SD of the number of cells per treatment group. Animal group numbers: Olive oil 
10wk n=3. CCl4 10wk n=5. C1-3-FITC 12wk n=8. C1-3-GT 12wk n=8. Data tested for statistical 
significance using Student’s two tailed T test; £ represents significance between C1-3-GT and 
10wk olive oil (p<0.05). 
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Figure 6-10 Synaptophysin IHC staining and quantification around CLV following 10-12wks 
of CCl4/olive oil treatment. A: 4μm sections were incubated with rabbit anti synaptophysin 
antibody. Images were taken at x400 magnification and are representative of each treatment 
group. Scale bar=50μm. B: For quantification, pictures were taken around 10 random PT at x400 
magnification and the number of positive cells with clear nuclear staining counted. Data presented 
are the mean and SD of the number of cells per treatment group. Animal group numbers: Olive oil 
10wk n=3. CCl4 10wk n=5. C1-3-FITC 12wk n=8. C1-3-GT 12wk n=8.Data tested for statistical 
significance using Student’s two tailed T test; * represents significance between 10wk CCl4 and 
10wk olive oil (p<0.0001); $ represents significance between C1-3-FITC and 10wk olive oil 
(p<0.0001); £ represents significance between C1-3-GT and 10wk olive oil (p<0.0001). & 
represent significance between C1-3-GT vs. C1-3-FITC (p<0.01).  
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The data in figures 6-7B and 6-9B show that the number of synaptophysin 
positive cells surrounding PT are relatively similar in all treatment groups at both 
time points. However centrilobular induced damage by CCl4 resulted in a 
significant increase in the number of synaptophysin positive cells surrounding 
CLV in all CCl4 treatment groups compared to olive oil controls at both time 
points (figures 6-8B and 6-10B). Furthermore, treatment of mice with C1-3-GT for 
a further 2 weeks following 10wks of CCl4 resulted in a 20% significant increase 
in synaptophysin positive cells compared to the C1-3-FITC controls (figure 6-
10B). No significant differences in synaptophysin cell number were observed in 
6wk CCl4 mice treated with C1-3-GT compared to the C1-3-FITC control. 
To determine if the synaptophysin cell counts were reflective of gene expression, 
synaptophysin was quantified by RT-PCR. Quantification revealed that 
synaptophysin gene expression remained relatively constant between all the 
treatment groups for both of the injury time points (figure 6-11). This would 
suggest that there is little proliferation of synaptophysin positive hepatic 
myofibroblasts following CCl4 induced centrilobular liver injury, however this 
would disagree with the IHC staining observed in figures 6-7 and 6-10.  
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Figure 6-11 Relative gene expression levels of synaptophysin in CCl4 and olive oil 
treatment groups. RNA was isolated from each mouse liver using Trizol, quantified and reverse 
transcribed using oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied 
Biosystems TaqMan software All experiments were performed in duplicate and data are the mean 
and SD of the fold change relative to 18S and normalised to expression levels in the relative olive 
oil controls. Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk n=6; 10wk n=5. C1-3-FITC 
6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8.  
Depletion of hepatic myofibroblasts during sustained injury may stimulate 
recruitment of myofibroblasts from other sources, e.g. bone marrow, and may 
account for the lack of difference between the C1-3-GT and C1-3-FITC treatment 
groups. Whilst research has shown that a significant proportion of myofibroblasts 
are derived from the bone marrow in human liver fibrosis [24], the contribution of 
these cells to matrix deposition is somewhat debated [261]. To determine if C1-3-
GT treatment had an effect on liver fibrosis, picro-sirius red staining was used to 
assess collagen deposition and quantified using Leica software analysis (figures 
6-12 and 13). 
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Figure 6-12 Picro-Sirius red staining and quantification following 4-6wks of CCl4 or olive oil 
treatment. A: 4μm sections were incubated in picro-sirius red stain. Images were taken at x200 
magnification and are representative of each treatment group. Scale bar=100μm. B: For 
quantification 10 random CLV were located and moved to the corner of the field of view to allow 
quantification of the band of collagen by Leica software analysis. Data are mean and SD of 
percentage area of picro-sirius red stain. Animal group numbers: Olive oil 4wk n=3. CCl4 4wk n=6. 
C1-3-FITC 6wk n=7. C1-3-GT 6 n=8. Data tested for statistical significance using the Student’s 
two tailed T test. * represents significance between 4wk olive oil and 4wk CCl4 (p<0.0001); £ 
represents significance between C1-3-FITC and 4wk olive oil (p<0.0001); $ represents 
significance between C1-3-GT and 4wk olive oil (p<0.0001). 
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Figure 6-13 Picro-Sirius red staining and quantification following 10-12wks of CCl4 or olive 
oil treatment. A: 4μm sections were incubated in picro-sirius red stain. Images were taken at 
x200 magnification and are representative of each treatment group. Scale bar=100μm. B: For 
quantification 10 random CLV were located and moved to the corner of the field of view to allow 
quantification of the band of collagen by Leica software analysis. Data are mean and SD of 
percentage area of picro-sirius red stain. Animal group numbers: Olive oil 10wk n=3. CCl4 10wk 
n=5. C1-3-FITC 12wk n=8. C1-3-GT 12wk n=8. Data tested for statistical significance using the 
Student’s two tailed T test. * represents significance between 10wk olive oil and 10wk CCl4 
(p<0.0001); £ represents significance between C1-3-FITC and 10wk olive oil (p<0.0001); $ 
represents significance between C1-3-GT and 10wk olive oil (p<0.0001). 
The data show that treatment with CCl4 results in a significant amount of collagen 
deposition in comparison to the olive oil controls (figure 6-12 and 13). Even after 
4 wks of CCl4 treatment the collagen deposition extends outwards from the 
centrilobular vein and after 10-12wks of CCl4 treatment these bands of scar 
connect together, termed bridging fibrosis. More importantly however, the 
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quantification data show that treatment with C1-3-GT did not affect the amount of 
collagen deposited when compared to the C1-3-FITC control mice at either of the 
two injury time points (figures 6-12B and 6-13B). RT-PCR was used to confirm 
that these data were reflective of the expression of the col1a1 gene (figure 6-14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-14 Relative gene expression levels of collagen 1a1 in CCl4 and olive oil treatment 
groups. RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed 
using oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied Biosystems 
TaqMan software. All experiments were performed in duplicate and data are the mean and SD of 
the fold change relative to 18S and normalised to expression levels in the relative olive oil 
controls. Data tested for statistical significance using the Student’s two tailed T test. * represents 
significance between olive oil and CCl4 (A:p<0.05; B:p<0.01); £ represents significance between 
C1-3-FITC and olive oil (A:p<0.0001; B:p<0.005)); $ represents significance between C1-3-GT 
and olive oil (A/B:p<0.0001). Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk n=6; 10wk 
n=5. C1-3-FITC 6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8. 
Figure 6-14A and B show that treatment with CCl4 results in a significant increase 
in collagen 1a1 gene expression relative to the olive oil controls. This correlates 
with the picro-sirius red staining and quantification in figures 6-12 and 6-13. 
Whilst the data in figure 6-14B show that collagen 1a1 expression in mice treated 
with CCl4 for 10wk was significantly higher than the 10wk olive oil, the fold 
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change in expression for the 10wk CCl4 group is not as high as that observed in 
figure 6-14A. This disagrees with the picro-sirius red quantification data which 
showed a substantial significant increase in collagen deposition in CCl4 treated 
mice compared to the olive oil controls (figure 6-13B). Nevertheless, collagen 1a1 
expression in both 6 and 12wk CCl4 treatment groups was unaffected by C1-3-
GT treatment. 
Regression of fibrosis is an event regulated by the delicate balance of matrix 
metalloproteinases (MMPs), which are responsible for the degradation of ECM, 
and tissue inhibitors of metalloproteinases (TIMPs), which inhibit MMP mediated 
degradation. Hepatic myofibroblasts are a known source of MMPs and TIMPs, 
both of which are significantly upregulated during activation. Research has shown 
that TIMP-1 can be used as a serum marker of fibrosis [193] and over expression 
results in increased scarring during liver fibrosis [262].  Therefore TIMP-1 gene 
expression was investigated for all treatment groups at both injury time points by 
RT-PCR.  
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Figure 6-15 Relative gene expression levels of TIMP1 in CCl4 and olive oil treatment 
groups. RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed 
using oligo dT. RNA was isolated from each mouse liver using Trizol, quantified and reverse 
transcribed using oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied 
Biosystems TaqMan software. All experiments were performed in duplicate and data are the 
mean and SD of the fold change relative to 18S and normalised to expression levels in the 
relative olive oil controls. Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk n=6; 10wk n=5. 
C1-3-FITC 6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8. 
Whilst the data in figure 6-15A shows a substantial increase in TIMP expression 
in mice treated for 4wks with CCl4, due to huge differences in TIMP-1 gene 
expression between the animals this difference is not statistically significantly in 
comparison to the olive oil controls or the C1-3 treatment groups. No further 
differences in TIMP-1 expression are seen between the treatment groups and 
time points (figure 6-15).  
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TGFβ plays a prominent role in liver fibrogenesis inducing the net accumulation 
of ECM by the following mechanisms [263]:  
1. Increasing synthesis of ECM components e.g. α2(I) procollagen 
2. Preventing collagen degradation through inhibition of tissue collagenase 
3. Stimulating production of inhibitors of ECM degrading enzymes  
e.g. TIMP-1 
Hepatic myofibroblasts are a major source of TGFβ-1 during liver fibrogenesis, 
with expression levels directly associated with cellular activation status.  
Persistence of TGFβ signalling during fibrosis is thought to directly relate to 
disease progression since it has been shown to inhibit both proliferation and 
apoptosis of rat hepatic myofibroblasts [98]. Therefore expression levels of 
TGFβ-1 were analysed by RT-PCR to determine if C1-3-GT treatment had any 
effect on the signalling pathway. The results summarised in figure 6-16 show that 
TGFβ-1 gene expression remained relatively constant throughout the experiment 
with no significant differences observed between the C1-3-GT treatment groups 
in comparison to the C1-3-FITC control.   
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Figure 6-16 Relative gene expression levels of TGFβ-1 in CCl4 and olive oil treatment 
groups. RNA was isolated from each mouse liver using Trizol, quantified and reverse transcribed 
using oligo dT. RNA was isolated from each mouse liver using Trizol, quantified and reverse 
transcribed using oligo dT. RT-PCR was carried out for 40 cycles and analysed using Applied 
Biosystems TaqMan software. All experiments were performed in duplicate and data are the 
mean and SD of the fold change relative to 18S and normalised to expression levels in the 
relative olive oil controls. Animal group numbers: Olive oil 4/10wk n=3. CCl4 4wk n=6; 10wk n=5. 
C1-3-FITC 6wk n=7; 12wk n=8. C1-3-GT 6/12wk n=8. 
Neutrophils form a vital part of the innate immune response to tissue injury and 
microbial infections. Their recruitment during injury or infection is thought to be 
aided by hepatic myofibroblast secretion of chemokines and cytokines [68]. 
Neutrophils were quantified by IHC staining to determine if C1-3-GT affected the 
number of neutrophils recruited in response to the CCl4 injury (figure 6-17 and 
18). 
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Figure 6-17 Neutrophil IHC staining and quantification in mice following 4-6wks treatment 
with CCl4 or olive oil. A: Formalin fixed paraffin embedded tissue samples from each animal 
were cut into 4μm sections. Sections were dewaxed, subjected to proteinase K antigen retrieval, 
blocked and rat anti neutrophil primary antibody. Images were taken at x400 magnification and 
are representative of each treatment group. Scale bar=50μm. B: For quantification, pictures of 10 
random CLV were taken at x400 magnification and the number of positive cells with clear nuclear 
staining counted. Data are the mean and SD of neutrophils per treatment group.  
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Figure 6-18 Neutrophil IHC staining and quantification in mice following 10-12wks 
treatment with CCl4 or olive oil A: Formalin fixed paraffin embedded tissue samples from each 
animal were cut into 4μm sections. Sections were dewaxed, subjected to proteinase K antigen 
retrieval, blocked and rat anti neutrophil primary antibody. Images were taken at x400 
magnification and are representative of each treatment group. Scale bar=50μm. B: For 
quantification, pictures of 10 random CLV were taken at x400 magnification and the number of 
positive cells with clear nuclear staining counted. Data are the mean and SD of neutrophils per 
treatment group. Data tested for statistical significance using the Student’s two tailed T test. * 
represents significance between 10wk olive oil and 10wk CCl4 (p<0.0001); £ represents 
significance between C1-3-FITC and 10wk olive oil (p<0.0001); $ represents significance between 
C1-3-GT and 10wk olive oil (p<0.0001). 
The data in figure 6-17 show that there are no differences in the number of 
neutrophils surrounding CLV between the treatment groups. The numbers of 
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neutrophils present in the olive oil controls after 4 weeks of treatment was 
relatively similar to the CCl4 mice at the same time point (figure 6-17B). After 10 
to 12 weeks of CCl4 treatment, neutrophil numbers were significantly higher than 
the olive oil controls (figure 6-18B) yet no differences were observed between the 
C1-3-FITC and C1-3-GT treatment groups. However, neutrophil numbers were 
significant reduced in the 10 week CCl4 mice comparison to the 4 week CCl4 
mice (figure 6-19) suggesting that the inflammatory infiltrate is dependent upon 
injury progression. 
 
 
 
 
 
 
 
Figure 6-19 Neutrophil quantification following 4/10wk CCl4 treatment. Data represent the 
average number (from 10 fields of view) of neutrophils surrounding CLV in 4/10wk CCl4 treatment 
groups. Data tested for statistical significance using the Student’s two tailed T test. * represents a 
significant reduction in neutrophils following 10wk CCl4 vs 4wk CCl4 (p<0.0001). 
There is a vast amount of evidence suggesting that depletion of hepatic 
myofibroblasts during liver injury is essential for promoting repair and 
regeneration [100, 126] however myofibroblasts also secrete cytokines and 
growth factors that prime and stimulate proliferation of hepatocytes. To 
investigate cellular proliferation in this study, BrDU incorporation into newly 
synthesised DNA was quantified by IHC staining. Representative images of the 
staining are shown in figures 6-20 and 6-21.  
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Figure 6-20 BrDU IHC staining and quantification of parenchymal and non parenchymal 
cells surrounding CLV in mice following 4-6 wks of treatment with CCl4 or olive oil. A: 4μm 
were incubated with mouse anti BrDU primary antibody. All images taken at x200 magnification 
and are representative of each treatment group. Scale bar=100μm. B: For quantification, the 
number of parenchymal and non parenchymal cells (as determined by cellular morphology) with 
clear BrDU nuclear staining surrounding 10 random CLV regions were counted at x200 
magnification. Data presented are the mean and SD of the average number of cells for each 
treatment group at each time point. Statistical significance was tested using Student’s two tailed T 
test, % represents significance of parenchymal cells between 4wk CCl4 vs. 4wk olive oil (p<0.05) 
£ represent significance of non parenchymal cells between 4wk CCl4 vs. 4wk olive oil.  
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Figure 6-21 BrDU IHC staining and quantification of parenchymal and non parenchymal 
cells surrounding CLV in mice following 10-12 wks of treatment with CCl4 or olive oil. . A: 
4μm were incubated with mouse anti BrDU primary antibody. All images taken at x200 
magnification and are representative of each treatment group. Scale bar=100μm. B: For 
quantification, the number of parenchymal and non parenchymal cells (as determined by cellular 
morphology) with clear BrDU nuclear staining surrounding 10 random CLV regions were counted 
at x200 magnification. Data presented are the mean and SD of the average number of cells for 
each treatment group at each time point. Statistical significance was tested using Student’s two 
tailed T test, % represents significance of parenchymal cells between 10wk CCl4 vs. 12wk olive oil 
(p<0.00001) £ represent significance of non parenchymal cells between 10wk CCl4 vs. 10wk olive 
oil (p<0.0001) * represents significance of parenchymal cells between C1-3-GT vs. C1-3-FITC 
(p<0.0001) £ non parenchymal C1-3-GT vs. C1-3-FITC (P<0.0001). 
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The data show that BrDU incorporation was significantly higher in mice treated 
for 4wks with CCl4 in comparison to the olive oil controls yet no significant 
differences were observed between the C1-3 treatment groups (Figure 6-20). A 
similar trend was observed in the 10wk CCl4 mice, furthermore C1-3-GT mice 
had a significantly higher number of BrDU positive parenchymal and non 
parenchymal cells when compared to the C1-3-FITC controls (Figure 6-21).   
196 
6.3 Discussion 
The current paradigm of hepatic stellate cell activation into ECM secreting 
hepatic myofibroblasts remains the foundation for defining events in hepatic 
fibrosis [253] and continued elucidation of their mechanistic actions have made 
them attractive targets in the development of novel anti-fibrogenic therapies.  
There is a growing body of evidence which implicates hepatic myofibroblast 
survival in the progression of hepatic fibrosis, with numerous animal studies 
concluding that reversal of liver fibrosis was associated with apoptosis of αSMA 
positive myofibroblasts [100-102, 126, 249] or eradication of the injurious agent 
[205]. A fundamental discovery by Wright et al [102] provided proof of concept 
data which showed that induction of hepatic myofibroblast apoptosis by gliotoxin 
was essential for reducing collagen deposition and improving liver function in a 
rat recovery model of liver fibrosis. Gliotoxin, a fungal metabolite, is a potent 
NFκB inhibitor [102] and is capable of inhibiting TNFα inducible NFκB DNA 
binding activity in hepatic myofibroblasts as well as stimulating their apoptosis 
through a specific thiol redox-dependent interaction with the adenine nucleotide 
transporter [105]. Furthermore, when conjugated to C1-3, a scAb which 
specifically binds synaptophysin expressing hepatic myofibroblasts, the apoptotic 
effect of gliotoxin could be specifically targeted providing a novel approach for 
depleting ECM secreting myofibroblasts during injury [126, 249] without removing 
cells essential in liver regeneration [264]. The major limitation with these and 
other fibrosis studies is that the anti-fibrogenic agents are tested in recovery 
models of fibrosis, i.e. where the injurious agents have been removed. Recent 
publications have demonstrated that hepatic myofibroblasts secrete key factors 
involved in liver regeneration [144, 146, 265]. Therefore it is essential to 
determine if depletion of myofibroblasts during sustained injury would promote or 
hinder liver regeneration. This chapter set out to investigate whether depletion of 
hepatic myofibroblasts during two different stages of liver fibrosis would promote 
reversal and regeneration during sustained injury. 
For this study, two liver injury time points were chosen to represent two different 
grades of fibrosis. Previous work investigating spontaneous resolution of liver 
fibrosis in rats has shown that following 4wks of CCl4 injury complete resolution of 
normal tissue architecture can be achieved following cessation of injury [100]. 
However after 12wks of treatment, remodelling of the ECM took substantially 
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longer and was incomplete with extensive collagen cross linking only allowing the 
mirconodular cirrhosis to be remodelled to macronodules [266].  
Mice were divided into treatment groups to either receive 4 or 10wks of CCl4 or 
olive oil treatment with further subgroups receiving C1-3-FITC or C1-3-GT for a 
following 2 weeks in combination with CCl4 treatment. This would allow for 
changes in fibrosis to be directly compared between C1-3 treatment groups as 
well as monitoring changes in collagen deposition in reference to baseline 
controls, i.e. 4 and 10wks of CCl4 or olive oil treatment.  
Initial experiments set out to confirm that the C1-3-GT had depleted hepatic 
myofibroblasts by quantifying myofibroblast number through IHC staining and RT-
PCR. Interestingly, no differences in αSMA/synaptophysin IHC staining or gene 
expression were observed in mice treated for 6wks with CCl4 with 2 weeks of C1-
3-GT in comparison to the C1-3-FITC control. This would suggest that the study 
had not worked, with mice not receiving an effective therapeutic dose of C1-3-GT 
since previous studies have shown that C1-3-GT depleted approximately 60% of 
hepatic myofibroblasts in a recovery model of liver injury [126]. Hepatic 
myofibroblasts derived from quiescent HSCs are not the only source of αSMA 
positive cells during liver injury, with portal myofibroblasts [55], biliary epithelial 
cells undergoing EMT [25, 62] and circulating bone marrow derived 
myofibroblasts [24, 60] also contributing to this population (Figure 6-23).  It is 
important to note that the contribution of bone marrow myofibroblasts and 
myofibroblasts derived from EMT is still debated. Recent publications have 
shown that hepatocytes do not undergo EMT [267] and genetic labelling failed to 
detect EMT in murine cholangiocytes [268]. Yet, there is convincing evidence in 
the literature that they sources do exist [24, 26, 60, 61, 269]  thus, it is possible 
that depletion of hepatic myofibroblasts may stimulate the recruitment of other 
myofibroblast populations. Whilst the synaptophysin RT-PCR and IHC data may 
discredit this idea somewhat, it is important to note that the number of 
synaptophysin positive cells was substantially lower than the number of αSMA 
positive cells suggesting that the commercial antibodies available may not detect 
all synaptophysin positive cells. This is possibly due to a splice variant of the 
protein, and thus is not an accurate reflection of synaptophysin expressing 
hepatic myofibroblasts.  Ideally, synaptophysin expressing hepatic myofibroblasts 
would be quantified using the C1-3 antibody itself, however since C1-3 does not 
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work in fixed tissue further optimisation of IHC staining protocols are required. To 
determine if αSMA myofibroblasts are derived from other cellular sources, it 
would be necessary to carry out a dual antibody stain combining αSMA with 
markers of portal myofibroblasts, e.g. elastin or markers of the EMT process e.g. 
S100A4 [26]. 
Mice treated for 12wks with CCl4 with the addition of C1-3-GT for a final 2 weeks 
had a significant 12% reduction in αSMA staining in comparison to the C1-3-FITC 
controls. However synaptophysin staining revealed that this decrease was 
associated with a 21% significant increase in synaptophysin positive cells around 
CLV. Synaptophysin is also expressed by oval cells, a progenitor cell population 
which contribute to liver regeneration by differentiation into hepatocytes and 
biliary epithelial cells. Since the number of synaptophysin positive cells quantified 
suggests that not all cells are being stained with the commercial antibody, it is 
possible that hepatic myofibroblast depletion, as determined by a decrease in 
αSMA staining, promotes liver regeneration through increased oval cell 
proliferation. To confirm if this is the case it would be necessary to do a dual label 
for synaptophysin and an oval cell marker, e.g. OV6. 
Hepatic myofibroblasts have been identified as the principal producer of the 
major component of the hepatic scar, collagen I [32, 270], which disrupts tissue 
architecture and function. Collagen deposition increases with continued injurious 
stimulus which correlates with an increasing number of αSMA expressing hepatic 
myofibroblasts [251]. Upon cessation of injury, regression of fibrosis is associated 
with a significant decrease in collagen 1a1 gene expression due to ECM 
remodelling. In this study, collagen deposition was quantified by picro-sirius red 
IHC staining and RT-PCR analysis. Both quantification methods showed that 
there were no significant differences in collagen deposition between the C1-3-GT 
and C1-3-FITC treatment groups. Whilst no difference in collagen levels in the 6 
week treatment groups can be explained by a failure of hepatic myofibroblast 
depletion, a significant decrease in αSMA staining typically correlates with 
decreases in collagen, as shown by previous animal models of fibrosis [100, 
126]. This may be the result of extensive collagen cross-linking making the scar 
degradation resistant [266] or a longer recovery time required to allow for tissue 
remodelling. Furthermore recent reports have suggested that hepatic 
myofibroblasts are not the only source of ECM components during fibrosis, with 
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studies implicating bone marrow myofibroblasts [24], portal fibroblast [22, 23] and 
fibroblasts derived by EMT [25] contributing to ECM deposition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-22 Sources of myofibroblasts during liver injury. Adapted from [80], this diagram 
illustrates all potential sources of activated myofibroblasts involved in liver fibrosis.  
TGFβ1 is secreted in a latent form by hepatic myofibroblasts in response to liver 
injury [37]. Once activated, this cytokine exerts its potent fibrogenic effects on 
cells in both an autocrine and paracrine manner promoting the net accumulation 
of ECM components during liver fibrosis [263]. TGFβ1 gene levels in human 
hepatic fibrosis have been found to closely correlate with serum type III 
procollagen peptide suggesting that TGFβ1 has an important role in the 
pathogenesis of liver fibrosis [271]. Interestingly, TGFβ1 gene expression 
remained relatively constant between the CCl4 and olive oil treatment groups for 
both injury time points which would suggest that this cytokine was not important 
in liver disease. However, TGFβ can be stored in an inactive form within the 
extracellular matrix thus it is possible that the extracellular stores may be being 
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used to drive fibrosis [272]. To confirm RT-PCR results, TGFβ1 protein 
expression could be investigated by immunohistochemical methods in the mouse 
liver tissue. 
Regression of fibrosis is dependent upon the delicate balance of MMPs and their 
inhibitors, TIMPs. High expression levels of TIMP-1, which are produced by 
hepatic myofibroblasts during liver injury [50], correlate with advanced fibrosis 
and prevent fibrosis regression through inhibition of the degradation of the scar 
matrix and inhibition of myofibroblast apoptosis [273]. Furthermore, spontaneous 
resolution of liver fibrosis was associated with a decrease in TIMP-1 expression  
[100] whilst over expression of TIMP-1 enhanced experimental fibrosis [262]. It 
was predicted that TIMP-1 gene expression would be significantly higher in CCl4 
treated mice in comparison to the olive oil controls however this was not the case 
in either treatment groups. Instead TIMP-1 gene expression remained relatively 
constant when fold change was calculated with respect to the olive oil controls 
indicating no difference in TIMP-1 gene expression. This result may reflect actual 
levels of TIMP-1 gene expression in the liver however only a small proportion of 
the tissue is used for RNA extraction thus this may not be reflective of the whole 
tissue levels. Analysis of key MMPs, e.g. MMP2, MMP13 [274], would be of 
interest since MMP catabolism of the ECM is an important feature of recovery.  
The neutrophil chemotactic response following liver injury is thought to be 
partially mediated by hepatic myofibroblast secretion of platelet activating factor 
[270] thus C1-3-GT mediated hepatic myofibroblast depletion may affect the 
inflammatory response during injury. Quantification of neutrophil IHC revealed 
that there were no differences in the number of neutrophils surrounding CLV 
following 4-6wks of olive oil or CCl4 treatment. The presence of neutrophils in the 
olive oil controls may reflect an inflammatory reaction in response to the regular 
dosing of ‘fat’. This is commonly seen in clinical practice in patients that consume 
excess amounts of fats and is termed non alcoholic steatohepatitis (NASH). As 
fibrosis progresses the number of neutrophils surrounding CLV decreased, 
particularly in the olive oil controls since neutrophils are an important part of the 
innate immune response to tissue injury and infection and only persist in the 
tissue in certain disease pathologies, e.g. alcoholic hepatitis [275] and ischemia 
reperfusion injury [276, 277]. Hepatic myofibroblasts are known to secrete 
cytokines and chemokines chemotactic for immune cells, thus it would be of 
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interest to investigate kupffer cell numbers following C1-3-GT treatment as they 
play an important role in modulating the inflammatory response and fibrosis 
progression/regression [5, 278]. 
The current scientific literature implicates hepatic myofibroblast apoptosis as a 
significant event in the stasis or reversal of liver fibrosis [100, 101, 126, 266], 
however there is emerging evidence that hepatic myofibroblasts provide essential 
factors which promote hepatocyte proliferation [144, 146, 265] thus their 
depletion may have unprecedented effects on subsequent liver regeneration.  
The data in this chapter show that hepatic myofibroblast depletion in mice treated 
for 12wks with CCl4 significantly increased cellular proliferation, as determined by 
parenchymal and non parenchymal cellular BrDU incorporation. This correlated 
with a significant increase in synaptophysin cell number which may be indicative 
of an oval cell response. To confirm this dual IHC staining with both 
synaptophysin and OV6 would be required. However no change in collagen 
deposition was observed suggesting that either hepatic myofibroblast depletion 
promoted recruitment of other myofibroblasts to the liver or extensive collagen 
cross linking made the scar resistant to degradation. Taken together the data 
suggest that hepatic myofibroblast depletion during sustained injury does not 
promote reversal of liver fibrosis and previous results obtained in recovery 
models imply that the removal/treatment of the injurious agent is critical for 
regeneration [205, 279, 280]. 
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Chapter 7. Final Discussion 
7.1 Results Summary 
Liver fibrosis refers to the accumulation of tough, fibrous scar tissue within the 
liver. It is a natural wound healing response to an injurious agent to encapsulate 
the damage and once the injurious agent is removed the distorted architecture is 
remodelled and the liver regenerates damaged hepatocytes by stimulating their 
proliferation.  However if the injurious agent is not removed, the liver becomes 
overwhelmed with the continued stimulation causing prolonged activation of 
hepatic myofibroblasts with excessive deposition of ECM distorting normal liver 
architecture and ultimately affecting liver function. Historically end staged liver 
disease, cirrhosis, was deemed to be irreversible with a liver transplant being the 
only viable treatment option. However further elucidation of the cellular and 
molecular fibrogenic wound healing pathways have identified new therapeutic 
targets [281] which are desperately needed. A recent report highlighted that 
approximately 1-2% of the US population suffer from HBV and HCV infection, 
which are leading causes of both cirrhosis and hepatocellular carcinoma resulting 
in the preventable deaths of approximately 15,000 US citizens each year [282].  
Despite the recent advances there are still no anti fibrotic therapies available 
which have been proven to slow fibrosis progression or even stimulate the 
fibrosis regression. Nevertheless even if a major breakthrough did occur, the poor 
diagnostic tools currently available prevent the accurate monitoring of disease 
progression, an essential criterion for any new treatment regime. Furthermore, 
the development of a highly sensitive, reproducible non invasive test to aid in the 
distinction between the stages of liver disease will allow the implementation of 
appropriate therapeutics that may slow/prevent further progression of fibrosis and 
favour liver regeneration. The data presented in this thesis show that the number 
of hepatic myofibroblasts within the liver, as determined by αSMA staining, is 
representative of the stage of fibrosis, with increasing cell number correlating with 
advanced fibrosis and collagen deposition. Interestingly, i.p. injection of C1-3-AF, 
which binds to synaptophysin positive hepatic myofibroblasts only, demonstrated 
a significant increase in total flux in CCl4 treated animals in comparison to the 
olive oil controls at selected time points during the live animal imaging and in the 
12wk CCl4 livers only. However, total flux did not increase proportionally with 
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CCl4 treatment time suggesting that C1-3-AF would not be a useful tool in the 
diagnosis of liver disease since it cannot clearly distinguish between the different 
stages of liver fibrosis.      
Previous work by the Wright group, as well as many others, have demonstrated 
that hepatic myofibroblast depletion (due to induced or spontaneous apoptosis) 
following cessation of liver injury enhances liver regeneration in comparison to 
controls [100-102, 126, 249, 266]. However, this is not representative of the 
clinical situation since the underlying injurious agent cannot always be removed. 
Furthermore, recent studies have identified that hepatic myofibroblasts produce 
factors that are critical in the regenerative response, such as IL-6, HGF and 
serotonin [131, 138, 146] thus further investigation of the effects of myofibroblast 
depletion are urgently required. In an attempt to answer this question, hepatic 
myofibroblasts were depleted in two different animal models; chronic injury and 
liver regeneration 
C1-3-GT or C1-3-FITC was administered during the final two weeks of CCl4 
treatment to determine if depletion during sustained injury promoted fibrosis 
reversal. Hepatic myofibroblast depletion was only successful in the 12wk CCl4 
model of end stage cirrhosis, as confirmed by a reduction in the percentage of 
αSMA staining. However, no significant differences in collagen deposition were 
observed suggesting that the collagen may be resistant to degradation. This 
result correlates with a previous report which has shown that remodelling of 
extensively crossed-linked collagen scar tissue was incomplete even after 366 
days following removal of the fibrosis causing agent [266]. To investigate if C1-3-
GT mediated depletion would enhance the resolution of fibrosis following the 
cessation of CCl4 injury, it would be necessary to extend the study and sacrifice 
the animals at a later time point, e.g. 6 months post injury.  
To investigate the role of hepatic myofibroblasts during liver regeneration, C1-3-
GT was administered at critical time points before and after PHx. The data 
obtained from this study were quite conflicting with synaptophysin and αSMA 
quantification failing to confirm successful depletion of hepatic myofibroblasts. 
Nevertheless, C1-3-GT treatment suggested that hepatic myofibroblasts have 
opposing roles in liver regeneration, both enhancing and inhibiting cellular 
proliferation. Since there is no evidence within the literature which can support 
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these findings, it would be necessary to confirm these results using another 
method of hepatic myofibroblast depletion.  
7.2 Project Limitations 
C1-3 has been shown to bind to synaptophysin positive hepatic myofibroblasts in 
vivo providing a novel method for targeting therapeutics [125, 126, 249], yet its 
use in the animal studies described above is subject to limitations. Historically 
hepatic myofibroblasts have been considered the principal cell type involved in 
the perpetuation of liver fibrosis due to excessive ECM deposition and resistance 
to apoptosis [37, 270]. However, there is now emerging evidence that other 
cellular sources contribute to the population of myofibroblasts present during liver 
disease [17, 22-26, 283] with a large proportion of them expressing the classical 
myofibroblast marker, αSMA. This means that C1-3-GT mediated depletion 
needs to be confirmed by both αSMA and synaptophysin quantification, a task 
which has proved difficult. Synaptophysin IHC staining was optimised with mouse 
pancreatic tissue however the number of cells staining positive for synaptophysin 
in the liver was substantially lower than expected, especially for CCl4 treatment 
groups. An example of this is the PHx study, whilst the data suggest that C1-3-
GT depletion has delayed subsequent liver regeneration, as demonstrated by 
BrDU incorporation, synaptophysin IHC and RT-PCR would suggest that only a 
small percentage of the αSMA myofibroblasts express synaptophysin. It is 
possible that other myofibroblast/liver cell populations regulate the pathways 
governing liver regeneration, for example C1-3-GT resulted in a significant 
increase in the proliferation of αSMA myofibroblasts surrounding PT with no 
significant differences observed in those surrounding CLV. The location of these 
cells would suggest that they are either portal myofibroblasts or derived from 
cholangiocytes by EMT or a combination of both. Whilst EMT is still debated in 
the literature, its contribution could be easily tested using markers of the EMT 
process: S100A4, vimentin and MMP2. These markers have been validated by 
groups investigating EMT [26, 66] and when used in combination with elastin, a 
marker of portal myofibroblasts, they would be sufficient to distinguish the 
populations of αSMA myofibroblasts within both animal models. However, it is still 
important to confirm myofibroblast depletion in order to validate the results 
generated in both animal models. To date, there are no unique hepatic 
myofibroblast markers making it very difficult to confirm C1-3-GT mediated 
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depletion by other methods and even if any were identified, it would be necessary 
to confirm that they were expressed by synaptophysin positive hepatic 
myofibroblasts thus further optimisation of synaptophysin detection methods are 
required. Since C1-3 does not work in fixed tissue, it would be necessary to 
develop a polyclonal antibody which detects the peptide 2 region of the 
synaptophysin protein in case a splice variant of the protein exists. 
RT-PCR, using commercially available TaqMan probes, has been extensively 
used in this project to confirm hepatic myofibroblast depletion and its subsequent 
effect on cytokines/growth factors associated with the cell type. On many 
occasions the data failed to show differences in cytokine/growth factor expression 
between the treatment groups, a result that was somewhat unexpected. Whilst 
some cytokines/growth factors, e.g. HGF and TGFβ, are stored in an inactive 
form within the ECM thus production is not required, it is possible that RT-PCR 
was not functioning under optimal conditions. In order to validate the RT-PCR 
data it would be necessary to perform a serial dilution of the cDNA template, 
plotting the log concentration vs. CT value. If the reaction is 100% efficient, the R2 
value should be 1. If the value is less than this, it would suggest problems with 
cDNA quantitation or quality. Furthermore, a range of endogenous controls, e.g. 
GAPDH; actin, should be evaluated to ensure that the absolute quantification 
values are accurate since any slight variations in the endogenous control will 
reflect in the fold change of gene expression recorded.  
The imaging data acquired using IVIS provides proof of concept that 
myofibroblasts can be used to distinguish between fibrotic and non fibrotic liver 
with data from the excised liver showing a significant increase in liver flux in 12wk 
CCl4 liver in comparison to the olive oil controls. However, the quenching of the 
fluorescent signal by the liver and other tissues means that the total flux obtained 
during the live animal imaging is not reflective of the actual value. To overcome 
this, a fluorophore which emits near the end of the infra red spectrum could be 
used since non specific absorption by the bodily fluids and tissue is substantially 
lower. Furthermore, the expression of synaptophysin by cells within the pancreas 
limits the use of C1-3 as a diagnostic tool as it would not be liver specific. To 
overcome this, a 3D scan could be used to map the fluorescence to a specific 
area within the body however this is not feasibly possible at the moment. Finally, 
C1-3-AF was only trialled as an imaging agent in liver disease caused by 
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centrilobular injury. Since research has implicated the portal fibroblast as the 
principal cell type in obstructive cholestasis [52, 53] further testing in different 
animals models of liver disease, e.g. obstructive cholestasis, are required.  
Whilst the animal studies described in this thesis provide useful pilot data, the 
group numbers used are too low to provide a statistically significant result, 
particularly in the RT-PCR data due to the large variations in gene expression 
between animals. Future studies need to take into account death from 
surgical/procedural complications and should be calculated using the power 
analysis method to estimate the minimum number of animal required to achieve 
statistically significant differences.    
7.3 Future Directions 
In order to understand the implications of the animal studies described in this 
thesis it is necessary to establish that C1-3-GT therapy has successfully depleted 
hepatic myofibroblasts in vivo. It is possible that problems associated with the 
conjugation process, excess PMPI:Gliotoxin addition favours protein precipitation, 
resulted in mice receiving a sub-optimal dose of C1-3-GT making it difficult to 
interpret the results. One way to confirm this would be to use C1-3 itself or a 
polyclonal antibody reactive with the peptide 2 region of the synaptophysin 
protein (in case a synaptophysin splice variant exists) in Western blotting and 
IHC analysis. Since C1-3 binds to synaptophysin under native conditions, i.e. 
unfixed cells, IHC needs to be carried out in frozen tissue where the 
synaptophysin protein will not have been affected by formalin fixation. However 
frozen tissue has poor morphology and results in diffuse staining patterns making 
it difficult to interpret results. In the final animal study C1-3-FITC was used as a 
conjugated scAb control in an attempt to quantify the number of synaptophysin 
positive cells in the CCl4 tissue since, in theory, it could be either visualised 
directly in the tissue by fluorescence or using an antibody that is directed against 
FITC and is directly conjugated to HRP (mouse anti FITC-HRP). However further 
optimisation of staining protocols are required since no fluorescence was visible 
when the tissue was excited at the appropriate wavelength and amplification of 
the fluorescent signal using a mouse anti FITC-HRP antibody resulted in high 
background staining making identification of individual cells difficult.  
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An independent method to confirm the results obtained by the sustained injury 
and PHx animal studies would be to use a genetic model of hepatic myofibroblast 
depletion. Studies have shown that the prolonged survival of hepatic 
myofibroblasts which favours progression of liver fibrosis is associated with 
constitutive NFκB signalling and prevents cellular apoptosis [106]. Administration 
of sulfasalazine resulted in the selective blocking of NFκB dependent gene 
transcription and promoted hepatic myofibroblast apoptosis in vivo. NFκB is an 
important signalling pathway in many biological processes, thus targeted 
inactivation in hepatic myofibroblasts can be achieved using transgenic mice in 
which the super repressor human IκB transgene is expressed under the control of 
glial fibrillary acidic protein (GFAP) promoter. Inactivation of NFκB signalling in 
astroglial cells has been shown to have a protective effect following spinal cord 
injury and was associated with a reduced inflammatory response [284]. GFAP 
expression correlates with activation of HSC into hepatic myofibroblasts thus the 
effect of myofibroblast depletion during sustained injury and liver regeneration 
could be investigated without the concern about therapeutic doses of C1-3-GT. 
A recent study has shown that hepatic myofibroblasts co-express p75NTR (p75 
neurotrophin receptor) and sortillin which allows the cells to respond to the pro 
apoptotic mature nerve growth factor (NGF) and the anti apoptotic pro NGF [285]. 
The group demonstrated that levels of pro NGF correlate with fibrosis 
progression, with the highest levels present at peak fibrosis and subsequently fall 
during recovery which is accompanied by a decrease in hepatic myofibroblast 
number. Furthermore p75NTR-/- mice subjected to CCl4 induced fibrosis had a 
reduced regenerative response due to a reduction in hepatic myofibroblast, 
hepatocyte and oval cell proliferation suggesting that hepatic myofibroblasts play 
an essential role in recovery. Whilst this data suggest that hepatic myofibroblasts 
promote recovery in a recovery fibrosis model, it would be interesting to subject 
these mice to PHx to investigate whether hepatic myofibroblasts are important in 
liver regeneration in the absence of inflammation. Not only would this be an 
independent method to confirm the C1-3-GT PHx study, if used in combination 
with 2-acetylaminofluorene [286] or retrosine [287] which inhibit hepatocyte 
proliferation, the model would investigate the effect of hepatic myofibroblast 
depletion on the oval cell regenerative response.  
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To investigate the potential clinical use of C1-3 as an imaging agent, the 
contribution of hepatic myofibroblasts to portal fibrosis resulting from obstructive 
cholestasis, hepatitis and NAFLD/NASH needs to be evaluated. Ideally C1-3 
conjugated to a near infra red fluorophore would be used in these animal models 
with fluorescence being ‘mapped’ to specific organs using 3D scans. This would 
overcome the limitation associated with synaptophysin expression in the 
pancreas allowing for accurate quantification. To improve resolution, C1-3 could 
be conjugated to a radioactive label, e.g. 18F SFB, with images generated by PET 
scans overlaid on CT images to provide accurate quantification.  
7.4 General Conclusions 
Since its initial discovery by von Kupffer in 1876, the hepatic myofibroblast has 
been shown to be the principal cell type involved in the initiation, perpetuation 
and termination of liver fibrosis caused by a vast array of aetiological agents. 
Whilst the continued elucidation of hepatic fibrogenesis has identified potential 
therapeutic targets to stimulate fibrosis stasis or regression, the lack of diagnostic 
tools to accurately grade and stage fibrosis would make it difficult to implement 
the therapeutics when they are most beneficial.  
The data presented in this thesis provide proof of concept that the hepatic 
myofibroblast can be as a non invasive measure of liver fibrosis, with cell number 
increasing with disease progression (as determined by αSMA quantification). 
However, the use of C1-3 as an imaging agent is somewhat limited since the total 
flux of C1-3-AF from both the live animal imaging and the excised liver failed to 
accurately distinguish between the different stages of fibrosis. Furthermore, the 
role of hepatic myofibroblasts in liver regeneration seems to be more complex, 
with further elucidation of their mechanistic actions required before hepatic 
myofibroblast depletion can be recommended as an effective therapy for liver 
fibrosis. Whilst expression of synaptophysin by beta cells within the pancreas 
limits it clinical use as both an imaging agent and a method for targeting 
therapeutic drugs, C1-3 is still the only method to date which can selectively 
target hepatic myofibroblasts without the need for genetic knockouts. Moreover, 
continued development of the antibody by the Wright group, through the 
conjugation of liposomes to C1-3, ensures that it will be a great scientific tool in 
the investigation of hepatic myofibroblasts in future studies.  
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